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Abstract
Myotonic dystrophy (DM) is the most prevalent form of adult muscular dystrophy and 
is characterised by myotonia and muscle weakness and atrophy. The genetic defect 
associated with DM is an unstable (CTG)n repeat in the 3’ untranslated region (UTR) 
of a protein kinase gene myotonic dystrophy protein kinase (DMPK) and the promoter 
region of a homeobox gene myotonic dystrophy associated homeodomain protein 
(DMAHP). These genes are both expressed in a wide range of tissues and their levels 
of expression have been shown to be altered in DM patients.
DMAHP is a member of the Six subfamily of genes of which 6 mammalian and 3 
Drosophila genes have been identified. All members of this family encode a 
homeodomain that is highly diverged from other known homeodomains and a second 
homologous domain, the Six domain, which lies immediately upstream of the 
homeodomain. Homeodomain proteins are known to be transcription factors that 
control gene expression by binding to DNA and activating or repressing transcription. 
The work presented in this thesis investigated the DNA binding properties of the 
DMAHP protein.
Human foetal cDNA libraries were screened for the presence of a full length DMAHP 
cDNA but none was identified. Therefore, a cloned RT-PCR product and a genomic 
cosmid were used to subclone the Six domain, the homeddomain and both domains 
together into the bacterial expression vector pGEX4T3. From these clones, 3 
glutathione S-transferase (GST)-DMAHP fusion proteins were produced and affinity 
purified by chromatography with a glutathione ligand. Affinity purified recombinant 
proteins and cell lysates from bacteria expressing the recombinant proteins were used 
in gel retardation assays with DNA oligonucleotides representing putative DNA 
binding sites. The putative sites included 2 in the promoter region of DMPK and the 
known DNA binding site of another Six subfamily member, AREC3/Six4 (the ARE). 
The recombinant fusion proteins showed no affinity for the 2 putative sites in DMPK. 
However, both the recombinant fusion proteins containing the homeodomain bound to 
the ARE, with the recombinant protein containing both domains (GST-Six+HD) 
forming 2 complexes, one of which was presumed to be a dimer complex. A cofactor 
present in the bacterial cell lysate increased the affinity of GST-Six+HD for the ARE.
Finally, a whole genome PCR based screen was used to identify genomic DNA 
sequences to which DMAHP binds, as an initial stage in the identification of genes 
regulated by DMAHP.
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1
Introduction
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1.1 Myotonic Dystrophy
Myotonic dystrophy, otherwise known as dystrophia myotonica (DM), was first 
described in 1909 as a disorder causing atrophy and weakness of the face and distal 
limb muscles and myotonia (Batten and Gibb, 1909; Steinert, 1909). DM is inherited 
as an autosomal dominant disorder and is the most frequently occurring form of adult 
muscular dystrophy, with a world wide incidence of 1 in 8,000 (Harper, 1989). 
Clinically the disease is now known to be highly variable with symptoms including; 
myotonia, progressive weakness and wasting of the muscles, cardio-respiratory 
problems, cataracts, gastro-intestinal problems, hyperinsulinism, hypersomnia, 
premature balding, mental retardation, gonadal atrophy and male sterility. Patients 
with the mildest form of the disease develop symptoms late in life and cataracts are 
often the only detectable sign. In the early stages of the classical form of DM, 
weakness of the facial, jaw and stemomastoid muscles are the earliest muscle 
symptoms followed by distal muscle weakness. This weakness is caused mainly by 
the atrophy of type I muscle fibres and proximal muscles become affected as the 
disease progresses. DM patient skeletal muscle biopsies show variation in muscle 
fibre size and shape and an increased number of split muscle fibres and connective 
tissue. An increased number of central nuclei are seen in the muscle fibres, which is 
presumably due to regeneration as a result of the atrophy.
Although the disease generally presents itself in the third or fourth decades, it can 
occur congenitally and in these cases the symptoms are usually more severe and 
include hypotonia, facial displegia and weakness of sucking and swallowing due to 
delayed muscle maturation. Congenital DM is inherited almost exclusively from DM- 
affected mothers and has a high mortality rate. Survivors develop the classic form of 
the disease at about 10 years of age (Harper, 1989).
1.2 The Pathophysiological Mechanism of DM
Several attempts have been made to establish the mechanism by which the properties 
of the diseased systems are altered. However, due to the use of denervated and 
aneurally grown skeletal muscle fibres (which are very different from adult tissue) in 
many of the studies, conflicting electrophysiological results have been reported and 
the complete mechanism is still unknown.
The protein kinase activity in erythrocyte membranes of DM patients was shown to be 
reduced compared to normal controls indicating a membrane abnormality in DM 
(Roses and Appel, 1973). Therefore, the activity of the N a \ K+ -ATPase pump,
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which is required for the removal of intracellular Na+ after the transmission of an 
action potential and Na+ concentration have been investigated. A decrease in the 
number of Na+ pumps have been reported (Desnuelle et a l , 1982) along with 
increased levels of Na+ ions in skeletal muscle fibres of DM patients (Edstrom and 
Wroblewski, 1989; Rudel and Lehmannhom, 1985). However, both a decrease in 
Na+, K+ -ATPase activity (Benders et a l,  1996; Benders et a l,  1993) and no change 
in activity have been reported (Roses and Appel, 1974).
Other ion channels have also been implicated in the pathology of DM. Apamin (a 
peptide from bee venom that blocks small conductance Ca2+-activated K+ channels) 
receptors are present in DM muscle but absent in normal adult control muscle (Renaud 
et a l,  1986). The possible role of these apamin sensitive K+ channels in the genesis 
of myotonia was investigated by the injection of apamin into the thenar muscles of DM 
patients. This decreased their basal electrical activity and reduced the intensity and 
duration of myotonic discharges suggesting that these K+ channels are involved in the 
mechanism of myotonia (Behrens et a l, 1994). However, other embryonic skeletal 
muscle markers, neural cell adhesion molecule (N-CAM) and 5.1H11, the regulation 
of which is coordinate with apamin binding, are both expressed in DM muscle (Walsh 
et a l, 1988). Therefore, the expression of these 3 embryonic genes in DM patient 
muscle may be a reaction to the pathology of the disease rather than a direct cause of 
the symptoms.
A recent study used the single-channel patch-clamp technique to investigate Ca2+- 
activated K+ channels of erythrocytes from patients with DM (Pellegrino et a l, 1998). 
The basic properties of single Ca2+-activated K+ channels; conductance, rectification, 
kinetics, voltage and calcium dependence were indistinguishable from normal 
controls. However, the activity of channels from DM patient erythrocytes exhibited 
mean patch currents that were significantly higher than the controls, due to a higher 
opening frequency, associated with a reduced mean channel closed time. Therefore, 
Ca2+-activated K+ channels of erythrocytes from DM patients either detect a higher 
intracellular Ca2+ concentration and/or express an increased Ca2+ sensitivity. These 
experiments identified defective kinase mechanisms at the molecular level.
1.3 The Myotonic Dystrophy Mutation
The primary genetic defect responsible for myotonic dystrophy was identified as an 
expanded trinucleotide (CTG)n repeat in the 3’ untranslated region (UTR) of a protein
kinase gene, myotonic dystrophy protein kinase (DMPK) on chromosome 19 
(Aslanidis et a l, 1992; Brook et a l, 1992; Buxton et a l, 1992; Fu et a l, 1992;
Harley et a l,  1992; Mahadevan et a l, 1992). Sequence analysis showed DMPK to
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have homology with members of the serine/threonine family of kinases. Generally, 
the greater the number of repeats that a patient has, the more severely affected they are 
(table 1.1). Normal individuals have between 5 and 37 repeats, mildly affected 
patients have 50-150 repeats, adult onset (classical) patients 100-1,000 repeats and 
congenital cases can have more than 2,000 repeats. In general there is an earlier onset 
of DM as well as an increase in severity of the clinical symptoms with transmission to 
successive generations within families (Harper et a l, 1992). This genetic anticipation 
is accompanied by an increase in the number of (CTG)n repeats (Mahadevan et a l,
1992).
Phenotype Clinical symptoms Repeat length
MILD Cataracts 50-150
CLASSICAL Myotonia, Muscle wasting, Premature 
balding, Gonadal atrophy, Cardiac conduction 
defects
100-1000
CONGENITAL Hypotonia, Mental Retardation, Facial 
displegia
>1000
Table 1.1 Correlates between phenotype and repeat expansion lengths
The meiotic instability of the DM mutation has also been shown to be dependent on 
the sex of the parent as well as the size of the parental repeat. For (CTG)n sequences
of less than 0.5 kb a positive correlation between size of repeat and intergenerational 
enlargement was found almost equally in both male and female meioses. With repeats 
greater than 0.5 kb intergenerational variation is more important in female meioses and 
contraction of repeat length occurs almost exclusively in male meioses for fragments 
greater than 1.5 kb (Lavedan et a l, 1993). This may, in part, be due to a selection 
barrier during spermatogenesis preventing the survival of sperm with long repeats. 
Congenital DM, which presents the most severe phenotype was thought to be 
exclusively maternally inherited (Hofmann-Radvanyi et a l, 1993). However, cases of 
paternally inherited congenital DM have been described, which shows that it is 
possible for transmission of a large allele by a male to occur although it is a very rare 
event. For an example see Nakagawa et a l (1994). This excludes maternal imprinting, 
mitochondrial inheritance or transplacental factors as being of importance in congenital 
DM.
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In addition to germline instability, somatic heterogeneity between and within tissues 
has been demonstrated. Repeat lengths were found to be greater in muscle than in 
lymphocytes from the same patient (Anvret et a l, 1993; Thornton et a l , 1994). As 
muscle is the tissue that is primarily affected, these results suggest that for 
presymptomatic testing, muscle DNA rather than lymphocyte DNA should be tested. 
The occurrence of mitotic repeat length variation within DM patients was assessed by 
analysing a broad range of tissues from single patients and monozygotic twins (Jansen 
et a l, 1994). Differences in the repeat length were seen in all tissues from single DM 
patients and the twins except when the patients carried extremely long repeats. The 
repeat lengths in fathers’ sperm were also compared to their offspring’s blood and 
were found to be significantly different. It was concluded that DM patients are both 
somatic and germline tissue mosaics and that (CTG)n expansions occur during early 
embryonic mitotic divisions in both somatic and germline tissue formation. Somatic 
variation within tissues has also been demonstrated by small pool PCR (Monckton et 
a l, 1995). Using standard techniques that analyse simultaneously at least 104 cells 
individual alleles cannot be distinguished and a heterogeneous smear of (CTG)n 
repeats is observed when visualising expanded alleles from DM patients. Small pool 
PCR demonstrated that the smear is composed of multiple coalesced fragments that 
can be resolved into discrete length alleles derived from single cells. It was also 
demonstrated that somatic expansions in the parent can contribute to apparent 
intergenerational repeat length differences. It is these somatic expansions that lead to 
different length repeats in different cells of the same tissue. It has also been shown 
that the repeat length within individual patients increases with age, showing ongoing 
mitotic instability in DM (Martorell et a l, 1995). The degree of expansion correlates 
with the initial size of the repeat.
1.4 Origin of the myotonic dystrophy mutation
The DM (CTG)n repeat is polymorphic in the general population, ranging from 5-37 
repeats (Brunner et a l, 1992). In African, Asian, European, Japanese and Native 
American populations a trimodal distribution of these normal sized repeats has been 
reported. (CTG)5 repeats form the first mode and are the most frequently occurring in 
European populations (Brunner et a l, 1992; Davies et a l, 1992). The second mode 
occurs most frequently in non-European populations and consists of repeats ranging 
in size from 11-15 (Davies et a l, 1992; Watkins et a l, 1995; Zerylnick et a l, 1995). 
Alleles with repeats greater than 19 form the third mode (Watkins et a l, 1995; 
Zerylnick et a l, 1995).
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The mutation responsible for DM has been found to be in complete linkage 
disequilibrium with an Alu element insertion/deletion (+/-) polymorphism. This 
suggests that DM stems from one, or possibly a few, ancestral mutations (Mahadevan 
et al., 1993b). Imbert et al. (1993) proposed a mulitistep model of evolution for the 
repeat and the origin of DM mutations. The linkage disequilibrium between normal 
alleles at the repeat and the nearby Alu (+/-) element was analysed and the major 
(CTG)5 allele and the large alleles (CTG)>]9 were found to show the same linkage
disequilibrium as the DM mutation chromosomes. They are all in linkage 
disequilibrium with the Alu (+) allele and alleles with 11-13 repeats are associated 
with the Alu (-) allele. This suggests that chromosomes with more than 19 repeats are 
derived from the (CTG)5 allele by a small number of events. The DM mutation 
chromosomes are then derived from a pool of alleles with 20-30 repeats. High 
resolution genetic analysis of the DM locus using PCR based assays of 9 
polymorphisms was performed and four main haplotypes were observed (A-D) 
(Neville et al., 1994). Haplotype A is Alu (+) whereas haplotypes B-D are Alu (-). 
DM is in complete association with haplotype A, the most common haplotype in the 
normal population. Haplotype A in the normal population is associated with 5-37 
(CTG)n repeats whereas haplotypes B-D are associated with only 11-14 repeats.
Again these results indicate that (CTG)2q 3q alleles on haplotype A act as ancestors for 
alleles with larger disease causing repeats. Neville et al. (1994) therefore proposed 
that the DM mutation occurred on the background of a particular haplotype (A) in 
which the (CTG)n repeat became unstable and predisposed to amplification. To test
this hypothesis the (CTG)n repeat distributions of 2 populations with a low incidence 
of DM and 2 populations with a high incidence of DM were examined (Rubinsztein et 
al., 1994). It was determined that populations with a low frequency of DM have fewer 
alleles with greater than 19 repeats, suggesting that large normal alleles are indeed a 
reservoir for the creation of new DM mutants. No repeats of less than 5 were detected 
and it was suggested that this may be due to selection against smaller alleles or that 
chromosomes with 5 repeats may mutate to larger expansions most of the time, if they 
mutate at all.
Krahe et al. (1995b) conducted a detailed haplotype analysis of the DM region of a 
Nigerian DM family. Affected members of the family each had one DM allele with an 
expanded (CTG)n repeat. However, there was dissociation of the allele from other 
alleles of the putative predisposing haplotype suggesting that the repeat expansion in 
this family was caused by an independent mutational event and thus refutes the 
hypothesis that a single haplotype predisposes to repeat expansion. However, this 
study supports the theory that an expanded (CTG)n repeat is required for DM to occur.
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The association between normal alleles at the (CTG)n repeat and two nearby 
polymorphisms (the Alu and (DMPK) (G/T) intron 9/H infl polymorphisms) in South 
African negroids has been analysed (Goldman et a l, 1995). No cases of DM have 
ever been described in this population and repeats > 19 are extremely rare. As well as 
finding the haplotypes seen in Caucasoids and Japanese other haplotypes not 
previously seen were observed. Goldman et a l (1995) suggest that only a small 
number of these “African” chromosomes were present in the progenitors of non- 
African peoples and that the rare mutations occurred after the migration from Africa.
The fact that DM, a disease which normally decreases reproductive fitness within a 
few generations, has been maintained in the population is very interesting. Carey et a l 
(1994) report on the distortion of the ratio of DM to normal alleles being transmitted to 
the next generation. They suggest that healthy male individuals heterozygous for DM 
alleles, in the normal size range, preferentially pass on alleles of greater than 19 
repeats, allowing potential DM mutations to be replenished in the population. A 
second group have also concluded that meiotic drive is responsible for maintaining the 
level of DM alleles in the population (Gennarelli et a l , 1994). However, it has been 
suggested that these results were not statistically valid and that the observed 
segregation distortion may be an artefact of testing multiple hypotheses from the same 
data (Hurst et a l, 1995). A simpler analysis that scored the alleles of an individual as 
either long or short and did not specifically look at alleles with greater than 19 repeats 
concluded that there is preferential transmission of the longer allele during female 
meiosis but not during male meiosis (Chakraborty et a l, 1996). In support of these 
results a study that analysed single sperm from 3 males who were heterozygous at the 
DM locus and had one allele larger than and one allele smaller than 19 repeats found 
no evidence of meiotic segregation distortion (Leeflang et a l, 1996).
1.5  Effects of (CTG)n Repeat
At the time of starting this project 7 other diseases were known to be caused by trinucleotide 
repeat instability; Kennedy’s disease (spinal and bulbar muscular atrophy, SBMA), fragile X 
syndrome (FRAXA), Huntington’s disease (HD), spinocerebellar ataxia, types 1 and 3 
(SCA1 and SCA3), FRAXE mental retardation and Haw-River Syndrome (dentatorubral 
pallidoluysian atrophy, DRPLA) (Kawaguchi et a l, 1994; Knight et a l,  1993; Koide et a l, 
1994; La Spada et a l, 1991; MacDonald et a l, 1993; Orr et a l, 1993; Verkerk et a l, 1991). 
Friedreich’s ataxia (FA), SCA2, SCA6 and SCA7 have since been added to this list 
(Campuzano et a l, 1996; David et a l, 1997; Imbert et a l,  1996; Zhuchenko et a l, 1997). In 
all these examples different pathophysiological mechanisms to those underlying DM have 
been invoked. FRAXA, FRAXE (CCG repeats) and FA (GAA repeat) are due to diminished
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expression of their gene products and are recessive in nature (Campuzano et a l , 1996; 
Pieretti et al., 1991). The other disorders arise through expansions of CAG trinucleotides 
encoding polyglutamine tracts in translated exonic regions of their genes, with an associated 
gain of function, potentially as a result of altered protein conformations (Trottier et a l , 
1995). Given the location of the repeat in the 3’-UTR of DMPK and the autosomally 
dominant inheritance, it seems likely that a different mechanism underlies the 
pathophysiology associated with DM.
1.5.1 DNA Effects
Expanded CTG repeats have been shown to form the strongest known natural nucleosome 
positioning elements (Wang and Griffith, 1995). The efficiency of the nucleosome 
formation was seen to increase with the size of the repeat. This suggests that expanded 
CTG blocks alter local chromatin structure which in turn affects the expression of DMPK 
and other neighbouring genes. Further evidence for repeat expansion altering chromatin 
structure came from studies in muscle nuclei of 3 unrelated DM patients with large 
expansions. They were shown to exhibit DNase I resistance and inaccessibility to 
nucleases on the expanded allele at the normally hypersensitive site adjacent to the repeat 
(Otten and Tapscott, 1995). Stabilisation of the nucleosome structure may account for the 
loss of DNase I hypersensitivity with concomitant repression of transcription through the 
region. However, the loss of hypersensitive sites may be due to the binding of other 
protein factors to the region as a result of repeat expansion.
The possibility of DMPK being an imprinted gene is unlikely given the lack of methylation 
differences of CpG islands within DMPK between paternally and maternally derived alleles 
in congenital and adult onset patients (Shaw et a l, 1993a). However, a recent report 
indicates that at least in congenital patients, increased methylation occurs on the 5’ side of 
the (CTG)n repeat on the DM allele and that this increased methylation leads to a decrease in 
binding of Spl to a consensus binding site (Steinbach et a l, 1998).
1.5.2 RNA and Protein Effects
As the expanded triplet repeat occurs in the 3’-UTR of the DMPK gene it cannot 
directly affect protein sequence. However, several possible mechanisms by which it 
affects DMPK gene expression have been suggested (Whiting et a l, 1995). These 
include:
(a) alteration in steady-state levels of DMPK expression.
(b) interference with normal splicing patterns for DMPK RNA.
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(c) interruption of normal regulatory role of DMPK transcripts.
(d) change in efficiency of translation.
When this project was initiated, conflicting data concerning the effect of the mutation 
on mRNA and protein levels had been published. Tissues from adult myotonic 
dystrophy patients were analysed by quantitative RT-PCR and radioimmunassay and 
this showed decreased levels of mRNA and protein expression implying that reduction 
in DMPK leads to the disease by disruption of signal transduction and amplification 
pathways (Fu et a l, 1993). Carango et a l (1993) also reported reduction in both the 
synthesis and the processing of DMPK mRNA. However, Sabourin et a l (1993) 
showed that DMPK steady state levels were markedly increased in congenital DM 
tissues and it was demonstrated that increases are due to elevated levels of transcripts 
derived from mutant DMPK alleles. These conflicting results may be due to 
differences in the tissues studied. Adult tissues were used by 2 groups (Carango et 
a l, 1993; Fu et a l, 1993) whereas cells and tissues from severely affected neonates 
were used by the third (Sabourin et a l, 1993). Congenital cases are known to have 
different symptoms to adult onset patients, for example, adults tend to be myotonic 
whereas infants tend to be hypotonic. The control tissues also differed between the 
two groups, one using tissues from patients with neurologic diseases (Fu et a l, 1993) 
and the another using mRNAs from healthy adults and foetal tissues (Sabourin et a l,
1993). Different molecular techniques were used in the studies, adding to the 
difficulties in directly comparing the results.
More recently, the allele-specific expression of DMPK has been investigated and shown 
not to be affected at the transcriptional level, but rather at the processing and maturation 
level (Krahe et a l, 1995a). The accumulation of transcripts from both normal and 
expanded alleles in patient muscle were compared with normal and myopathic controls 
(Wang et a l, 1995). Only a small decrease of DMPK RNA in the total RNA pool from 
muscle was found and this was not disease specific, as the myopathic controls showed a 
similar decrease. However, dramatic decreases of both mutant and normal DMPK poly 
(A)+ RNA were observed and this was disease specific. The authors speculate that normal 
and expanded DMPK genes are transcribed in patient muscle, but RNA with an abnormal 
expansion has a dominant effect on RNA metabolism preventing the accumulation of 
poly(A)+ RNA. The intracellular localisation of transcripts from the DMPK gene in 
fibroblasts and muscle biopsies from DM patients and normal controls was determined 
using a fluorochrome-conjugated probe which hybridised specifically to the (CTG)n repeat 
expansion. No significant difference in the cytoplasmic location of the DMPK mRNA was 
observed (Taneja et a l, 1995). However, the probe detected transcripts as bright foci in 
the nuclei of DM patient fibroblasts and muscle but not in samples from normal controls.
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Using a probe that hybridised to the 5’ end of the DMPK gene, and would therefore detect 
all DMPK sequences, as well as the expansion specific probe it was shown that focal 
accumulation of post transcriptional RNA only occurs with transcripts from the affected 
allele. In the steady-state, nuclear export from the affected allele does not appear to be 
significantly suppressed, as RNA containing the repeat is present in the cytoplasm at a 
level similar to that of normal RNA. However, post transcriptional foci may inhibit other 
nuclear functions indirectly. It is now believed that the earlier contradictory reports were 
due to the use of different RNA extraction methods. Some methods remove only 
cytoplasmic DNA which results in a decrease in the number of DMPK transcripts 
recovered, whereas if both nuclear and cytoplasmic RNA are analysed an increase in the 
number of DMPK transcripts is detected, due to the their accumulation in the nuclei. More 
recent theories on the effect of the (CTG)n repeat expansion at the RNA level, including the 
identification of CUG binding proteins are discussed in section 7.6.2.
Biochemical and histochemical studies have suggested that a 53 kDa DMPK product is 
localised at sites of cell-cell contacts in neuromuscular tissues, in particular at neuromuscular 
and myotendinous junctions of human and rodent skeletal muscles and intercalated disks in 
cardiac muscle. This indicates that DMPK probably plays a specialised role in intercellular 
communication in striated muscle. It is possible that defects in communication could lead to 
muscle atrophy, myotonia and heart failure (Van der Ven et a l, 1993). A similar sized 
protein (54 kDa) that is recognised by DMPK antiserum has recently been characterised and 
shown to display a serine/threonine kinase activity in the heart and tyrosine kinase activity in 
the skeletal muscle (Etongue-Mayer et a l, 1998). As the predicted molecular weight of 
DMPK is approximately 70 kDa it is possible that this protein is a cross-reacting kinase 
species and unrelated to DMPK. It has also been demonstrated that DMPK knockout mice 
still express this 54 kDa protein which supports the theory that this protein is not DMPK 
(Jansen et a l, 1996). A monoclonal antibody has now been used to identify a 64 kDa protein 
in type 1 skeletal muscle localised to the triadic region, and a 79 kDa protein in brain (Dunne 
et a l, 1996). Comparisons of proteolytic digests of the muscle protein and recombinant 
DMPK show similar mobilities, indicating that the 64 kDa protein is likely to be a bonafide 
isoform. In severely affected DM patients redistribution of this isoform to the peripheral 
sarcoplasmic masses, consistent with previously reported altered localisation and expression 
of transcripts has been seen (Sabourin et a l, 1993).
A new panel of monoclonal antibodies has recently been used in an attempt to determine the 
true size of the DMPK protein and its localisation within tissues (Pham et a l, 1998). This 
study identified 2 isoforms of DMPK that have molecular weights of 72 and 80 kDa. The 72 
kDa isoform but not the 80 kDa isoform was detected in all tissues tested. Previous studies 
have also detected doublets of approximately these molecular weights (Maeda et a l, 1995; 
Whiting et a l, 1995). The presence of DMPK in the intercalated disks of cardiac muscle but
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not in the neuromuscular junctions of skeletal muscle was confirmed. A 55 kDa protein was 
detected in skeletal muscle by 2 of the 12 monoclonal antibodies but it was not thought to be 
an alternatively spliced form of DMPK as it was not detected by antibodies raised against the 
coil domain. To date no isoforms of DMPK lacking the coil domain have been reported (Fu 
et a l, 1993; Jansen et a l, 1992; Mahadevan et a l, 1993a).
1.6 Other Genes in the Region of the (CTG)n Repeat
The complexity of the clinical phenotype of DM along with the initial contradictory 
data concerning the effects of (CTG)n repeat expansion on the expression of DMPK 
and the alteration in chromatin structure surrounding the repeat, led researchers to look 
for genes neighbouring DMPK.
1.6.1 DM-N9 (59 gene)
DM-N9 is a murine gene that is located, with its 3’ end, 1.1 kb upstream of the Dmpk 
gene (Jansen et a l, 1995; Jansen et a l, 1992). This 7 kb gene contains 5 exons and 
codes for a 650 amino acid protein. Two regions within this gene show significant 
homology to WD repeats, which are highly conserved amino acid sequences found in 
a family of proteins involved in signal transduction of cell regulatory functions, 
although the actual function of DM-N9 is, as yet, unknown. DM-N9 is expressed 
strongly in brain and testis and could therefore be a candidate for involvement in 
mental and testicular symptoms in severe cases of DM. The human homologue to DM- 
N9 (59) has been identified and shown to be expressed in heart, brain, liver, kidney, 
spleen and testis (Shaw et a l, 1993b).
1.6.2 DMAHPISixd
The presence of an extensive CpG island at the 3’ end of DMPK indicated that a novel 
gene lay immediately downstream of the (CTG)n repeat. This region was sequenced 
and murine and human sequences were found to share 86% identity at the putative 
amino acid level (Boucher et a l, 1995). The (CTG)nrepeat was shown to be within a
3.5 kb CpG island. Sequence data indicated that the gene encoded a homeodomain 
protein and was therefore called DM locus-associated homeodomain protein 
(DMAHP). DMAHP has now been identified as being one of a growing number of 
members of the sine oculis related homeobox (Six) subfamily of genes (section 1.8), 
so called because the original member to be identified was the Drosophila eye 
development gene sine oculis (so). Therefore, when a murine cDNA DMAHP
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homologue was identified it was named Six5 (Kawakami et a l , 1996b). All members 
of the Six subfamily share a region of a high sequence homology which encodes a 60 
amino acid homeodomain and immediately upstream of the homeodomain a domain 
unique to the Six subfamily, the Six domain which is approximately 116 amino acids. 
RT-PCR on mRNA preparations showed that DMAHP is expressed in many tissues 
including skeletal muscle, fibroblasts, lymphocytes, heart and brain in both normal 
adults and DM patients. An enhancer element that controls the expression of DMAHP 
was recently identified within the DNase I hypersensitive site adjacent to the (CTG)n 
repeat (section 1.5.1). A 2 to 4 fold reduction in the steady state transcript levels of 
DMAHP from the expanded allele compared to the normal allele of DM patient’s, was 
seen in fibroblasts and skeletal muscle cells implying that expansion of the (CTG)n 
repeat does indeed alter local chromatin structure in such a way as to reduce 
expression of DMAHP, which in turn is involved in the pathogenesis of DM (Klesert 
et a l, 1997). A second group have also reported a reduction in the levels of DMAHP 
mRNA synthesis from the DM allele in primary myoblast cultures and postmortem 
muscle, heart and brain tissues from DM patients (Thornton et a l,  1997). However, a 
contradictory report indicated that levels of DMAHP expression were unchanged in 
cell lines from DM patients (Hamshere et a l, 1997). Gene expression patterns can 
differ between tissues and myoblast cultures and therefore gene expression data from 
cell lines may not be representative of what occurs in human tissue. This is partially 
due to the lack of innervation in cell lines. However, the dynamics of the (CTG)n 
repeat are also altered in cultured lymphoblastoid cell lines from DM patients and this 
may affect the expression of genes that are altered by the repeat expansion (Ashizawa 
et a l, 1996). The structure of the DM locus indicating DMAHP, DMPK and 59 is 
illustrated in figure 1.1.
1.6.2.1 Genomic Structure of DMAHP
Two alternative transcripts of human DMAHP were identified by RT-PCR (Boucher 
et a l, 1995). One isoform contains exons A, B and C and the second isoform 
contains only exons A and C and has a different reading frame in exon C (figure 1.2). 
The Six box and homeobox are situated in exon A and therefore encoded by both 
isoforms. To date only the A-B-C isoform has been identified in mouse (Heath et a l, 
1997). The A-B-C isoform is predicted to encode a protein of about 82 kDa and the A- 
C isoform a protein of about 36 kDa. DMAHP lacks a consensus TATA box upstream 
of the open reading frame and consistent with this finding multiple transcription 
initiation sites have been identified in both the human and mouse genes (Klesert et a l, 
1997; Murakami et a l,  1998). The human transcriptional start sites cover a 50-70 bp
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Figure 1.1 Genomic structure of the DM region
A schematic diagram of the DM region showing the relative positions of 59, D M PK  
and DMAHP.  The extensive CpG island, the (CTG)n repeat and the 1 kb Alu
insertion/deletion polymorphism are indicated.
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region and are all within 400 bp of the coding region and the mouse sites are in an 
equivalent position in the mouse gene. Transient transfection assays were used to 
identify regulatory regions in the mouse gene promoter region. Positive elements were 
identified between -434 and -344, -317 and-270 and -137 and -97 and negative 
elements were identified between -344 and -317 and -224 and -178. Gel retardation 
assays using nuclear extracts from P I9 cells along with super-shift assays using Spl 
and Sp3 antibodies confirmed that the 3 positive regulatory regions and 1 of the 
negative regulatory regions contained Spl/Sp3 binding elements. These Spl/Sp3 
binding sites are conserved between mouse and human and the enhancer element in 
the human gene (section 1.6.2) was also shown to be active in mouse (Murakami et 
a l,  1998).
1.7 Homeobox Genes
Transcription factors are proteins that bind to DNA in a sequence-specific manner and 
interact with other components of the transcriptional machinery to enhance or inhibit 
transcription of specific target genes. The majority of transcription factors contain a 
DNA binding domain and a transcriptional activation domain (Engelkamp and van 
Heyningen, 1996). Homeobox genes encode a conserved domain of about 60 amino 
acids (the homeodomain) that can bind to DNA and a transcriptional 
activation/repression domain, thus acting as transcription factors. Recently, the 
Drosophila homeodomain protein bicoid, that transcriptionally activates target genes 
by binding to DNA has been shown to act as a repressor of translation by binding to 
the 3’-UTR of the caudal mRNA, thus blocking the initiation of caudal translation 
(Dubnau and Struhl, 1996). Therefore, homeodomain proteins can bind to both DNA 
and RNA.
1.7.1 Structure of the Homeodomain
The structures of several homeodomain proteins have been determined using nuclear 
magnetic resonance (NMR) spectroscopy. The homeodomain of the Drosophila 
Antennapedia homeodomain was expressed in a T7 expression vector in E.coli and 
purified to homogeneity (Muller et a l, 1988). NMR spectroscopy of free 
Antennapedia homeodomain in solution demonstrated that the homeodomain consists 
of a short N-terminal arm of 6 amino acids, and 4 helices (Billeter et a l, 1993; Otting 
et a l, 1988; Qian et a l, 1989). Helices I and II are arranged antiparallel to each other 
and are connected by a hexapeptide loop. Helices II and III are connected by a 
tripeptide, that forms a P-tum, constituting a helix-tum-helix motif and helix IV
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immediately follows helix III, separated only by a slight bend. Together, helices III 
and IV are aligned perpendicular to the first two helices. The homeodomain has a 
compact globular structure from which helix IV protrudes and helices I, II and III are 
held together by a core of 11 amino acids (figure 1.3). Later NMR studies of 
Drosophila engrailed and the yeast mating type determinant MATa2 homeodomain 
proteins, in their DNA complexes, indicated that they too have a similar structure with 
the exception that the third and fourth helices form a single helical region (Kissinger et 
a l , 1990; Wolberger et a l, 1991).
1.7.2 DNA Binding Specificity of the Homeodomain
Based on comparisons with bacteriophage repressor proteins, the second a-helix of 
the helix-tum-helix motif (helix III of the homeodomain) was hypothesised to be the 
recognition helix, responsible for determining the DNA binding specificity of 
homeodomain proteins. Mutagenic analysis was used to determine which amino acids 
of this putative recognition helix are used to discriminate between different DNA 
sequences (Hanes and Brent, 1989). When the recognition helix of bicoid was 
exchanged for that of Antennapedia the protein had the binding specificity of 
Antennapedia. Further analysis determined that exchanging just the ninth amino acid 
in the recognition helix (amino acid 50 of the homeodomain) resulted in an identical 
change in binding specificity. DNA-protein binding experiments using the Drosophila 
homeodomain protein paired containing point mutations in the homeodomain also lead 
to the conclusion that amino acid 50 of the homeodomain is responsible for much of 
the protein’s binding specificity (Treisman et a l, 1989). These experiments 
demonstrated the importance of amino acid 50 in determining DNA binding 
specificity.
NMR spectroscopy showed that Antennapedia binds to a 14 bp duplex as a monomer 
(Otting et a l, 1990). Helices in  and IV lie in the major groove of the DNA and the N- 
terminal arm makes specific contacts with bases in the minor groove and the loop 
between helices I and II interacts with the DNA back bone on the other side of the 
major groove. In vitro analysis has been utilised to identify the binding specificity of 
many homeodomain proteins (table 1.2). The majority of the preferred binding sites 
contain the core sequence ATTA. Bases of this core sequence have been shown to 
interact, in the major groove, with amino acids 47 (isoleucine) and 51 (asparagine), 
which are in the recognition helix, and in the minor groove with amino acids 3 
(arginine) and 5 (arginine), which are in the N-terminal arm, of Antennapedia and 
engrailed homeodomains (Billeter et a l, 1993; Kissinger et a l, 1990; Otting et a l, 
1990). Yeast MATa2 differs from Drosophila Antennapedia and engrailed at amino
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Figure 1.3 Structure of the Antennapedia homeodomain as determined by 
NMR spectroscopy
A schematic diagram of the homeodomain of the Drosophila  Antennapedia 
protein. The a-helical regions (I-IV) are represented as cylinders. The positions 
of the amino acids mentioned in the text are indicated. Adapted from Latchman 
(1998).
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acid positions 3, 5 and 47 and binds to the sequence GTAA rather than the classical 
core sequence which emphasises the importance of these amino acids with regard to 
binding specificity (Wolberger et a l , 1991). For homeodomain proteins that bind to 
the ATT A core sequence the amino acid at position 50 of the homeodomain (discussed 
above) is important in defining the 2 bases prior to the ATT A core. Homeodomain 
proteins that bind to GGATTA with a high affinity contain a lysine at position 50, for 
example bicoid and fushi tarazu. A consensus protein sequence has been derived from 
a compilation of 346 homeodomain sequences. Seven positions in this sequence are 
conserved in more than 95% of the 346 sequences, these include amino acids: 5 
(arginine), 51 (asparagine) and 53 (arginine) that are directly involved in DNA binding 
(Gehring et a l, 1994). The analysis of the crystal structures of several homeodomain- 
DNA complexes has identified clear patterns between the amino acid at a particular 
position in the homeodomain and the DNA base pair with which it interacts.
However, these patterns are only true for very related proteins, because recognition 
domains have distinct structures and therefore bind to the DNA at different angles.
Protein Consensus sequence R eference
Antennapedia CATTA (Muller et a l, 1988)
bicoid GGGATTAGA (Driever and Nusslein-Volhard, 
1989)
MATa2 ACATGTAATT (Wolberger et a l,  1991)
Ultrabithorax CCATTAA (Ekker er a/., 1991)
AREC3/Six4 GGTGTCAGGTTGC (Suzuki-Yagawa et a l, 1992)
Table 1.2 Examples of homeodomain binding sites
ATTA consensus site is underlined when present
1.7.3 Cooperative Binding of Homeodomains
Highly diverged homeodomain proteins that mediate very different transcriptional 
processes have been shown to bind, in vitro, to identical DNA sequences (Hoey and 
Levine, 1988). As mentioned in section 1.7.2, the majority of homeodomains bind to 
the core sequence ATTA. Therefore, other mechanisms are required to achieve further 
DNA binding specificity. Several classes of homeodomain proteins contain a second
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DNA binding domain and both recognition sequences are required for specific 
binding.
1.7.3.1 The Paired Domain
Several homeodomain proteins, including the Drosophila proteins paired and 
gooseberry (Bopp et al., 1986) and the mammalian Pax proteins which have a critical 
role in the development of the nervous system (Kessel and Gruss, 1990) have been 
shown to contain a homeodomain characterised by a serine at position 50 (most 
homeodomains have a lysine or a glutamine at this position) and a second 128 amino 
acid DNA binding domain, known as the paired domain. Both the paired domain and 
the characteristic homeodomain have a specific binding activity of their own and many 
DNA binding proteins contain only the paired domain or the homeodomain. However, 
when combined with a homeodomain, the paired domain increases binding specificity 
and the distance between the 2 DNA binding domains adds to this specificity 
(Treisman et al., 1991).
1.7.3.2 The POU Domain
A DNA binding domain of between 67 and 70 amino acids, the POU domain is found 
in several homeodomain proteins and is separated from the homeodomain by a 15-27 
amino acid variable spacer region (Herr et a l, 1988). To date the POU domain has 
only been found in conjunction with a homeodomain and together they recognise an 8 
bp A/T rich DNA sequence, which differs between different members of the family. 
This octamer does not contain the ATTA core sequence. Interestingly, amino acid 50 
of the homeodomain of the POU domain containing protein Pit-1, does not have an 
important role in determining the binding specificity of this protein (Ingraham et al., 
1990). High affinity binding required the presence of both binding domains. The 
homeodomain of mammalian Oct-1 was shown by kinetic analysis, using quantitative 
gel retardation assays to have a very rapid association/dissociation constant and that 
the POU domain increases the binding affinity of the homeodomain by increasing the 
half life of the retarded complex (Verrijzer et al., 1992). The POU domain alone also 
bound to the 8 bp DNA sequence, but with low affinity and it was concluded that high 
affinity, sequence specific DNA binding requires both domains.
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1.7.3.3 The Zinc-Finger Motif
A third method of enhancing binding specificity is likely to have been due to a 
recombination event between a developmental gene containing one or more 
homeodomains and another containing one or more zinc-finger motifs. ATBF-1 
contains 4 homeodomains and 17 zinc fingers (Morinaga et al., 1991). Of the 4 
homeodomains 3 have a glutamine at position 50 of the homeodomain and 1 has an 
arginine. The homeodomain containing the arginine at position 50 is preceded by a 
POU domain. Together these factors greatly increase the binding specificity of the 
protein as many DNA sequences are required to be present in a specific order and a 
specific distance apart.
1.7.3.4 Dimerisation
Although homeodomain proteins will bind as monomers in vitro, several examples are 
now known where the affinity of one protein for a particular DNA sequence is greatly 
enhanced in the presence of the binding of a second protein. The homeodomain of the 
paired class (described above) and the paired-like class (that lack the characteristic 
serine at position 50 and are not associated with a Paired domain, but contain 
sequences similar to the paired homeodomain) can bind as homodimers or 
heterodimers to palindromic DNA sequences (Wilson et a l, 1993). The homeodomain 
of Drosophila paired was shown to bind as a monomer to TAATTG, but as a dimer 
and with stronger affinity to TAATTGATTA. The dimer is formed by the direct 
interaction of the 2 homeodomains which is made possible by the occurrence of a 20° 
bend in the DNA. Further analysis using other paired and paired-like homeodomains 
demonstrated the importance of the amino acid at position 50 in determining the 
spacing between the 2 half sites. Homeodomains with a glutamine at position 50 
preferred 3 bp and those with a lysine also preferred 3 bp between the half sites but 
had a more stringent requirement for the identity of the base pairs. Heterodimers were 
also detected between paired and gooseberry which are known to be expressed at the 
same time in developing Drosophila cells.
The DNA binding specificity of the yeast homeodomain protein, MATa2, is enhanced 
by its association with either the homeodomain protein MATal or the non- 
homeodomain protein MCM1 (Goutte and Johnson, 1988; Goutte and Johnson, 1993; 
Mead et al., 1996). The 2 heterodimers bind to different DNA sequences. The 
cooperative binding of a l/a2  relies on the 21-residue C-terminal tail of a2  binding to 
the al homeodomain. This alters the conformation of a2  which results in the DNA to
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which the heterodimer binds, bending 60°. When the a2 homeodomain binds alone, it 
results in a negligible bend in the DNA.
The homeotic genes {Horn) of Drosophila and their mammalian homologues the Hox 
genes are essential for the correct development of diverse organisms. In vitro 
Drosophila Horn proteins Antennapedia and Ultrabithorax bind to the same 6 bp 
consensus sequence. However, the 2 proteins control different developmental 
pathways. The majority of Hom/Hox proteins have a short conserved stretch of amino 
acids to the N-terminal side of their homeodomains, the hexapeptide (Mann and Chan,
1996). Sequence comparison with Hox/Hom proteins between and within species 
suggests that the hexapeptide has evolved with the homeodomain. Members of the 
same species may share only 4 amino acids, whereas proteins from different species 
may share up to 12 amino acids in this region. Drosophila, extradenticle and 
mammalian PBX proteins (collectively known as the PBC family) interact with the 
hexapeptide and alter the DNA binding specificity of the homeodomain thus increasing 
the differences in binding specificity between members of the Hom/Hox family of 
homeodomain proteins.
1.7.3.5 DNA Bending Proteins
To allow transcription factors to interact with each other cofactors are often required to 
interact indirectly by binding to the DNA and bending it to enable other DNA bound 
proteins to interact with each other. The lymphoid enhancer-binding factor (LEF-1) is 
an example of a sequence specific DNA binding factor that can induce a sharp bend in 
the DNA which allows the interaction of 3 transcription factors that bind at sites 
flanking the LEF-1 sites (Love e ta l,  1995).
1.7.4 Homeobox Genes and Disease
Recently, several human diseases have been shown to be linked to mutations in 
homeobox genes. Mammalian paired family Pax genes have been implicated in 
pathways involved in development (reviewed in Gruss and Walther, 1992) and 
mutations in the human homologues of the mouse Pax genes have been identified in a 
range of human diseases affecting the nervous system. Waardenburg syndrome I an 
autosomal dominant disorder which results in a combination of pigmentary 
disturbances, lateral displacement of the inner canthus of each eye, deafness and 
mental retardation was linked to PAX3. Mutations in the PAX3 gene have now been 
identified in several families (Baldwin et a l, 1992; Tassabehji et al., 1992). Pax6 and
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its Drosophila homologue (eyeless) are known to regulate genes involved eye 
development (reviewed in Oliver and Gruss, 1997). Mutations in the mouse Pax6 
gene lead to a small eye phenotype and in the human homologue {PAX6) cause 
aniridia (a complete or partial absence of the iris), Peters’ anomaly (malformations of 
the anterior chamber) or keratitis (inflammation of the cornea) (Hanson and van 
Heyningen, 1995; Hanson et al., 1993; Mirzayans et al., 1995; Ton et al., 1991).
Homozygous mutations in the human POU domain encoding gene PIT1 result in 
combined pituitary hormone deficiency which leads to irreversible mental and growth 
retardation due to a deficiency in thyroid stimulating hormone, growth hormone and 
prolactin (Andersen and Rosenfeld, 1994). X-linked mixed deafness has been shown 
to be caused by mutations in the POU3F4 gene. Interestingly, mutations have been 
found between 15 and 400 kb upstream of the gene in affected individuals (De Kok et 
a l, 1995). This indicates that mutations in the regulatory elements of POU3F4 are 
responsible for the disease.
Human HOX genes are arranged in 4 genomic clusters of approximately 100 kb in 
length. Each cluster contains several HOX genes arranged in an homologous order 
and genes belong to any one of 13 homology groups. These genes control the identity 
of the various regions along the body axis. 3’ HOX genes are expressed early in 
development and the more 5’ a gene is in a cluster the later it is expressed (Boncinelli,
1997). Surprisingly until very recently no severe developmental phenotypes had been 
linked to these important genes (Engelkamp and van Heyningen, 1996). However, 
several disorders are now known to be caused by mutations in HOX genes. In 2 
unrelated families, synpolydactyly has been shown to be linked to a duplication of 9 
residues in a polyalanine tract in the intron of the HOX gene HOXD13 (Akarsu et a l, 
1996). A mutation that converts a highly conserved tryptophan residue in the 
homeodomain of HOXA13 to a stop codon causing the production of a truncated 
protein leads to hand-foot-genital syndrome (Mortlock and Innis, 1997). The number 
of diseases associated with homeobox genes is rapidly growing and therefore the 
study of these transcription factors has become increasingly important.
1.8 The Six Subfamily of Homeobox Genes
At the time this project was instigated 5 mammalian members and 1 Drosophila 
member of this subfamily had been identified. Recently a sixth mammalian gene 
(Optx2) and its Drosophila homologue (optix) were reported (Toy et al., 1998) and a 
third Drosophila gene is currently being analysed (Graham Hamilton, personal 
communication). Six subfamily genes have now been identified in chicken, zebrafish 
and medaka (Bovolenta et a l, 1996; Bovolenta et al., 1998; Loosli et a l, 1997; Seo et
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a l, 1998a; Seo et a l, 1998c; Toy et a l, 1998). These recent findings are discussed in 
section 7.3.
1.8.1 sine oculis
Drosophila sine oculis {so) was the first member of the Six subfamily to be identified 
(Cheyette et a l, 1994; Serikaku and O'Tousa, 1994). It is expressed in the optic lobe 
prior to its invagination from the embryonic ectoderm and is essential for eye 
development. Full length cDNAs were isolated from 4-8 hour embryonic and third 
instar eye disc cDNA libraries and the gene shown to encode a 2.8 kb transcript which 
contains an open reading frame that is predicted to encode a 416 amino acid 
polypeptide, so contains 8 exons, including an alternatively spliced untranslated first 
exon and the homeodomain is encoded by exons 3 ,4  and 5. The homeodomain of so 
has diverged considerably from previously described homeodomains and shares only 
68% identity over the last 2 helices (which includes the recognition helix) with its 
closest homeodomain outside of the Six subfamily, the homeodomain of the MAT1-P 
protein from the fission yeast Schizosaccharomycespombe (Kelly et a l, 1988). 
Importantly, it lacks 2 highly conserved amino acids; arginine at position 5 and 
glutamine at position 12 of the homeodomain. Arginine at position 5 which is 
conserved in 97% of isolated homeodomains is known to contact base pairs in the 
ATTA core sequence and this indicates that so may bind to an alternative DNA 
sequence (Gehring et a l, 1994).
1.8.2 Mammalian Six Genes
Mouse Sixl and Six2 were the first of the mammalian Six genes to be identified and 
they were initially shown to be expressed during the development of the limb tendons 
and the head and body mesenchyme (Oliver et a l, 1995b). A third mammalian Six 
gene (Six3) was isolated from a mouse E14.5 brain cDNA library that was screened 
using an 800 bp fragment containing the homeobox of Sixl. Early expression of 
mouse Six3 is restricted to the anterior neural plate, with later expression in the 
ectoderm of the nasal cavity, the olfactory placode, Rathke’s pouch, the ventral 
forebrain including the optic recess, the hypothalamus and the optic vesicles (Oliver et 
a l, 1995a). Mouse AREC3 /Six4 transcripts were originally detected in skeletal 
muscle, heart, lung, kidney and brain (Kawakami et a l, 1996a). More recent 
developments in this field are discussed in section 7.3.
The 6 mammalian members of the Six subfamily and Drosophila so and optix are 
highly homologous in the Six domain and the homeodomain (figure 1.4). However
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Figure 1.4 Comparison of the predicted amino acid sequences of members of the Six 
subfamily
The homologous regions of the predicted mouse Six subfamily proteins (S ix l,  Six2, Six3, 
Optx2, Six4/AREC3 and Six5/Dmahp), Drosophila so and human DM AHP have been 
aligned. The homeodomain of Drosophila optix, minus the final amino acid, is also 
included (no further optix cDNA sequence is available). The arrowhead indicates the start 
of  the homeodomain and the asterisks indicate amino acids 5, 12 and 50 of the 
homeodomain. The residues corresponding to the 3 helices of the homeodomain are shown. 
The Six domain is contained within the region of homology upstream from the homeodomain. 
Conserved residues are highlighted in black and semi-conserved residues in grey. This figure 
was created using PILEUP from the GCG package on the UK Human Genome Mapping 
Project online computing service.
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outside of these 2 domains the structures of the proteins differ greatly. The 
mammalian members of this subfamily also differ from known homeodomains at 
amino acid positions 5 and 12 of the homeodomain. The amino acid at position 5 is a 
valine in DMAHP/Six5 and AREC3/Six4, a serine in Sixl, Six2 and so and a 
threonine in Six3, Optx2 and optix and the amino acid at position 12 is a serine in all 
members of the subfamily with the exception of Six3, Optx2 and optix in which it is a 
threonine (Boucher et a l, 1995; Cheyette et a l, 1994; Kawakami et a l, 1996a; Oliver 
et a l, 1995a; Oliver et a l, 1995b; Toy et a l, 1998). These 2 amino acids are likely to 
be very important with regard to the binding specificity of these proteins.
1.8.2.1 AREC3/Six4
DMAHP has a greater homology with AREC3/Six4 than with any other member of 
the Six subfamily. The amino acid sequence similarity is 70.3% in the Six domain and 
homeodomain. AREC3/Six4 was originally identified as one of the cell-type specific 
factors that binds to the Na+ K+ ATPase a l  subunit regulatory element (ARE) and was 
therefore named Na+ K+ ATPase a l  subunit regulatory element complex 3 (AREC3) 
(Suzuki-Yagawa et a l, 1992). Na+ K+ ATPase is the enzyme responsible for 
maintaining the Na+ and K+ gradients across the cell membrane and is composed of 2 
subunits a  and p. There are at least 3 isoforms of the a  subunit, a l ,  a2  and a3 and 
the a l  subunit is expressed in all tissues and is important for cellular homeostasis.
The ARE is a positive regulatory region situated from position -102 to -62 upstream of 
the transcription start site of the Na+ K+ ATPase a l  subunit gene (ATP1A1). The 
function of AREC3/Six4 is of particular interest as defects in Na+ and K+ gradients 
have been identified in DM patients (section 1.2).
DNase I footprinting and methylation experiments identified the binding site of 
AREC3/Six4 as GGTGTCAGGTTGC and a possible minimum sequence for binding 
as GGNGNCNGGTTGC (Suzuki-Yagawa et a l, 1992). A full length mouse 
AREC3/Six4 cDNA was obtained from a skeletal muscle cDNA library and used to 
construct GST-AREC3 recombinant fusion proteins containing different regions of the 
protein (Kawakami etal., 1996a). The abilities of these deletion constructs of GST- 
AREC3 to bind to the ARE were tested by gel retardation assays. It was concluded by 
competition assays that both the Six domain and the homeodomain were required for 
specific binding to GGTGTCAGGTTGC although the homeodomain alone bound 
specifically to some other unidentified region of the ARE. This is a similar situation to 
that found in the Paired and POU classes of homeodomain proteins in which the 
presence of 2 domains is required for specific DNA binding (section 1.7.3).
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1.9 Aims and General Strategy
DMAHP is a member of a subfamily of proteins that encode a homeodomain that has 
diverged considerably from other known homeodomains. However, many of the 
conserved residues that have been shown to interact with DNA are present although 
the conserved arginine at position 5, which when present in a homeodomain is known 
to contact the ATTA consensus sequence, is absent. This information along with 
reports that AREC3/Six4 is a cell-type specific factor that binds to the consensus 
sequence GGTGTCAGGTTGC within the ARE, indicates that DMAHP is a DNA and 
or RNA binding protein that regulates the expression of other genes.
It was decided to investigate the DNA binding properties of recombinant DMAHP 
fusion proteins and to initiate the identification of genes regulated by DMAHP. 
Therefore, the aims of the project were:
• To isolate a full length human DMAHP cDNA.
• To use a bacterial expression system to overexpress and affinity purify GST- 
fusion proteins containing the Six domain, the homeodomain and both domains 
together.
• To investigate the binding activities of these 3 fusion proteins by gel retardation 
assays using double stranded oligonucleotides representing putative DNA binding 
sites. (It was hypothesised that the Six domain would have DNA binding 
properties distinct from the homeodomain and that both domains would be 
required for specific DNA binding. Putative DNA binding sites were predicted 
from the known binding sites of AREC3/Six4 and classical homeodomain 
proteins).
• To develop and use a whole genome PCR based screen to identify DNA 
sequences to which DMAHP binds, as an initial stage in the identification of genes 
which it regulates.
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Chapter
2
Materials and Methods
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2.1 Materials
2.1.1 Bacterial Strains
The Escherichia coli bacterial strains used, are listed in table 2.1 along with their 
genotype and supplier.
S tra in G enotype S u p p lie r
DH5a F-, cp80d lac ZAM15, A (lac ZYA-argE), U169, deoR, 
rec A l, end A l ,  /w*ZR17(rK-,mK+), supE44, X', thi-1, 
gyrA96, rel A l.
Life
Technologies
Ltd.
Jm l09 recAl, end A l , gyrA96, thi, /zs<iR17(rK-,mK+), rel A l, 
supE44, A(lac-proAB), [F’, traD36, pro AB, 
tacIqZAM15]
Promega
MOS Blue end A l,  /wdR17(rK-,mK+), supE44,thi-l, gyr A96, rel A l ,  
lac, [F’praAB, /acIqZAM15, TnlO(tetr)], rec A l
Amersham
International
pic.
TOP 10 mrcA, A (mrrhsdRMS'mcr BC), F80D/ac ZAM15, A lac 
X74, deoR, recAl, ara D139, A (ara, leu), 1691, gal U, 
galK, I-, rps L, end A l ,  nupG, F"
Invitrogen
XL-Blue supE44, h sdR ll, thi-l, gyrA96, endAl, recAl, relAl 
lac FproAB+, M qZAM 15 Tni6> (Tetr)
Stratagene
Table 2.1 B acterial S trains
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2.1.2 Chemicals and Reagents
AnalaR and molecular biology grade chemicals were obtained from Merck Ltd. (BDH 
Laboratory Supplies) and Sigma Chemical Company Ltd, with the exception of the 
items in table 2.2.
S u p p lie r Chem icals and  reagents
BIO-RAD Kaleidoscope prestained standards, 30% (w/v) 
acrylamide/bis 29:1 (3.3% C) and 30% (w/v) 
acrylamide/bis 37.5:1 (2.6% C)
Boehringer Mannheim Fraction V, fatty acid free, BSA, agarose, IPTG, 
X-gal, PMSF, trizma base
Calbiochemica® Nonidet® P-40
Difco Laboratories Agar, Bacto® tryptone, Bacto® yeast extract 
(without amino acids)
Eastman Kodak Company Formamide
Fisher Scientific U.K. Ltd Acetic acid, boric acid, chloroform
Fluka Biochemica Guanidine hydrochloride
FMC BioProducts NuSieve agarose
Genetic Research Instrumentation Developer and fixer
Kodak Scientific Imaging Systems LMP agarose
ICN [a-32P] dCTP (3000 Ci/nmol) and [y-32P] ATP 
(3000 Ci/nmol)
Life Technologies Ltd 1 kb DNA ladder
Pharmacia Biotech Dextran sulphate, dNTPs, Ficoll®400, 
Glutathione, Glutathione Sepharose®4B, 
Phastgel™ Blue R, random hexamers, 
Sephadex® G-50 and Sephadex® G-25, 
poly[dI/dC].poly[dI/dC]
Premier Beverages Skimmed milk powder
Severn Biotech Ltd Acrylamide premix
Table 2.2 Chem icals and  Reagents
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in Ltd. Inoculating loops and 90 mm Petri 
:ientific and 15 ml and 50 ml Falcon Tubes
e (pMOS-DMAHP-ABC) and cosmid 
sr (Keith Johnson’s group).
rs were obtained from Boehringer 
j w  England Biolabs Ltd. Bacteriophage T4 
IAP were obtained from Promega. The 
vas obtained from Boehringer Mannheim. 
)tained from Sigma Chemical Company Ltd. 
ringer Mannheim, Promega and Perkin
2.1.6 Immunochemicals
Polyclonal goat anti-Schistosoma japonicum GST serum was obtained from 
Pharmacia Biotech and polyclonal donkey anti-goat IgGs conjugated with HRP from 
Serotec. Polyclonal rabbit anti-DMAHP 2 R254„ GST depleted serum was a gift from 
Catherine Winchester (Keith Johnson’s group). Polyclonal donkey anti-rabbit IgGs 
conjugated with HRP were obtained free of charge from SAPU.
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2.1.7 Kits
The following kits were used during the project (table 2.3).
S u p p lie r K it
Amersham International pic. ECL™ western blotting analysis system, pMOSBlue 
T-vector kit
Millipore Centricon 10 membrane units
Perkin Elmer ABI Prism™ Dye Terminator Cycle Sequencing 
Ready Reaction Kit
Promega pGEM® -T-Easy vector system
Scotlab Nucleon II genomic DNA preparation kit
Qiagen Plasmid DNA mini, midi and maxi kits, gel extraction 
DNA purification kit
Table 2.3 Kits
2.1.8 Membranes and Paper
Hybond™-N nylon membrane and Hybond™-N ECL nitrocellulose membranes were 
obtained from Amersham International pic. 3MM chromatography paper was supplied 
by Whatman and blot absorbent filter paper by BIO-RAD. Saran wrap was obtained 
from Dow.
2.1.9 Oligonucleotides
Oligonucleotides for both DNA sequencing and for use as DNA fragments in gel 
retardation assays were supplied by Genosys, Perkin Elmer and Cruachem.
Sequences are given in table 2.4.
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O ligonucleo tide Sequence 5 ’-3 ’
T7 T A AT ACGACTC ACT AT AGGG
T3 AATTAACCCTCACTAAAGGG
SP6 GATTTAGGTGACACTATAG
pGEXFl GGCGACCATCCTCCAAAATC
pGEXBl TTTTCACCGTCATCACCGAAAC
U-19mer GTTTTCCCAGTCACGACGT
DMAHPFB ATGTGCACCTCATCAACTCC
DMAHPRC TT AGTTCC AGCCCTGCTGAC
CBR005 AGGACCTGGGAGACGAGCAT
CBR0013 AGGAGGCTCAGTCGGAGG
KJDME2R GCAGGGCAAGATCATCCTCA
DMAHPF AGTGGACAAGTATCGACT
DMAHPRSEH GTCCAGCCGAAGTCCTGAGG
V-SU GATCGGACTTGCTACGGTAATCAG
TSP AATTGGACTTGCTACGGTAATCAG
V-NL CTGATTACCGTAGCAAGTCC
ARE1 GATCCCCGGTGTCAGGTTGCTCCG
GTAACGGTGACGTGCG
ARE2 A ATTCGC ACGTC ACCGTT ACCGGAG 
CAACCTGACACCGGG
AREmutl GATCCCCGGTGTGAGGTTGCTCCG
GTAACGGTGACGTGCG
AREmut2 AATTCGCACGTCACCGTT ACCGGAG 
CAACCTCACACCGGG
ARE-likel GATCCTGGAAGCCCCTCAGGTTCCT
CCCTGTCCCGCAGGG
ARE-like2 AATTCCCTGCGGGACAGGGAGGAA
CCTGAGGGGCTTCAAG
GGATTA1 GATCCTGTTTCTGTTTCTAATCCCAG
CCTGGGAAGGAATG
GGATTA2 AATTCATTCCTGCCCAGGCTGGGAT
TAGAAACAGAAACAG
Table 2.4 O ligonucleotides
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2.1.10 Photography and Autoradiography
Agarose gels were photographed using UVP gel documentation system 7500. Fugi 
RX X-ray film was obtained from Genetic Research Instrumentation Ltd and 
developed using an X-Ograph Ltd. X-Ograph Compact X2.
2.1.11 Plasmid cDNA Libraries
The pCDM8 human foetal brain and foetal muscle cDNA libraries were a gift from 
David Simmons (Cell Adhesion Laboratory, ICRF, IMM, John Radcliffe Hospital, 
Oxford, 0X3 9DU). The pcDNAII human foetal brain cDNA library was a gift from 
Kay Davies (Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, 0X3 
9DU).
2.1.12 Vectors
The vectors used for subcloning regions of DNA are listed in table 2.5.
S u p p lie r V ector
Amersham International pic pMOSBlue T-vector
Pharmacia Biotech pGEX4T3 bacterial expression vector
Promega pGEM®-T Easy vector
Stratagene pBluescript® SK(+) phagemid
Table 2.5 Vectors
2.2 Solutions and Media
Solutions and media were sterilised by autoclaving at 121°C for 15 minutes or by 
filtration through a sterile 0.2 pm pore filter obtained from Gelman Science.
2.2.1 Solutions
Denaturing solution
1.5 M NaCl, 0.5 M NaOH.
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100 x Denhardt’s solution (Denhardt. 1966)
2% (w/v) Ficoll®400, 2% (w/v) polyvinylpyrolidine, 2% (w/v) BSA.
5 x DNA loading dye
0.5% (w/v) SDS, 0.25% (w/v) xylene cyanol, 0.25% (w/v) bromophenol blue, 1.5% 
(w/v) Ficoll®400, 3 x TBE.
DL-Dithiothreitol (DTD
Stock solution: 0.1 M in H20  (stored at -20°C).
Working solution: 1-5 mM.
DNase I dilution buffer
50 mM Tris-HCl (pH 8.0), 50 mM NaCl, 0.1 mM EDTA (pH 8.0), 50% (v/v) 
glycerol
DNase I stop solution
95% (v/v) formamide, 20 mM EDTA (pH 8.0), 0.05% (w/v) bromophenol blue. 
0.05% (w/v) xylene cyanol.
1.5 x DNA-protein binding buffer
50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 10 mM DTT, 1 mM PMSF.
0.5 M EDTA pH 8.0
0.5 M EDTA with NaOH to pH 8.0.
Ethidium Bromide
Stock solution: 10 mg/ml in H20.
Working solution: 200 ng/ml.
Hybridisation solution (Tor Southern analysis!
5 x Denhardt’s solution, 5 x SSPE, 0.1% (w/v) SDS, 6% (w/v) PEG, 200 p,g/ml 
sheared and denatured salmon sperm DNA.
1 kb ladder
60 ng/pl 1 kb ladder, 1 x DNA loading dye, 1 x TBE.
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10 x Lvsogen Extraction Buffer
0.5 M Tris-HCl (pH 7.5), 5 mM EDTA (pH 8.0).
Diluted to 1 x strength and 1 mM-5 mM DTT and 1 mM PMSF added, prior to use. 
Manual Sequencing Gel Mix
8.3 M Urea, 6% (w/v) acrylamide/bis premix (19:1), 1 x TBE, 0.05% (w/v) APS, 
0.05% (v/v) TEMED.
MTPBS Buffer
5 x PBS, 0.5 M NaCl, 0.05 M EDTA (pH 8.0), 5 mM PMSF.
Neutralising solution
1.5 M NaCl, 0.5 M Tris-HCl (pH 6.5).
Non-denaturing Polyacrylamide Gel Mix (Dow-ionic strength!
0.007 M Tris-HCl (pH 7.9), 0.002 M EDTA (pH 8.0), 8% (w/v) acrylami de/bis 
(37.5:1), 2.5% (v/v) glycerol, 0.075% (w/v) APS, 0.085% (v/v) TEMED.
Non-denaturing PAGE fLow-ionic strength) Running Buffer
0.007 M Tris-HCl (pH 7.9), 0.003 M sodium acetate, 0.001 M EDTA (pH 8.0).
Non-denaturing Polyacrylamide Gel Mix t l x  Tris/Glvcine)
0.05 M Tris.Glycine (pH 9.4), 0.0001 M EDTA (pH 8.0), 8% or 4% (w/v) 
acrylamide/bis (37.5:1), 0.12% (w/v) APS, 0.06% (v/v) TEMED.
Non-denaturing PAGE t l x  Tris/Glvcinel Running Buffer 
0.05 M Tris.Glycine (pH 9.4), 0.0001 M EDTA (pH 8.0).
Oligo-labelling buffer tOLBl
30% (v/v) TE pH 8.0, 30 OD units/ml of random hexamers, 1 M HEPES (pH 6.6), 
0.35% (v/v) p-mercaptoethanol, 0.1 mM dATP, 0.1 mM dGTP, 0.1 mM dTTP, 0.24 
M Tris-HCl (pH 8.0), 0.0024 M MgCl2.
Orange G loading dve
0.06% (w/v) Orange G, 50% (v/v) glycerol
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Phenvlmethvlsulphonyl Fluoride (PMSF1
Stock solution: 100 mM in propan-2-ol (stored at -20°C).
Working solution: 0.1-1 mM
10 x Phosphate Buffered Saline fPBSl
1.4 M NaCl 0.027 M KC1, 0.1 M N a ^ O , ,  0.021 M KH2P 0 4 (pH 7.2 with HC1). 
PBS-T
1 x PBS, 0.1% (v/v) Tween®20.
10% fw/vl SDS 
10% (w/v) SDS in H20 .
SDS-Polyacrylamide Separating Gel mix
0.375 M Tris-HCl (pH 8.7), 0.1% (w/v) SDS, 10% or 15% (w/v) acrylamide/bis 
(29:1), 0.05% (w/v) APS, 0.05% (v/v) TEMED.
SDS-Polyacrvlamide Stacking Gel mix
0.125 M Tris-HCl (pH 6.8), 0.1% (w/v) SDS, 4% (w/v) acrylamide/bis (29:1), 
0.05% (w/v) APS, 0.1% (v/v) TEMED.
2 x SDS-PAGE Loading Buffer
0.125 M Tris-HCl (pH 6.8), 20% (v/v) glycerol, 2% (w/v) SDS, 0.5% (v/v) (3- 
mercaptoethanol, 0.025% (w/v) bromophenol blue.
5 x SDS-PAGE Loading Buffer
0.313 M Tris-HCl (pH 6.8), 50% (v/v) glycerol, 5% (w/v) SDS, 1.25% (v/v) 0- 
mercaptoethanol, 0.0625% (w/v) bromophenol blue.
5 x SDS-PAGE Running Buffer (Mini Protean II Apparatus)
0.25 M Tris, 0.5% (w/v) SDS, 1.85 M glycine.
20 x SSC
3 M NaCl, 0.3 M Na3C6H50 7.2H20 .
20 x SSPE
0.14 M Na2H P 04.2H20 , 0.06 M NaH2P 0 4.H20 , 3.6 M NaCl, 0.01 M EDTA (pH 
8 .0 ).
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1 x TBE
0.009 M Trizma base, 0.09 M orthoboric acid, 2 mM EDTA (pH 8.0).
TE buffer (TE)
10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0).
1 M Tris pH 8.0
1 M Trizma base and HC1 to pH 8.0.
1 M Tris pH 7.9
1 M Trizma base and HC1 to pH 7.9 
1 M Tris pH 7.5
1 M Trizma base and HC1 to pH 7.5 
1 M Tris pH 6.8
1 M Trizma base and HC1 to pH 6.8
1.5 M Tris pH 8.7
1.5 M Trizma base and HC1 to pH 8.7
2.2.2 Bacterial Solutions, Media and Antibiotics
Ampicillin
Stock solution of 50 mg/ml in H20 , stored at -20°C.
Working solution of 50 jug/ml.
IPTG
Stock solution of 100 mg/ml in H20, stored at -20°C.
Working stock of 10 p,g/ml.
Luria-Bertani fLBl medium
1% (w/v) Bacto®tryptone, 0.5% (w/v) Bacto® yeast extract, 1% (w/v) NaCl. 
LB agar contained LB with 1.5% (w/v) agar.
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SOB medium
2% (w/v) Bacto®tryptone, 0.5% (w/v) Bacto® yeast extract, 0.85 mM NaCl, 0.25 
mM KC1 (pH 7.0 with NaOH). Sterilised 10 mM M gS04 added prior to use.
Tetracycline
Stock solution of 100 mg/ml in 50% (v/v) ethanol, stored at -20°C.
Working concentration of lOpg/ml.
Xzgai
Stock solution of 50 mg/ml in dimethylformamide, stored at -20°C.
Working solution of 50 pg/ml.
2YT medium
1.6% (w/v) Bacto® tryptone, 1% (w/v) Bacto® yeast extract, 1% (w/v) NaCl.
2.3 Methods
2.3.1 Preparation of DNA
2.3.1.1 Preparation of Plasmid and Cosmid DNA
Minipreparations of plasmid DNA (for use in diagnostic tests of insert size) were 
performed using an alkaline lysis method (Bimboim and Doly, 1979; Ish-Horowicz 
and Burke, 1981). 5 ml LB or 2YT, 50pg/ml Ampicillin, lp l glycerol stock or 1 
single colony was incubated for 18 hours, shaking at 37°C. 1.5 ml of culture was 
centrifuged at 10,000 g for 10 minutes and the supernatant discarded. The pellet was 
resuspended in IOOjliI of 50 mM glucose, 10 mM EDTA, 25 mM Tris (pH 8.0). 200 
p] of fresh 1% SDS and 200 mM of NaOH was added, mixed gently and incubated on 
ice for 5 minutes. 150 pi of 3 M CH3COOK (pH 5.5) was added, mixed immediately 
but gently and incubated in ice for 5 minutes. The sample was centrifuged at 10,000 g 
for 15 minutes and the supernatant removed to a new tube. A phenol/chloroform 
extraction was then performed. 1 ml of 100% (v/v) ethanol was added and incubated 
at -70°C for 10 minutes before being centrifuged at 10,000 g for 15 minutes. The 
supernatant was removed and the pellet washed in 500 pi of 70% (v/v) ethanol before 
being air dried and resuspended in 20 pi H20 and 0.025 pg/pl RNaseA.
Qiagen kits were also used, according to manufacturer’s instructions, for the 
preparation of plasmid and cosmid DNA and were used at all times when the purity of 
the DNA was essential.
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2.3.1.2 Preparation of Genomic DNA
DNA was extracted from human blood using Nucleon II kits, according to 
manufacturer’s instructions.
2.3.2 Agarose Gel Electrophoresis
DNA molecules were separated according to size by agarose gel electrophoresis. 
Solutions of 1.0-3.5% (w/v) agarose, Nusieve agarose or LMP agarose in 1 x TBE 
were prepared in a microwave. The solution was allowed to cool to 50°C and then 
200 ng/ml ethidium bromide was added and the gel cast in a horizontal tray with a 1.5 
mm comb. DNA samples were mixed with 5 x DNA or Orange G loading dye and 
electrophoresed in 1 x TBE for 1 hour to overnight at 2-10 V/cm. 600 ng of a 1 kb 
ladder was also run as a DNA size marker. DNA samples were visualised using a UV 
transilluminator (wavelength 254 nm) and photographed.
2.3.3 DNA Purification
2.3.3.1 Phenol/Chloroform Extraction of DNA
Protein and salt contaminants were removed from plasmid DNA by the addition of an 
equal volume of 1:1 (v/v) phenol/chloroform. The mixture was vortexed and then 
centrifuged at 10,000g for 5 minutes. The aqueous phase, containing the DNA, was 
transferred to a fresh tube and an equal volume of chloroform added, to remove any 
remaining traces of phenol. The mixture was vortexed and then centrifuged at 10,000g 
for 2 minutes. The aqueous layer was then transferred to a clean tube and the DNA 
precipitated with ethanol.
2.3.3.2 Ethanol Precipitation of DNA
2.5 volumes of 100% (v/v) ethanol and 0.1 volume of 3 M CH3COONa (pH 5.2) 
were added to a DNA solution. The mixture was vortexed and placed at -70°C or in 
ice for 10 minutes, before being centrifuged for 15 minutes. The pellet was washed in 
70% (v/v) ethanol, to remove excess salt and then air dried and resuspended in a 
suitable volume of 1 mM Tris (pH 8.0) or H20 .
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2.3.3.3 Purification of DNA from Agarose Gels
2.3.3.3.1 Hot Phenol Extraction
DNA fragments were cut out of a low melting point agarose or Nusieve agarose gel 
and weighed. Assuming a density of 1 g/ml, 3 volumes of H20  were added and the 
gel melted a 65°C. An equal volume of phenol was added, mixed, incubated for 3 
minutes at 65°C and centrifuged at 10,000g for 5 minutes. The top aqueous layer was 
phenol/chloroform extracted and the DNA ethanol precipitated.
2.3.3.3.2 Qiagen Gel Extraction
Qiagen gel extraction kits were also used, according to manufacturer’s instructions, to 
purify DNA from agarose gels.
2.3.4 DNA Concentration
DNA samples were diluted 5 pi in 750 pi K^O. A spectrophotometer was baseline 
corrected using H20  before the sample was analysed in the range 200 to 300 nm. 
DNA concentration was calculated as [50 x 750 x OD (at 260 nm)]/5 pg/ml.
2.3.5 DNA Sequencing
DNA sequencing was performed on either an ABI 373A sequencer or an ABI 377 
sequencer, by the Molecular Biology Support Unit at the University of Glasgow. 
Reactions were performed as stated in the ABI PRISM™ Dye Terminator Cycle 
Sequencing Ready Reaction Kit protocol. Ethanol precipitation protocol 1 was used 
for purifying extension products.
2.3.5.1 Computer Analysis of DNA Sequences
DNA sequences were edited and aligned using Sequence Navigator, version 1.0 
(Applied Biosystems). MacVector, version 4.1.4 (Kodak Scientific Imaging Systems) 
was used to predict the molecular weights of the recombinant fusion proteins. 
Database searches of GenBank, EMBL, DDBJ and PDB were performed at the 
National Centre for Biotechnology Information using BLASTN network services, 
accessed via the UK Human Genome Mapping Project online computing service.
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DNA sequences were analysed for restriction sites using MAP, and compared to find 
sequence homology using BESTFIT and LALIGN from the GCG package on the UK 
Human Genome Mapping Project online computing service.
2.3.6 Polymerase Chain Reaction (PCR)
Except where stated PCRs contained 0.25 pM each primer, 0.2 mM each dNTP 
1.25U Taq polymerase 1-5% (v/v) DMSO and lx buffer in a 25 pi total volume. 
Reactions were thermal cycled under the following conditions on either a Perkin Elmer 
DNA Thermal Cycler 480 or Gene Amp® PCR System 9700:
1 cycle: 94°C for 4 minutes
30 cycles: 94°C for 1 minute
55-60°C for 1 minute
72°C for 2 minutes
1 cycle: 72°C for 7 minutes
2.3.7 Southern Blotting
Gels were incubated in denaturing solution for 45 minutes, neutralising solution for 
45 minutes, and the capillary blot was assembled using Hybond™-N nylon 
membrane. All sheets of Hybond™-N and 3 MM paper were rinsed in 20 x SSPE 
before assembly, and care was taken to eliminate any air bubbles. Gels were blotted 
for 16 hours, and then the membrane was baked at 80°C for 2 hours.
2.3.8 Preparation of Radiolabelled Double Stranded probes
20-50 ng DNA and H20  to a final volume of 32 pi was denatured at 100°C for 10 
minutes, and briefly quenched on ice. 10 pi OLB, 2pl 1 mg/ml BSA, 5 pi [a-32P] 
dCTP (3000 Ci/mmole) and 2U Klenow were added, and incubated at room 
temperature for 3 hours.
A 1 ml Sephadex® G-50 column was prepared in a 1.5 ml eppendorf with polymer 
wool and 4% (w/v) Sephadex® G-50 in TE. The sephadex was compacted by 
centrifuging twice at 1,800 rpm for 4 minutes. 50 pi 30 mM NaCl in TE was added to 
the column to elute the radiolabelled probe, and centrifuged at 1,800 rpm for 4 
minutes. The eluate was collected and the incorporation as a percentage of the total 
was calculated by taking cpm readings before and after purification.
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2.3.9 Southern Hybridisation (using double stranded probes)
Filters to be hybridised were place in a hybridisation bottle with 20 ml of hybridisation 
solution and rotated at 65°C for 3 hours. The purified radiolabelled probe was 
denatured at 100°C for 10 minutes and quenched briefly on ice before being added to 
the bottle. Hybridisation was carried out at 65°C, overnight in a rotating hybridisation 
oven.
Filters were washed, in 0.1 % SDS, sequentially to the following stringency’s:
2 x SSPE room temperature 20 minutes
2 x SSPE 65°C 20 minutes
1 x SSPE 65°C 20 minutes
0.1 x SSPE 65°C 20 minutes
At each stage the filter was monitored with a Geiger counter, and washing was 
stopped if the reading was below 10 cps. Filters were wrapped in Saran wrap whilst 
still damp, and exposed to X-ray film in the presence of an intensifying screen at - 
70°C. Autoradiographs were developed after overnight - 3 day exposure.
2.3.10 DNA Cloning Techniques
2.3.10.1 Restriction Enzyme Digests of Plasmid DNA
1 jig DNA was incubated with 5-10U restriction endonuclease in 1 x restriction 
endonuclease buffer (as recommended by the manufacturer) in a final volume of 20 pi 
at the appropriate temperature for 4 hours.
2.3.10.2 Calf Intestinal Phosphatase Treatment (CIAP) - to remove 5’ 
phosphate groups from DNA
1 jig digested DNA was CIAP treated in 80 jxl volume with 2 pi 1:10 dilution CIAP 
enzyme (5U) in 1 x manufacturer’s supplied buffer at 37 °C for 1 hour.
2.3.10.3 Klenow Treatment - to fill recessed 3’ termini
1U of the Klenow fragment of DNA polymerase I and 1 jil 1 mM each required dNTP 
were added to a 20 pi digest and incubated at room temperature or 37°C for 15
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minutes. The reaction was terminated by heating to 75°C for 10 minutes or by 
phenol/chloroform extraction.
2.3.10.4 Ligations
A total of 25-30 ng DNA was ligated with 1U DNA ligase in 1 x ligase buffer 
(supplied by the manufacturer) in a 10 pi volume at 4°C overnight. A molar insert to 
vector ratio of 3:1 was used with sticky ended ligations and of 5:1 for blunt ended 
ligations.
2.3.10.5 Preparation of Competent Cells
A 50 ml culture inoculated with 500 pi overnight culture was grown with aeration in 
medium A [LB with 10 mM M gSO ^K y), 0.2% (w/v) glucose] to mid logarithmic 
phase. The cells were kept on ice for 10 minutes, then pelleted at 1500g for 10 
minutes at 4°C. The cells were resuspended gently in 500 pi of pre-cooled medium A, 
then 2.5 ml storage solution B [36% (w/v) glycerin, 12% (w/v) PEG (MW7500), 12 
mM MgSC^JE^O added to LB (pH 7.0)] was added and mixed well without 
vortexing. The competent cells were divided into aliquots of 100 pi each and stored at 
-80°C until use.
2.3.10.6 Transformations
100 pi competent cells for each transformation were thawed for 10 minutes on ice. 5 
pi ligation mixture was added and the tube tapped gently to mix. They were then 
incubated on ice for 30 minutes. The cells were then heat shocked at 42°C for 90 
seconds and cooled on ice for 2 minutes. 500 pi pre-warmed LB was added and the 
samples incubated at 37°C for 1 hour. 30 pi of each transformation was spread on an 
LB plate containing the appropriate antibiotics and where appropriate 30 pg/ml IPTG 
and 50 pg/ml X-gal and allowed to dry for 10 minutes, before being incubated 
overnight at 37°C.
2.3.10.7 Generation of Plasmid Stocks
Bacteria transformed with recombinant plasmids were prepared for long term storage 
by inoculating 5ml of 2YT or LB medium containing 50 pg/ml ampicillin with a single 
colony from an agar plate. This was incubated overnight, shaking at 37°C. 500 pi of
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overnight culture was mixed with 500 pi of 40% (v/v) glycerol, 60% (v/v) 2YT 
medium and stored at -70°C.
2.3.11 Small Pool PCR-Based Screening of cDNA Libraries
2.3.11.1 Pooling cDNA Libraries
XL-1 BLUE competent cells were transformed (section 2.3.10.6) with 1 x 106clones 
from a plasmid cDNA library. Following 1 hour incubation at 37°C, 6.4 ml of pre­
warmed LB and 50 pg/ml ampicillin were added to the transformation. The 
transformed cells were divided equally between 64 wells in an 8 x 8 matrix, in a 
microtitre plate (100 pi of culture, containing 15,625 individual, unamplified clones 
per well) and allowed to grow overnight at 37°C, shaking at 150 rpm. The microtitre 
plate was placed in a sandwich box containing damp paper towels to prevent the 
cultures drying out. The wells from each row and column were pooled to give 16 
individual pools, each pool containing 25 pi of its constituent wells. An equal volume 
of 60% 2YT/40% glycerol (v/v) was added to each pool and well and they were stored 
at -70°C.
1 pi glycerol stock of each pool was used, to prepare 5 ml overnight cultures. Plasmid 
DNA from 1.5 ml of each culture was prepared (section 2.3.1.1) and resuspended in 
30 pi of H20, before being diluted 1/100 in H20. 1 pi of diluted DNA from each pool 
was used as a template in a PCR. 70% (v/v) of each PCR was electrophoresed in a 
2% (w/v) agarose gel. DNA was transferred to Hybond™-N membrane and 
hybridised to a radiolabelled DNA probe (sections 2.3.7-2.3.9). DNA from positive 
wells was prepared and 1 pi of a 1/100 dilution used as a template in another round of 
PCR. 70% (v/v) of each PCR was electrophoresed in a 2% (w/v) agarose gel and the 
gel was Southern blotted and probed with a radiolabelled DNA probe.
To determine the number of clones in a positive well lp l of glycerol stock was diluted 
in LB to give dilutions of 1 x 10'4, 1 x 10'5 and 1 x 10'6 and spread on LB plates 
containing 50 pg/ml ampicillin and incubated overnight at 37°C. 40,000 clones from a 
positive well were divided between 64 wells (100 pi of culture, containing 625 clones 
per well) in a microtitre plate. The clones were amplified and pooled as described 
above and analysed by PCR. Clones from a positive well were screened by 
hybridisation to a radiolabelled probe (sections 2.3.11.2 -2.3.11.4).
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2.3.11.2 Plating Out Plasmid Library
Hybond™ -N+ was placed on the surface of 6 LB agar + ampicillin plates. 500 clones 
were plated out on the surface of each membrane and incubated at 37°C for 24 hours. 
Replica plates were made by laying a master filter colony side down onto a second 
Hybond™-N+ filter, placed on a sheet of 3MM paper and then covering with a second 
sheet of 3MM paper. They were then pressed between two glass plates. Orientation 
marks were made through the Hybond N™+ filters using a sterile needle. Master 
filters were then incubated on fresh plates for 6 hours and replica filters for 10 hours. 
After 6 hours a second set of replica filters was made and both master and replica 
plates were incubated for 4 hours after which the second set of replica plates were left 
at room temperature overnight. The master plates and first set of replica plates were 
stored at 4°C overnight. The replica filters were then placed colony side up on 3MM 
paper wetted with denaturing solution and left for 7 minutes and then neutralised in the 
same way for 7 minutes. The filters were then immersed in 2 x SSC and cell debris 
was removed by rubbing the filter gently before being rinsed in fresh 2 x SSC and 
baked at 80°C.
2.3.11.3 Preparation of Radiolabelled Oligonucleotide Probes
10 pmoles of oligonucleotide were mixed with 10U polynucleotide kinase, 10 pCi [y- 
32 P] ATP and lx  kinase buffer in a 20pl final volume and incubated a 37°C for 2 
hours.
A 1 ml Sephadex® G-25 column was prepared in a 1.5 ml eppendorf with polymer 
wool and 4% (w/v) Sephadex® G-25 in TE. The sephadex was compacted by 
centrifuging once at 1,800 rpm for 5 minutes. The radiolabelled oligonucleotide was 
added to the column and centrifuged at 1,800 rpm for 4 minutes. The eluate was 
collected and the percentage incorporation was calculated by taking cpm readings 
before and after purification.
2.3.11.4 Hybridisation of Replica Filters
The filters were pre-hybridised for 3 hours in a sealed petri dish at 53°C. An 
oligonucleotide probe was radiolabelled and added to 12 ml prewarmed hybridisation 
mix. Filters were transferred to a new petri dish with 1 ml of probe and hybridisation 
mix inbetween each layer. The petri dish was sealed and hybridisation was carried out 
at 53°C overnight.
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Filters were washed twice in 6 x SSPE, 0.1% SDS for 5 minutes at room 
temperature. Filters were wrapped in Saran wrap whilst still damp, and exposed to X- 
ray film in the presence of an intensifying screen at -70°C.
2.3.12 Protein Expression
2.3.12.1 Generation of Recombinant Proteins
Recombinant protein was generated in a bacterial expression system for use in gel 
retardation assays and a whole genome PCR based screen, to determine the target 
DNA binding sites of the recombinant protein. A pGEX bacterial expression vector, 
that allows inducible expression by IPTG under the control of the tac promoter, was 
used. The gene fragments to be expressed were subcloned in frame into the MCS, 
which is situated downstream of Schistosoma japonicum Glutathione S-transferase 
(GST). GST fusion proteins were purified by affinity chromatography with 
glutathione as the ligand. Diagnostic restriction digests and sequencing were used to 
check for the correct insert and reading frame.
2.3.12.2 Optimisation of Protein Expression
2 ml SOB medium containing 50 pg/ml ampicillin was inoculated with a single colony 
of appropriate recombinant bacteria and incubated overnight at 37 °C. A culture was 
also grown that contained a vector only clone, as a positive control. 100 ml SOB 
medium containing 50 pg/ml ampicillin was then inoculated with 400 pi overnight 
culture and incubated at 37°C until an O D ^  of 0.6 was reached. 1 ml of culture was 
then centrifuged at 10,000g for 10 minutes and the supernatant discarded. The pellet 
was resuspended in 100 pi 1 x PBS and stored at -20°C. The remainder of the culture 
was split into 25 ml fractions and induced with various concentrations of IPTG (0-5 
mM). The cultures were then incubated at either 30°C or 37°C for up to 30 hours. The 
OD6oo was monitored at hourly intervals with 1 ml of culture. 1 ml of each culture was 
also removed to determine the amount of protein expression by SDS-PAGE. It was 
centrifuged at 10,000g for 10 minutes and the supernatant removed. The pellet was 
resuspended in 100 pi lx  PBS and stored at -20°C. Incubation was continued 
overnight and the culture was sampled once again. The cells from each time point 
were lysed by freezing in a dry ice/methanol slurry and incubating briefly, at 42°C to 
rapidly thaw. This was repeated 6 times and the samples were centrifuged at 10,000g 
for 10 minutes. The supernatant was removed and both supernatant and pellet were 
snap frozen on dry ice. 100 pi of 2 x SDS loading buffer was added to all samples
63
and then they were boiled at 100°C for 10 minutes to denature the proteins before 
SDS-PAGE analysis. Where no overexpressed protein was visible by Coomassie 
Blue staining it was detected by western blot analysis.
2.3.12.3 Large Scale Production of Recombinant GST Fusion Proteins
5 ml SOB medium containing 50 pg/ml ampicillin and 2% (w/v) glucose was 
inoculated with a single colony of appropriate recombinant bacteria and incubated 
overnight at 37°C. 500 ml SOB medium containing 50 pg/ml ampicillin and 2% (w/v) 
glucose was then inoculated with 400 pi overnight culture and incubated at 37°C until 
and OD^q of 0.6 was reached. 1 mM IPTG was added to the culture to induce protein 
expression and incubation was continued at 30°C for the pre-determined optimum 
time. The cells were harvested in 200 ml fractions at 10,000g for 10 minutes at 4°C 
and the supernatant discarded. The pellet was resuspended in 10 ml of 1 x lysogen 
extraction buffer containing 5 mM DTT and 0.1 mg/ml lysozyme. The cells were 
lysed by sonicating on ice 5 times, each time for 10 seconds, with a 1 minute 
incubation on ice between bursts. At this stage, the samples were either pooled and 
centrifuged at 7740g at 4°C for 10 minutes and the supernatant snap frozen and stored 
at -70°C or 1% (v/v) Triton X-100 was added and incubated at room temperature for 
30 minutes. Unless otherwise stated samples to be affinity purified had 1% (v/v) 
Triton X-100 added. The samples were pooled and centrifuged at 7740g at 4°C for 10 
minutes. The supernatant and pellet were snap frozen separately and stored at -70°C. 
When the pellet was shown to contain the recombinant protein the inclusion bodies 
were solubilised.
2.3.12.4 Inclusion Body Solubilisation
The pellet was resupended in 40 ml of buffer 1 [50 mM Tris (pH 8.0), 1 mM EDTA 
(pH 8.0), 100 mM NaCl] and 1 mg/ml lysozyme. This was incubated at room 
temperature for 20 minutes before being centrifuged at 5,000g for 10 minutes. The 
supernatant was removed and stored at -20°C. The pellets were transferred to ice and 
resuspended in 40 ml of ice cold buffer 2 [50 mM Tris (pH 8.0), 1 mM EDTA (pH 
8.0), 100 mM NaCl, 0.1% (v/v) sodium deoxycholate] and incubated for 10 minutes. 
8 mM MgCl2 and 10 pg/ml DNase I were added and incubation continued at 4°C until 
the viscosity disappeared. The inclusion bodies were removed by centrifugation at 
10,000g for 10 minutes. The supernatant was removed and stored at -20°C. The 
pellets were washed by resuspending in 12 ml of buffer 3 [50 mM Tris (pH 8.0), 1 
mM EDTA (pH 8.0), 100 mM NaCl, 1% (v/v) Nonidet® P-40]. Centrifugation was
64
again carried out at 10,000g for 10 minutes and the pellets washed in 12 ml of buffer
1. After further centrifugation the pellets were resuspended in 8 ml 8 M urea followed 
by dialysis against 1 x PBS.
2.3.12.4.1 Dialysis
Dialysis tubing was washed with distilled followed by dialysis buffer. One end 
was clipped shut and the solution added to the other end, before that too, was clipped 
shut. Dialysis was performed at 4°C in 500 ml of dialysis buffer which was stirred for 
1 hour and 30 minutes. The buffer was changed twice during this time and then the 
sample was removed from the dialysis tubing and snap frozen on dry ice.
2.3.12.5 Affinity Purification of Recombinant Protein
Glutathione Sepharose® 4B beads were prepared as a 50% (w/v) slurry in MTPBS 
buffer according to the manufacturers instructions. 100 jllI of 50% (w/v) slurry were 
mixed with 1.25 ml of sonicated cell lysate or 500 pi of solubilised pellet fraction in 
lx PBS by rotating at room temperature for 30 minutes. The samples were centrifuged 
at 500g for 10 minutes. The supernatant was removed carefully and 50 pi snap frozen 
for analysis by SDS-PAGE. The beads were washed 4 times in 6 ml of MTPBS to 
remove non-specifically bound protein. Glutathione Sepharose® 4B beads to be used 
in the whole genome PCR screen (section 2.3.18) were resuspended in 33 mM Tris 
(pH 8.0), 80 mM NaCl, 6.7 mM DTT, 0.67 mM PMSF and 20% (v/v) glycerol to 
give a 50% (v/v) slurry and snap frozen. The recombinant proteins were eluted from 
the Glutathione Sepharose® 4B beads by the addition of 375 pi of elution buffer [50 
mM Tris (pH 8.0), 120 mM NaCl, 10 mM DTT, 1 mM PMSF, 20 mM reduced 
glutathione] per 100 pi of protein-bound beads. The samples were rotated at room 
temperature for 15-30 minutes and centrifuged at 500g for 10 minutes. The eluants 
were snap frozen on dry ice in 500pl aliquots and the elution step repeated.
2.3.12.6 Determination of Protein Concentration
The concentration of small aliquots of affinity purified recombinant protein was 
estimated by comparison to Coomassie Blue stained BSA standards which had been 
electrophoresed in a SDS-polyacrylamide gel.
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2.3.12.7 Concentrating Proteins
Several methods were used in an attempt to concentrate the affinity purified 
recombinant proteins:
a) 2 ml of affinity purified protein was reduced to 200 pi using a Centricon 10 
membrane unit, according to the manufacturer’s instructions.
b) An equal volume of cold 100% (v/v) ethanol was added to affinity purified protein 
and incubated at -20°C for 30 minutes. The sample was centrifuged at 10,000g for 30 
minutes at 4°C and the supernatant removed. The pellet was resupended in a suitable 
volume of buffer and snap frozen immediately.
c) An equal volume of cold 100% (v/v) acetone was added to affinity purified protein 
and incubated at -20°C for 30 minutes. The sample was centrifuged at 10,000g for 30 
minutes at 4°C and the supernatant removed. The pellet was resupended in a suitable 
volume of buffer and snap frozen immediately.
2.3.12.8 Thrombin Cleavage of Recombinant Proteins
In an attempt to remove the GST-tag from the recombinant protein, various conditions 
were tried, to cleave the protein at a thrombin site present between the GST and the 
expressed protein of interest:
a) 0.01U thrombin were mixed with 1.0 pg of affinity purified protein in a total 
volume of 200 pi and incubated at room temperature for 24 hours. 15 pi aliquots were 
taken for SDS-PAGE analysis every 2 hours.
b) 0.05U thrombin were mixed with 5.0 pg of affinity purified protein in a total 
volume of 200pl and incubated at room temperature for 24 hours. 15 pi aliquots were 
taken for SDS-PAGE analysis every 2 hours.
c) 0.10U thrombin were mixed with 5.0 pg of affinity purified protein in a total 
volume of 200 pi and incubated at room temperature for 24 hours. 15 pi aliquots were 
taken for SDS-PAGE analysis every 2 hours.
2.3.13 SDS-Polyacrylamide Gel Electrophoresis
Proteins were analysed using dissociating, discontinuous SDS-PAGE (Laemmli, 
1970). Electrophoresis was carried out in mini separating gels containing 10% or 15% 
(w/v) acrylamide/bis (29:1) in a BIO-RAD MiniProtean II gel apparatus. 0.75 mm 
thick mini gels with 15 wells were used. Separating gels were overlaid with 4% (w/v)
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acrylamide/bis (29:1) stacking gels. Protein samples were mixed with 5 x or 2 x SDS- 
PAGE loading buffer, boiled for 10 minutes and electrophoresed in 1 x SDS-PAGE 
running buffer at 100V, 50mA until the dye band just left the bottom of the gel. 6 p,g 
of low molecular weight marker proteins (Pharmacia Biotech) was electrophoresed in 
analytical gels and 16 \ig of kaleidoscope prestained protein standard was also 
electrophoresed in gels that were electroblotted onto Hybond™-N ECL nitrocellulose 
membranes.
2.3.14 Protein Detection Methods
2.3.14.1 Coomassie Blue Staining
SDS polyacrylamide gels were stained with 0.1% (w/v) PhastGel Blue R (Coomassie 
R 350 stain) in 30% (v/v) methanol, 10% (v/v) acetic acid for 15 minutes, followed 
by destaining in 20% (v/v) methanol, 5% (v/v) acetic acid overnight.
2.3.14.2 Silver Staining
SDS polyacrylamide gels were prefixed in 50% (v/v) methanol, 10% (v/v) acetic acid 
for 30 minutes, followed by 5% (v/v) methanol, 7% (v/v) acetic acid for 30 minutes. 
The proteins were fixed in 10% (w/v) gluteraldehyde for 20 minutes and washed in 
distilled H20  overnight. Gels were stained in 0.1% (w/v) A gN 03 for 15 minutes, 
developed in 0.27 M N a^O ^  0.05% (v/v) formaldehyde until bands were clearly 
visible. The reaction was stopped by adding 2 g of citric acid crystals. The stained 
gels were stored prior to drying in 10% (v/v) ethanol, 5% (v/v) glycerol.
2.3.15 Storage of SDS Polyacrylamide gels
Gels were stored by drying under vacuum at 80°C on a BIO-RAD Model 583 Gel 
dryer, onto 3 MM grade chromatography paper.
2.3.16 Western Blot Analysis
Recombinant proteins to be investigated by western analysis were separated by SDS- 
PAGE. Gels, Hybond™-N ECL nitrocellulose membrane and thick absorbent filter 
paper were equilibrated in western blot transfer buffer (25 mM Tris, 192 mM glycine, 
20% (v/v) methanol) for 15 minutes. Proteins were transferred from the
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polyacrylamide gel to the membrane with the BIO-RAD Trans-Blot® semi dry transfer 
cell for 60 minutes at 10-15V with maximum current.
Membranes were blocked in PBS-T/5% (w/v) skimmed milk powder at room 
temperature for 1 hour. The membranes were washed in PBS-T at room temperature 
for 30 minutes, with the PBS-T being changed every 5 minutes. The primary antibody 
was diluted (1/1000) in 5 ml of PBS/5% (w/v) skimmed milk powder. Diluted 
antibody was added to the membrane and incubated overnight at 4°C. The membranes 
were washed as previously in PBS-T and the secondary HRP-conjugated antibody 
was diluted (1/1000 for donkey anti-rabbit HRP-conjugated serum or 1/10000 for 
donkey anti-goat HRP-conjugated serum ) in 5 ml of PBS/5% (w/v) skimmed milk 
powder. The diluted secondary antibody was added and incubated at room 
temperature for 1 hour before being washed as previously. To specifically detect 
proteins containing the GST-tag, a polyclonal goat anti-GST serum was used as the 
primary antibody with polyclonal donkey anti-goat IgGs conjugated with HRP as the 
secondary antibody. However, to confirm that proteins were DMAHP recombinant 
proteins, R254 DMAHP antiserum was used as the primary antibody with polyclonal 
donkey anti-rabbit IgGs conjugated with HRP as the secondary antibody. R254 
DMAHP antiserum contains GST depleted polyclonal antibodies that were raised 
against a GST-DMAHP recombinant protein containing the homeodomain and 17 
amino acids from the 3’ end of the Six domain
Detection reagents from the ECL™ western analysis system (Amersham International 
pic.) were used according to the manufacturer’s protocol to detect the signal produced 
by the antigen-antibody-antibody interactions. Detection reagent 1 and detection 
reagent 2 were mixed in an equal volume so that the final volume was 0.125 ml/cm2 of 
membrane. The membranes were covered with the detection solution for 1 minute at 
room temperature and after removal of excess detection solution they were sealed in 
Saran® wrap and exposed to X-ray film in the presence of an intensifying screen. 
Autoradiographs were developed after 15 seconds to 20 minutes.
2.3.17 Gel Retardation Assays
2.3.17.1 Subcloning of DNA Probes
40 bp double stranded oligonucleotides representing putative DNA binding sites were 
created by annealing two single stranded oligonucleotides to give a sequence with a 
BamR  I half site at one end and a EcoR I half site at the other end. The 
oligonucleotides used are listed in table 2.4. ARE1 and ARE2 represent the ARE 
[from -96 to -62 / Suzuki-Yagawa, 1992 #4664] and include the 13 bp AREC3
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binding site and 21 bp of flanking sequence. ARE-likel and ARE-like2 (nucleotides 
726-760, accession number L08835) represent the ARE-like sequence and GGATTA1 
and GGATTA2 (nucleotides 1311-1346, accession number L08835) the GGATTA 
consensus site present in the promoter region of D M PK . A mutant ARE sequence that 
has been shown not to bind AREC3 was also produced (oligonucleotides, AREmutl 
and AREmut2) (Kawakami et al., 1996a). The double stranded oligonucleotides were 
subcloned into the BamH. I I E c o R  I sites of pBluescript® SK(+) phagemid.
2.3.17.2 End-labelling of DNA Fragments
1-2 pg plasmid DNA, containing the putative DNA binding site, was digested with 
one or two restriction endonucleases, in a 20 pi volume, to produce a fragment 
containing at least one 5’ overhang, consisting of at least one guanine. 20 pCi [a-32P] 
dCTP (3000 Ci/nmol), 0.2 mM dNTPs(-dCTP) and 2U Klenow were added and 
incubated at room temperature for 20 minutes. The DNA was purified by 
phenol/chloroform extraction, ethanol precipitated and resuspended in 20 pi 1 mM 
Tris (pH 8.0).
2.3.17.3 Binding Reaction
7% (v/v) glycerol, 0.01 pg/pl poly[dl/dC].poly[dl/dC], 10 pi affinity purified 
recombinant protein or unpurified cell lysate diluted in 1.5 x binding buffer, 3.33x10" 
3% (w/v) bromophenol blue, 100 cps radiolabelled probe and H20  to bring the total 
volume to 15 pi were mixed on ice. They were incubated for 20 minutes at room 
temperature.
2.3.17.4 Non-denaturing Polyacrylamide Gel Electrophoresis
Binding reactions were analysed using non-denaturing PAGE. Electrophoresis was 
carried out in a BIO-RAD Protean II gel apparatus. 4% (w/v) or 8% (w/v) non­
denaturing acrylamide/bis (37.5:1) gels were used (low ionic strength or 1 x 
Tris/glycine). The monomeric acrylamide gel mix was degassed for 15 minutes prior 
to the addition of the polymerising agents, APS and TEMED. Samples were 
electrophoresed in a pre-run gel for 3 hours at 200V, 32mA with continuous re­
circulation of the appropriate non-denaturing polyacrylamide gel running buffer at 
4°C. The gel was dried under vacuum at 80°C on a BIO-RAD Model 583 Gel dryer, 
onto 3 MM grade chromatography paper and exposed to X-ray film in the presence of 
an intensifying screen at -70°C.
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2.3.18 Whole Genome PCR Screen
2.3.18.1 Preparation of DNA
1 pg of high molecular weight human lymphocyte DNA was cleaved to completion 
with either Sau3A I or Tsp5091. The DNA cleaved with Sau3A I was then ligated to 
linkers consisting of 5pg of oligonucleotides V-SU and V-NL annealed together and 
the DNA cleaved with Tsp509 I was ligated to linkers consisting of 5 pig of 
oligonucleotides TSP and V-NL annealed together. The DNA was heated to 95°C, 
precipitated using 1.3 volumes of propan-2-ol and 0.3 volumes of 10 M ammonium 
acetate air dried and resuspended in 10 jxl H20 .
2.3.18.2 Optimisation of Binding Reaction
To determine the optimum length of time that the DNA needs to bind to the GST- 
Six+HD, Glutathione coated Sepharose® 4B beads a time course was performed.
1,000 cps of radiolabelled ARE fragment and pBluescript® SK(+) were mixed with 
either 200 or 500 pi of a 50% (v/v) slurry of GST-Six+HD coated Sepharose® 4B 
beads (about 4 or 10 pg of protein) or GST coated Sepharose® 4B beads (about 8 or 
20 fig of protein) in an eppendorf tube. Three tubes were prepared for each protein. 
Samples were rotated at room temperature for either 15 minutes, 30 minutes or 1 hour 
before being centrifuged at 10,000g for 5 minutes and the supernatant removed. The 
specific activity of both beads and supernatant were measured. The beads were 
washed in 1 x DNA-protein binding buffer and the specific activity of beads and wash 
buffer were measured. DNA was eluted by the addition of 100 jllI of lx DNA-protein 
binding buffer plus 1M NaCl. The samples were rotated at room temperature for 30 
minutes before being centrifuged at 10,000g for 5 minutes and the eluant removed. 
Again the specific activity of eluant and beads was measured.
2.3.18.3 Binding Reaction
300 ng of linkered genomic DNA (either Sau3A I cleaved or Tsp509 I cleaved) was 
mixed with 200 pi of a 50% (v/v) slurry of GST-Six+HD, Glutathione coated 
Sepharose® 4B beads (about 4pg of protein) in an eppendorf tube. The sample was 
rotated at room temperature for 1 hour before being centrifuged at 10,000g for 5 
minutes and the supernatant removed. The beads were washed in 1 ml of 1 x DNA- 
protein binding buffer. Bound DNA was then eluted by the addition of 100 pi lx 
DNA-protein binding buffer plus 1 M NaCl. The sample was rotated at room
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temperature for 30 minutes before being centrifuged at 10,000g for 5 minutes and the 
eluant removed. The DNA was precipitated by the addition of 1.3 volumes of propan-
2-ol, air dried and resuspended in lOjul H20 .
2.3.18.4 Optimisation of PCR Conditions
PCR conditions were optimised using unbound linkered genomic DNA as a template. 
The basic conditions are described in section 2.3.6. The primer utilised was 0.5 pM 
of V-NL. Perkin Elmer AmpliTaq Gold™was used and as this enzyme is thermostable 
a 12 minute 94°C pre-PCR stage was added to the basic cycle to provide an efficient 
hot start. Annealing temperatures of 55°C and 59°C were tried in conjunction with 1 
mM and 2 mM spermidine and 1% -7% (v/v) DMSO. Reactions were performed on 
Gene Amp® PCR System 9700
2.3.18.5 PCR
PCR was carried out using Perkin Elmer AmpliTaq Gold™, 0.5 pM of primer V-NL, 
an annealing temperature of 59°C and 5% DMSO. The templates used were 5 pi of 
eluted, bound and precipitated DNA , 5 pi of 1/10 and with later rounds 1/100 and 
1/1000 dilutions of the DNA. 12 pi of PCR reaction was electrophoresed in a 1% 
(w/v) agarose gel. 100-400 ng of PCR product was used in another round of 
selection.
2.3.18.6 Subcloning of PCR products
Rounds of binding and PCR were performed until discrete bands could be seen on an 
agarose gel. At this stage PCR products were purified by adapting the Qiagen gel 
extraction kit protocol. 60 pi of PCR product, from multiple reactions was mixed with 
180 pi of solution QG from the kit. The manufacturer’s instructions were then 
followed with the omission of the heating step required to melt agarose. Purified DNA 
was then subcloned into pGEM®-T Easy vector following the manufacturer’s 
instructions. Clones were sequenced using T7 and SP6 primers.
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2.3.19 DNase I Footprinting
2.3.19.1 End-labelling of DNA Fragment
A DNA fragment for DNase I footprinting must be labelled at only one end.
Therefore, 1-2 pg plasmid DNA was digested with 2 restriction endonucleases to 
produce a fragment containing only one 5’ overhang, consisting of at least one 
guanine. For each fragment to be labelled, 4 identical restriction digests were 
performed. The restriction digests were electrophoresed in a 1% (w/v) agarose gel and 
the fragments cut out of the gel, pooled and purified using a Qiagen gel extraction kit. 
The DNA was eluted in 32 pi 1 mM Tris (pH 8.0). 10 pi DNA, 25 pCi [a-32P] dCTP 
(3,000 Ci/nmol), 0.25 mM dNTPs(-dCTP), 4U Klenow, 1 x Life Technologies Ltd 
React 2 in a total volume of 20 pi were incubated at room temperature for 25 minutes. 
0.25 mM dCTP was added and incubated for a further 5 minutes. The DNA was then 
purified by phenol/chloroform extraction, ethanol precipitated, air dried and 
resuspended in 20 pi 1 mM Tris (pH 8.0).
2.3.19.2 DNase I reaction
7% (v/v) glycerol, 0.01 pg/pl poly [dl/dC] .poly [dl/dC], 10 pi of 1.5 x DNA-protein 
binding buffer or unpurified GST-Six+HD cell lysate or GST cell lysate, diluted 1/10 
or 1/20 in 1.5 x DNA-protein binding buffer, 200 cps radiolabelled probe and H20  to 
bring the total volume to 15 pi were mixed on ice. They were then incubated for 20 
minutes at room temperature, before being divided into 3 ,4  pi aliquots. 1 mg/ml 
DNase I stored in DNase I dilution buffer was diluted to 12.50 pg/ml, 6.25 pg/ml and 
3.13 pg/ml in DNase I dilution buffer plus 50 mM MgCl2. 1 pi of diluted DNase I 
was added to each of the three tubes, such that all samples containing each protein 
dilution were digested by each dilution of DNase I and incubated at room temperature 
for exactly 5 minutes. A no DNase I control was carried out on a fourth 1.5 x DNA- 
protein binding buffer tube. 5 pi of DNase I stop solution was then added to each 
tube. Restriction digests of the radiolabelled DNA probe were performed, to create 
size markers. 5 pi of each digest was removed and placed in separate tubes to which 5 
pi of DNase I stop solution was added. All samples were heated to 90°C for 2 
minutes before being cooled on ice.
2.3.19.3 Denaturing Polyacrylamide Gel Electrophoresis
DNase I footprinting reactions were analysed in a 6% (w/v) acrylamide/bis (19:1) 
manual sequencing gel. BIO-RAD AG 501-XB (D) resin (20-50 mesh) was added to
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the urea, acrylamide and water to de-ionise the mix. This mix, together with the TBE 
was degassed for 10 minutes before the addition of the polymerising agents, APS and 
TEMED. 5 pi of each reaction was loaded onto a pre-run gel and electrophoresed for 2 
hours 10 minutes at a constant power of 40W. The gel was dried under vacuum at 
80°C on a BIO-RAD Model 583 Gel dryer, onto 3 MM grade chromatography paper 
and exposed to X-ray film in the presence of an intensifying screen at -70°C.
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Chapter
3
Screening for a Human DMAHP cDNA Clone
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3.1 Introduction
The aim of the work presented in this chapter was to isolate a human DMAHP cDNA, 
that could be cloned into an expression vector, for the production of recombinant 
protein. The recombinant protein could then be utilised in DNA-protein binding 
studies to investigate the DNA binding properties of DMAHP. Prior to the start of this 
project over 6 million independent cDNA clones had been screened by conventional 
hybridisation methods and no DMAHP cDNA identified. These were from mouse 
heart (King, 1996), human foetal brain, human adrenal gland, human foetal muscle, 
human adult muscle (Boucher, 1996), and human foetal muscle (Winchester, 1997) 
cDNA libraries. Therefore, it was decided to screen libraries using a small pool PCR- 
based method, which is more sensitive to rare DNA sequences (Israel, 1993).
3.2 Optimisation of PCR
PCR primers, DMAHPFB and DMAHPRC were specifically designed to reduce the 
likelihood of DNA from sources other than the cDNA libraries interfering with results. 
DMAHPFB is situated in exon B and DMAHPRC is in exon C, downstream of any 
cloned RT-PCR products present in the laboratory (figure 3.1). Therefore, genomic 
PCR products can be distinguished from cDNA PCR products and cloned RT-PCR 
products will not amplify. The primers are also situated outside of any region of 
homology to other known members of the Six subfamily.
200 ng of human genomic lymphocyte DNA was used as a template for the 
optimisation of PCR conditions. The basic PCR conditions are described in section 
2.3.6. An annealing temperature of 57°C and a range of DMSO concentrations from 
0-5% (v/v) were used. Each set of reaction conditions was tested using Taq 
polymerase supplied by Boehringer Mannheim and Promega (storage buffer A) using 
buffer supplied with the enzyme. 70% (v/v) of each PCR product was electrophoresed 
in a 2% (w/v) agarose gel (figure 3.2a). 4% (v/v) DMSO and Boehringer Mannheim 
Taq polymerase were chosen as the optimum conditions. As multiple bands were 
present, the annealing temperature was raised to 59°C and this resulted in the 
amplification of a single product of the expected size (708 bp) (figure 3.2b).
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ATG TGA
CBR013 DMAHPFB
Exon A Exon B Exon C
Six box homeobox KJDM E2R DMAHPRC
500 bp
Figure 3.1 Structure of DMAHP  showing PCR prim ers
A schematic diagram of D M AH P  indicating the positions of the primers DMAHPFB, 
CBR013, KJDM E2R and DM AHPRC, used to screen cDNA libraries for DMAHP. 
The predicted translation start site (ATG) and the stop site for the ABC isoform (TGA) 
are shown.
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Figure 3.2 Analysis of PCR optimisation
Human genomic DNA was amplified using primers DM AHPFB and DMAHPRC. 
70% (v/v) of each reaction was electrophoresed in a 2% (w/v) agarose gel.
To optimise the PCR the following conditions were tried with an annealing 
temperature of 57°C: Boehringer Mannheim Taq polymerase and DM SO 
concentrations, 0, 1, 2, 3, 4 and 5% (v/v) DM SO (lanes 1-6 respectively), Promega 
Taq polymerase and DM SO concentrations, 0, 1, 2, 3, 4 and 5% (v/v) DM SO (lanes 
7-12 respectively). Boehringer Mannheim Taq polymerase, 4% (v/v) DM SO and an 
annealing temperature of 59°C resulted in a single band of 708 bp (lane 13).
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3.3 PCR-based screening of cDNA Libraries
PCR using optimised conditions (section 3.2) was performed on 10 ng, 1 ng and 0.1 
ng of various plasmid cDNA libraries (table 3.1). Brain and muscle cDNA libraries 
were chosen as RT-PCR analysis demonstrated that Six5/Dmahp is expressed in these 
tissues in mouse (King, 1996).
tissue vector method of 
production
human foetal brain pcDNAII oligo dt primed
human foetal brain pcDM8 oligo dt primed
human foetal muscle pcDM8 oligo dt primed
human foetal brain pcDM8 random hexamer 
primed
Table 3.1 cDNA libraries screened by PCR
70% (v/v) of each PCR was electrophoresed in a 2% (w/v) agarose gel. As no DNA 
was visible on the agarose gel when viewed under ultra violet light, it was transferred 
to Hybond™-N membrane. 1.8S2 (a gift from Catherine Boucher), a pBluescript® 
SK(+) clone containing a 1.8 kb genomic DMAHP Sac II fragment covering the 
region amplified by the PCR, was digested with Sac II. The excised fragment was cut 
out of a 1% (w/v) LMP agarose gel and purified with hot phenol, before being 
radiolabelled. The radiolabelled probe was used to screen the Hybond™-N membrane 
for PCR products. The human foetal brain cDNA library in vector pcDNAII produced 
a band of the correct size (470 bp), which reduced in intensity as the amount of 
template DNA decreased. A faint band, of 470 bp, was also visible in the 10 ng 
random hexamer primed human foetal brain cDNA library in vector pcDM8 (figure 
3.3). These results indicate the presence of a DMAHP cDNA in these two libraries.
As the human foetal brain cDNA library in vector pcDNAII library gave the strongest 
bands, it was decided to continue with this library.
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1.6 kb
506 bp 
470 bp
Figure 3.3 Southern blot analysis of an initial PCR-based library screen
A range of concentrations of 4 plasmid cDNA libraries was amplified using primers 
DM AHPFB and DM AHPRC. 70% (v/v) of each reaction was electrophoresed in a 2% 
(w/v) agarose gel. The gel was Southern blotted and probed with 1.8S2.
The lanes are as follows: 1 kb ladder (lane 1), human foetal brain (vector pcDNAII), 
10 ng (lane 2), 1 ng (lane 3), 0.1 ng (lane 4), oligo dt primed foetal brain 
(vector pcDM8), 10 ng (lane 5), lng  (lane 6), 0.1 ng (lane 7), oligo dt primed foetal 
muscle (vector pcDM8), 10 ng (lane 8), 1 ng (Dne 9), 0.1 ng (Dne 10), pcDM8,
10 ng (lane 11), 1 ng (lane 12), 0.1 ng (lane 13), random hexamer primed foetal brain 
(vector pcDM8), 10 ng (lane 14), 1 kb ladder (lanes 15 and 16), random hexamer 
primed foetal brain (vector pcDM8), 1 ng (lane 17), 0.1 ng (lane 18), genomic DNA, 
200 ng (lane 19) and H2O (lane 20).
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3.4 Cloning and Sequencing of PCR product
To confirm that the PCR product was indeed DMAHP, the PCR was repeated on 10 
ng of the library. 70% (v/v) of the PCR was electrophoresed in a 2% (w/v) agarose 
gel and a slice was excised from the gel at the position where the 470 bp PCR product 
was expected. 15 pi of H20  was added to the slice and vortexed before being frozen (- 
70°C) and thawed (by incubation at room temperature) three times, lp l was used as a 
template for 6 identical PCRs to re-amplify the DNA present in the gel slice. Two 
major bands of between 4 and 500 bp were amplified (figure 3.4). The bands were 
excised from the gel, identical sized bands pooled and the DNA purified using a 
Qiagen gel extraction kit. The DNA was subcloned into the T-vector, pMOSBlue 
(following manufacturer’s instructions) and sequenced with the T7 primer. The 
sequences were compared to the GenBank, EMBL, DDBJ and PDB databases using 
the BLASTN program at NCBI. This confirmed that the larger product was amplified 
from DMAHP and was 470 bp in length and the smaller product was sequence from 
an unknown source and was presumably amplified as the result of the primers 
annealing non-specifically. The 470 bp DMAHP PCR product clone will now be 
referred to as DMAHP-470.
3.5 Small Pool PCR-Based Screening of a cDNA Library
XL-l BLUE competent cells were transformed with 1 x 106 clones from the human 
foetal brain cDNA library in pcDNAII vector. This library was originally amplified 
from 3 x 106 clones (Derek Blake, personal communication). The cells were grown in 
an 8 x 8 matrix in a microtitre plate and then pooled to limit the number of samples for 
analysis to 16 (section 2.3.11.1). Plasmid DNA was extracted from each pool, diluted 
1/100 and amplified by primers DMAHPFB and DMAHPRC using optimised PCR 
conditions (section 3.2). 70% (v/v) of each PCR was electrophoresed in a 2% (w/v) 
agarose gel. No bands were visualised on the ethidium bromide stained agarose gel 
with the exception of the positive control, which used 200 ng of genomic DNA as a 
template, giving a 708 bp product. Therefore, the DNA was transferred to Hybond™- 
N membrane and hybridised to radiolabelled DMAHP-470. Seven pools contained the 
470 bp DMAHP PCR product, indicating 12 possible positive wells (figure 3.5a). 
Several pools either contained genomic clones or were contaminated with genomic 
DNA as indicated by the presence of a 708 bp band. DNA from the 12 possible 
positive wells was prepared and 1 pi of a 1/100 dilution, used as a template for further 
PCR reactions. Again no bands were visualised on an ethidium bromide stained 2%
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tfttte506 bp —
396 bp —
Figure 3.4 PCR amplification of hum an foetal brain cDNA library
Human foetal brain cDNA library was re-amplified using primers DMAHPFB 
and DM A HPRC. 70% (v/v) of each reaction was electrophoresed in a 2% (w/v) 
agarose gel. The lanes are as follows: 1 kb ladder (lane 1), re-amplified human 
foetal brain cDNA library (vector pcDNAII) (lanes 2-7), 200 ng human genomic 
DNA (lane 8).
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Figure 3.5 Southern blot analysis of PCR-based library screen
PCRs were performed on 1 pi of a 1/100 dilution of plasmid DNA prepared from 
cultures of all the pools and appropriate wells at each stage of the library screening. 
70% (v/v) of each PCR product was electrophoresed in a 2% (w/v) agarose gel. Gels 
were Southern blotted and probed with DMAHP-470.
a) First Round Pools
1 kb ladder (lanes 1, 15 and 16), pools 1-8 (lanes 2-9), pools A-H (lanes 10-14 and 
17-19), 200 ng genomic DNA (lane 20), H20  control (lane 21).
b) First Round Wells
1 kb ladder (lane 1), well 2A (lane 2), 2G (lane 3), 2H (lane 4), 6A (lane 5), 6E (lane
6), 6G (lane 7), 6H (lane 8), 7A (lane 9), 7E (lane 10), 7G (lane 11), 7H (lane 12), 
200 ng genomic DNA (lane 13), control (lane 14).
c) Second Round Pools - made from 2A
1 kb ladder (lanes 1, 16-17), pools 1-8 (lanes 2-9), pools A-H (lanes 10-15 and 18- 
19), 200 ng genomic DNA (lane 20), H20  control (lane 21).
d) Second Round Pools - made from 6H
1 kb ladder (lanes 1, 16-17), pools 1-8 (lanes 2-9), pools A-H (lanes 10-15 and 18- 
19), 200 ng genomic DNA (lane 20), H ,0  control (lane 21).
e) Second Round Wells 
from plate 2A
1 kb ladder (lane 1), well 1A (lane 2), IB (lane 3), 1C (lane 4), ID (lane 5), IE (lane
6), 1H (lane 7), 2B (lane 8), 3B (lane 9), 5B (lane 10), 6B (lane 11), 7B (lane 12),
8B (lane 13), 200 ng genomic DNA (lane 13).
from plate 6H
1 kb ladder (lane 15), well 5B (lane 16), 5C (lane 17), 5F (lane 18), 5G (lane 19), 1C 
(lane 20), 2C (lane 21), 3C (lane 22), 6C (lane 23), 200 ng genomic DNA (lane 24), 
H20  control (lane 25).
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Figure 3.5 Southern blot analysis of PCR-based library screen
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(w/v) agarose gel. However, when the gel was blotted and probed, three wells (2A, 
6E and 6H) gave bands of 470 bp (figure 3.5b). 6E also contained genomic DNA and 
therefore it was decided to proceed with 2A and 6H. The number of clones in wells 
2A and 6H was determined (section 2.3.11.1) to be 6 x 105and 1 2 x 103clones/pl 
respectively.
40,000 clones from each of these wells were grown in an 8 x 8 matrix in a microtitre 
plate and then pooled. Plasmid DNA was prepared from the 16 pools, diluted 1/100 
and amplified using primers DMAHPFB and DMAHPRC. 2% (w/v) agarose gels 
were once again blotted and the DNA hybridised to DMAHP-470. Plate 2A (figure 
3.5c) contained 13 positive pools and plate 6H (figure 3.5d) contained 8 positive 
pools, indicated by 470 bp PCR products. Again some of the pools contained 
genomic DNA, indicated by 708 bp products. DNA from 12 of the possible positive 
wells from plate 2A and 8 of the possible positive wells from plate 6H was prepared 
and tested by PCR, blotting and hybridisation. Three wells from each plate (2A-1 A, 
2A-1H, 2A-2B, 6H-5B, 6H-1C and 6H-3C) contained the 470 bp DMAHP PCR 
product (figure 3.5e).
3.6 Determination of cDNA Insert Size
To determine the size of the inserts present in the positive clones within the three 
positive wells (2A, 6E and 6H), plasmid DNA was purified and 2 pg digested with 
EcoR I to release the inserts. The DNA was electrophoresed in a 1% (w/v) agarose gel 
and the DNA transferred to Hybond™-N membrane. The membrane was screened 
with radiolabelled DMAHP-470. Surprisingly, no positive inserts were identified 
(results not shown).
3.7 Screening of Clones from Positive Well
As 21 of the 32 pools from plates 2A  and 6H in the previous round were positive for 
DMAHP it was decided to screen individual clones from a single positive well from 
one of these plates. The number of clones in well 6H-5B was determined (section 
2.3.11.1) to be 4.7 x 103clones/pl. 3,000 clones from 6H-5B were screened by 
hybridisation to radiolabelled oligonucleotide KJDME2R, which lies in the region 
amplified by DMAHPFB and DMAHPRC (figure 3.1), to replica filters (sections 
2.3.11.2-2.3.11.4). No positive clones were identified (results not shown).
84
3.8 Confirmation of Positive PCR Results
As no positive clones were identified by hybridisation of DMAHP to the inserts 
released from the clones in wells 2A, 6E and 6H or by the screening of replica filters, 
it was hypothesised that some of the DNA preparations may have been contaminated 
with DMAHP-470. Therefore 10 ng of the library and the three positive wells (2A, 6E 
and 6H) from the first round of screening were re-screened, by PCR, using primers 
CBR013 (which lies 356 bp upstream of DMAHPFB, figure 3.1) and DMAHPRC. 
PCR conditions were optimised as section 3.2. No DMSO, an annealing temperature 
of 57°C and Boehringer Mannheim Taq polymerase were chosen as the optimal 
conditions. 70% (v/v) of each PCR product was electrophoresed in a 1.5% (w/v) 
agarose gel which was blotted and probed with DMAHP-470 (figure 3.6). Only 10 ng 
of library gave a product of the expected size (826 bp). These results indicate that 
some of the DNA preparations were indeed contaminated with cloned PCR product, 
DMAHP-470, and that the DMAHP cDNA identified in the human foetal brain cDNA 
library, was not present in the DNA prepared from the transformed XL-1 BLUE 
competent cells in wells 2A, 6E and 6H.
3.9 Direct Cloning of cDNA by Vector to Internal Primer PCR
As no DMAHP cDNA was present in the transformed XL-1 BLUE competent cells, 
direct cloning of the cDNA from the library, using vector and internal primers was 
attempted. The orientation of the insert within the vector was unknown. Figure 3.7 
shows the two possible orientations and the primers that were chosen for this 
experiment. The idea was to perform PCR using vector and internal primers to 
produce two overlapping PCR products that could be cloned, separately into vectors 
and then ligated via a restriction site in the overlapping region, to produce the cDNA 
that is present in the library.
To determine the orientation of the insert, 8 PCRs were performed on 10 ng of human 
foetal brain cDNA library in pcDNAII vector using the following combinations of 
primers, T7-DMAHPFB, T7-DMAHPRC, T7-CBR013, T7-CBR005, SP6- 
DMAHPFB, SP6-DMAHPRC, SP6-CBR013, SP6-CBR005. DMAHPFB and 
DMAHPRC were used as a positive control. No DMSO, an annealing temperature of 
55°C and Boehringer Mannheim Taq polymerase were used in the PCR. 70% (v/v) of 
each PCR product was electrophoresed in a 1% (w/v) agarose gel and the DNA 
transferred to Hybond™-N membrane. Radiolabelled DMAHP-470 was hybridised to 
the membrane. DMAHPFB-DMAHPRC amplified a cDNA product of 470 bp and 
also a genomic DNA product of 708 bp indicating the presence of genomic DNA in
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Figure 3.6 Southern blot analysis of PCR, using prim ers CBR013 and 
DMAHPRC
PCR was performed using primers CBR013 and DM AHPRC. 70% (v/v) of each 
reaction was electrophoresed in a 1.5% (w/v) agarose gel which was Southern 
blotted and probed with DMAHP-470. The lanes are as follows: 1 kb marker (lane 
1), 10 ng human foetal brain cDNA library (lane 2), lp l  1/10 dilution 2A (lane 3), 
6E (lane 4) and 6H (lane 5).
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T7 CBR013 FB
A B C
KJDME2R____ RC SP6
CBR005
CBR005 
T7 RC KJDME2R
C B A
FB CBR013 SP6
FB = EMAHPFB 
RC = DMAHPRC
Figure 3.7 D M A H P  and Primers
A schematic diagram of DMAHP showing the two possible orientations in pcDNAII 
and the positions of the internal DMAHP (DMAHPFB, DMAHPRC, CBR013, 
CBR005, KJDME2R) and vector (T7, SP6) primers.
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DMAHP-470
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1.6 kb
—  708 bp
  470 bp
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KJDME2R
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470 bp
Figure 3.8 Southern blot analysis of direct cloning PCR
PCR was performed on 10 ng human foetal brain cDNA library using 8 different com ­
binations of internal and vector primers (figure 3.8). 70% (v/v) of each reaction was 
electrophoresed in a 1% (w/v) agarose gel. The gel was Southern blotted and probed 
with DM AHP-470 (a), stripped and then probed with KJDM E2R (b).The lanes are as 
follows: 1 kb ladder (lane 1), T7-DM AHPFB (lane 2), T7-D M A H PR C (lane 3), T7- 
CBR013 (lane 4), T7-CBR005 (lane 5), SP6-DM AHPFB (lane 6), SP6-DM AHPRC 
(lane 7), SP6-CBR013 (lane 8), SP6-CBR005 (lane 9), D M A HPFB-DM AH PRC (lane 
10).
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the reaction. Four bands were present in the T7-CBR005 lane (figure 3.8). To 
confirm that they were DMAHP the membrane was stripped and hybridised to a 
radiolabelled oligonucleotide KJDME2R, which lies in the region amplified by T7- 
CBR005. Disappointingly no bands were detected, with the exception of the two 
bands in the positive control lane (figure 3.8). The T7-CBR005 PCR was repeated 
and the four bands excised from an agarose gel. The DNA was purified using a 
Qiagen gel extraction kit and subcloned into the T-vector, pMOSBlue and sequenced. 
None of the clones contained DMAHP. However, two of the sequences were present 
in the GenBank database and when they were analysed they were shown to contain 
regions 100% homologous to the 10 most 3’ bases of CBR005 although the rest of 
the sequence showed no homology to DMAHP. Regrettably, at this point, the search 
for a DMAHP cDNA was abandoned and an alternative method for the production of 
DMAHP expression constructs was devised (chapter 4).
3.10 Database searching
The GenBank, EMBL, DDBJ and PDB databases were regularly searched using the 
human genomic DMAHP sequence (accession number x848413) with the BLASTN 
program at NCBI to see if a cDNA was available from another source. One such 
database search revealed the presence of an EST which may be a DMAHP cDNA 
(accession number N23083). The clone was obtained and sequenced, but 
unfortunately contained a human haemoglobin gene. At some stage the clones were 
mislabelled and the distributors are now unable to supply the correct clone.
3.11 Discussion
The aim of the work described in this chapter was to isolate a full length human 
DMAHP cDNA. As conventional hybridisation techniques had previously failed to 
isolate such a cDNA, the more sensitive method of small pool PCR was undertaken.
A 470 bp fragment of DMAHP was successfully amplified by PCR from a human 
foetal brain cDNA library and cloned. This fragment contains 322 bp of previously 
uncloned cDNA. Unfortunately the full sequence of this cDNA failed to be isolated.
XL-1 BLUE competent cells were transformed with 1 x 106 clones from the cDNA 
library. However, it appears that DMAHP was not present in the DNA prepared from 
cells, post-transformation. This may have been due to low levels of DMAHP clones in 
the cDNA library chosen and therefore competent cells with a higher transformation 
efficiency may be required when using this particular cDNA library, or the clone may
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have been unsuitable for transformation. It is possible, that the DMAHP clone was 
present in the transformed cells, but leaky expression of DMAHP caused reduced 
growth of cells containing the positive clone and thus they were lost during the 
screening. The growth kinetics of cultures expressing DMAHP, in bacterial 
expression systems have been investigated and DMAHP expression has been shown 
to significantly reduce the growth rate of cultures in which it is being expressed 
(section 4.3 and Winchester, 1997).
The most likely explanation for the false positive results during the small pool PCR 
screen is that some of the preparations of DNA from the library pools and wells 
became contaminated with the cloned 470 bp PCR product. Alternatively the 
contamination occurred during the setting up of the PCRs. However, as the H20  
controls were always negative, this seems unlikely. Unfortunately, due to the 
sensitivity of the PCR, combined with the sensitivity of the hybridisation, this type of 
experiment will always be vulnerable to contamination problems. Future experiments 
should be performed under meticulous conditions designed to help prevent 
contamination, for example the DNA preparation and the PCR should be carried out 
away from any source of cloned DNA containing the primer sites. Contamination by 
human genomic DNA may also have occurred at one of these stages. Alternatively, the 
cDNA library contained genomic clones as contamination of cDNA libraries by 
genomic clones is known to be a problem when screening libraries. A previous cDNA 
library screen of a human foetal brain cDNA library (Stratagene) for a DMAHP cDNA 
clone, by conventional hybridisation led to the isolation of a genomic DMAHP clone 
(Boucher, 1996).
Direct cloning of the cDNA by PCR using vector to internal primers failed to amplify 
any DMAHP sequence. Of the sequences that were amplified, 2 are present in the 
GenBank database and were shown to contain regions 100% homologous to the 10 
most 3’ bases of the primer CBR005. This explains their amplification by PCR. The 
reason for their hybridising to DMAHP-470 is unclear, but is likely to be due non­
specific hybridisation, to the relatively high concentrations of PCR amplified DNA 
present on the membrane. DMAHP-470 has a high G+C content and will therefore 
hybridise preferentially to other DNA sequences with a high G+C content. The 4 
sequences that hybridised to DMAHP-470 all contained over 50% G+C. As 
oligonucleotide hybridisation tends to be more specific, KJDME2R would not have 
hybridised.
These results suggest that although a partial cDNA is present in the human foetal brain 
cDNA library (vector pcDNAII), it is either present at very low levels or is a 
rearranged clone. When this project was instigated, no human or murine DMAHP
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cDNA had been isolated despite the screening of over 6 million independent clones. 
However, one extensively rearranged clone with additional mitochondrial DNA had 
been isolated from a mouse 5’ stretch heart library (Catherine Boucher, personal 
communication). It is therefore likely, that DMAHP is not suitable for cloning in 
conventional systems and may be toxic to E.coli. Problems have been encountered 
when expressing DMAHP in bacterial expression systems including reduced growth 
rates of cultures expressing DMAHP (discussed above) failure to express any protein 
at all, the expression of truncated proteins and low levels of protein (section 4.3, 
Charles Thornton, personal communication and Winchester, 1997).
5’ and 3’ RACE have been attempted, to identify the 5’ and 3’ ends of DMAHP but 
have been unsuccessful (Catherine Boucher and Simon Came personal 
communications). A partial mouse Six5/Dmahp has now been isolated from a mouse 
retina cDNA library (Kawakami et a l , 1996b) and therefore a human retina cDNA 
library has been screened using 5’ and 3’ DMAHP probes (Catherine Winchester, 
personal communication). Two truncated cDNA clones have been isolated, one a 5’ 
clone and one a 3’ clone. Five major transcription start sites of DMAHP have been 
identified by RNase protection analysis (Klesert et a l,  1997). Therefore, despite not 
being able to obtain a full length human DMAHP cDNA, the full structure of the gene 
is gradually emerging.
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Chapter
4
Expression of Recombinant DMAHP Proteins
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4.1 Introduction
The objectives of the work described in chapter 4 were to overexpress and affinity 
purify regions of DMAHP that could be used to characterise the DNA binding 
properties of this transcription factor. DMAHP shares a 528 bp region of sequence 
homology with other members of the Six subfamily of genes (section 1.8). This 
region encodes a homeodomain and immediately upstream of this, the Six domain 
(Oliver et al., 1995a). At the time of starting this project nothing was known about the 
function of the Six domain. AREC3/Six4 was originally identified as one of the 
proteins that binds to the Na+ K+ ATPase a l  subunit regulatory element (ARE) 
(Suzuki-Yagawa et al., 1992). It was shown that the homeodomain of murine AREC3 
was required for DNA binding and the Six domain was required for specific binding 
to the ARE (Kawakami et al., 1996a). To investigate the functions of these two 
domains in human DMAHP and to identify specific DNA binding sites, recombinant 
proteins encoded by the Six box and the homeobox were generated.
As no full length DMAHP cDNA was available, it was decided to subclone regions of 
the gene using pMOS-DMAHP-ABC (a 1.15 kb RT-PCR product, subclone, primed 
from DMAHPF and KJDME2R, figure 4.1) and cosmid F I8894 (a 40 kb genomic 
clone containing DMAHP in its entirety). A Glutathione S-transferase (GST) Gene 
Fusion System (Pharmacia Biotech) was chosen for the expression and purification of 
the gene fragments as this system had previously been used with success in our 
laboratory (Winchester, 1997). It allows inducible overexpression of recombinant 
proteins as fusion proteins attached to the carboxyl terminus of GST. The recombinant 
proteins can be purified from bacterial cell lysates, if required, by affinity 
chromatography using Glutathione Sepharose® 4B.
4.2 Subcloning of the Six box and Homeobox into 
pGEX4T3
The Six box and the homeobox of human DMAHP were subcloned both separately 
and together, into pGEX4T3 for expression and purification. Figure 4.1 shows a 
schematic diagram of DMAHP and indicates the regions that were subcloned and 
expressed.
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ATG TGA
DM AHPF
Exon CExon BExon
I —
Six box homeobox D M A H PR SEH  KJDM E2R
500 bp
pM OS-D M A HP-ABC
pGEX.HD
pGEX.Six
pGEX.Six+HD
Figure 4.1 S tructure of DMAHP  showing subcloned regions
A schematic diagram of D M AH P  indicating the region present in the RT-PCR 
product subclone, pM OS-DM AHP-ABC and the regions subcloned into pGEX4T3 
for bacterial over expression (pGEX.HD, pGEX.Six and pGEX.Six+HD). PCR 
primers, DM AHPF, D M A HPRSEH and KJDM E2R are indicated. The predicted 
translation start site (ATG) and the stop site for the ABC isoform (TGA) are shown.
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4.2.1 Subcloning of the Homeobox into pGEX4T3
The homeobox (180 bp), 52 bp of the Six box and 79 bp of sequence 3’ to the 
homeobox were amplified from pMOS-DMAHP-ABC by PCR using primers 
DMAHPF and DMAHPRSEH (figure 4.1) (section 2.3.6 with 1% (v/v) DMSO, 
Boehringer Mannheim Taq polymerase and an annealing temperature of 57°C). The 
311 bp PCR product (figure 4.2a) was subcloned into the T-vector, pMOSBlue 
(pMOS.HD), following manufacturer’s instructions. To confirm that the sequence had 
not been mutated by the PCR and to determine the orientation of the insert within 
pMOSB/we, pMOS.HD was sequenced using the T7 primer. No mutations were 
detected (results not shown) and the orientation of the insert is shown in figure 4.3. 
The orientation of the insert needed to be known to enable further subcloning.
As no suitable restriction endonuclease sites were present in pMOSZ?/«£ to allow the 
homeobox to be subcloned in frame into the expression vector pGEX4T3, the 
homeobox, from pMOS.HD, was subcloned into pBluescript® SK (+) (pSK 
(+).HD). This vector has an extensive MCS which is helpful when doing further 
subcloning (figure 4.4). pBluescript® SK(+) was digested with Sma. I and CIAP 
treated to prevent it religating and the DNA extracted using phenol/chloroform. The 
PCR product containing the homeobox was released from pMOS.HD by digestion 
with BamR  I and Hind III and the polymerase activity of the Klenow fragment used to 
fill the recessed termini. The fragment was purified from a 3% (w/v) LMP agarose gel 
(figure 4.2b) using hot phenol and ligated into the Sma I site of pBluescript® SK(+). 
DH5a cells were transformed with the construct and 6 clones digested with Acc I to 
determine the orientation of the insert. Five of the 6 clones contained the insert in the 
same orientation. The sixth clone appeared to contain multiple inserts (figure 4.2d). 
Although the digest indicated that the 5 clones were in the same orientation both 
orientations would give a band of 272 bp and then a second band of either 114 bp or 
55 bp depending on the orientation of the insert, which would electrophorese below 
the smallest visible band (134 bp) in the marker lane (figure 4.2d). However, as the 5 
clones were identical it was impossible to determine which orientation they were in. 
Therefore, pSK(+).HD was sequenced with T7 and T3 (results not shown). This 
confirmed the identity and integrity of the insert and that the 5’ end of the homeobox 
was at the EcoR I side of the MCS and the 3’ end at the Not I side (figure 4.4).
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Figure 4.2 Subcloning of the homeobox into pGEX4T3
Vector and insert DNA used in the subcloning of the homeobox into pGEX4T3 were 
analysed by electrophoresis in 1, 2 or 3% (w/v) agarose gels. LMP agarose gels were 
utilised when the fragment was purified.
a) The homeobox (180 bp) plus 131 bp of flanking sequence was amplified from 
pMOS-DMAHP-ABC using primers DMAHPF and DMAHPRSEH (lane 1).
b) pMOS.HD was digested with BamH I and Hind III and the polymerase activity of 
the Klenow fragment used to fill the recessed termini. The 365 bp fragments were 
electrophoresed in a 3% (w/v) LMP agarose gel (lanes 2-5) and gel purified.
c) 5 pi of the 365 bp gel purified insert (lane 6) and 1 pi of Sma I digested, CIAP 
treated 2.9 kb pBluescript®SK(+) (lane 8) were electrophoresed in a 2% (w/v) agarose 
gel next to a low DNA mass marker (lane 7). It was estimated that the concentration of 
insert was 8 ng/pl and the concentration of vector was 200 ng/pl.
d) Six colonies of pSK(+).HD were screened for the presence of an insert by 
digesting the plasmid DNA with Acc I and electrophoresing in a 2% (w/v) gel. Five of 
the six colonies contained a single insert, digested into 2 fragments (lanes 9, 10, 11,
13 and 14). One colony contained multiple inserts (lane 12).
e) Two aliquots, each containing lp g  of pGEX4T3 were digested with EcoR I and 
Not I and electrophoresed in a 1% (w/v) LMP agarose gel (lanes 15 and 16), from 
which they were purified.
f) Four aliquots, each containing 200 ng of pSK(+).HD were digested with EcoR I 
and Not I and electrophoresed in a 2.5% (w/v) LMP agarose gel (lanes 17-20), from 
which 405 bp inserts were purified.
g) 5 pi of gel purified 405 bp insert (lane 23) and 1 pi of gel purified EcoR UNot I 
digested 4.9 kb pGEX4T3 (lane 22) were electrophoresed in a 2% (w/v) agarose gel 
next to a low DNA mass marker (lane 24) and 100 ng undigested pGEX4T3 (lane 
21). It was estimated that the concentration of insert was 4 ng/pl and the concentration 
of vector was 10 ng/pl.
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Figure 4.2 Subcloning of the homeobox into pGEX4T3
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Figure 4.3 Structure of pMOS.HD
311 bp o f DM AHP, including the entire homeobox, 52 bp of the Six box and 79 bp 
downstream of the homeobox were amplified from pM OS.D M AH P-A BC using 
primers DM A H PF and DM AHPRSEH. The PCR product was subcloned into the T- 
vector pM O SBlue, to generate pMOS.HD.
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Figure 4.4 Structure of pSK(+).HD
The PCR product containing the homeobox and 52 bp of the Six box was released from 
pM OS.HD by digestion with Bam H  I and H ind  III and subcloned into the Sma I site of 
pBluescript SK(+) to generate pSK(+).HD.
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pGEX4T3 and pSK(+).HD were digested with EcoR I and Not I. Both, pGEX4T3 
and the fragment released from pSK(+).HD were purified from 1% and 2.5% (w/v) 
LMP agarose gels respectively, using hot phenol (figure 4.2 e and f) and the 
homeobox containing fragment was ligated into pGEX4T3 to give pGEX.HD (figure 
4.5). TOPIO cells were transformed with pGEX.HD. 17 out of 18 colonies analysed 
contained the insert. pGEX.HD was sequenced using primers pGEXFl and pGEXBl 
and this confirmed that the insert was present in the correct reading frame and no base 
changes had occurred (results not shown).
4.2.2 Subcloning of the Six Box into pGEX4T3
As the Six box is upstream of the RT-PCR product present in pMOS-DMAHP-ABC, 
it was necessary to subclone this fragment from cosmid F I8894. The Six box lies 
within a 420 bp BamH 11 Acc I fragment. This fragment was subcloned into 
pBluescript® SK(+) (pSK(+).Six) to permit the use of the extensive MCS present in 
this vector (figure 4.6). However, as the cosmid is about 40 kb in size it was not 
considered possible to isolate the fragment from an agarose gel. Therefore, F18894 
was digested with BamH I and Acc I and shotgun subcloned into the BamH 11 Acc I 
sites of pBluescript® SK(+).
F I8894 DNA was prepared using a Qiagen Maxiprep kit, following the 
manufacturer’s instructions. 60 p,g of F18894 was digested with BamH I and Acc I 
and the DNA extracted using phenol chloroform and ethanol precipitated and 
resuspended in 10 pi H20 . 1 (xl of the DNA was electrophoresed in a 1% (w/v) 
agarose gel alongside 1 jliI BamH 11 Acc I digested, phenol chloroform extracted, 
pBluescript® SK(+) (figure 4.7a). It was estimated that the concentration of 
pBluescript® SK(+) was 100 ng/jal and that of the 420 bp fragment released from 
F I8894 was 9 ng/pl Based on these estimations a ligation reaction was set up with a 
molar insert to vector ratio of 3:1.
DH5a cells were transformed with the construct. BamH 11 Acc I digests of 18 clones 
indicated that they all contained 2 inserts (results not shown). Three of the clones 
(clones 13, 15 and 17) contained at least one insert of about 400 bp ( figure 4.7b) and 
were sequenced using the T7 primer (results not shown). Sequence analysis showed 
that the Acc I site of pBluescript® SK(+) had failed to cleave and that two inserts had 
ligated into the BamH I site. Clones 15 and 17 contained the Six box fragment. This 
fragment was released, from clone 15, by a BamH 11 Acc I digestion (figure 4.7c) and 
ligated into the BamH 11 Acc I sites of pBluescript® SK(+). D H 5a cells were
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Figure 4.5 Structure of pGEX.HD
The PCR product containing the homeobox and 52 bp of the Six box was released from 
pSK(+).HD by digesting with EcoR  I and N ot I and subcloned into pGEX4T3 to 
generate pGEX.HD.
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Figure 4.6 Structure of pSK(+).Six
A 420 bp BamWMAcc I fragment of cosmid F18894, containing the Six box, 56 bp 
upstream of the Six box and 17 bp of the homeobox was subcloned into 
pBluescriptSK(+) to generate pSK(+).Six
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Figure 4.7 Subcloning of the Six box and the Six + homeobox into 
pG EX4T3
Vector and insert DNA used in the subcloning of the Six box and Six+homeobox into 
pGEX4T3 was analysed by electrophoresis in 1,2, 2.5 or 3% (w/v) agarose gels. 
LMP gels were utilised when the fragment was gel purified.
a) 1 pi of BamH I/Acc I digested FI 8894 DNA (lane 1) and 1 jul of gel purified BamH 
11 Acc I digested pBluescript®SK(+) (lane 2) were electrophoresed in a 1% (w/v) 
agarose gel next to a low DNA mass marker (lane 3). It was estimated that the 
concentration of a 2 kb fragment of F418894 was 40 ng/jul and therefore the 
concentration of the 420 bp fragment was 9 ng/pl. The concentration of the vector was 
estimated to be 100 ng/pl.
b) Three colonies (13,15 and 17) were shown to contain one insert of about 400 bp, 
when digested with BamH I and Acc I and electrophoresed in a 2.5% (w/v) agarose 
gel (lanes 4, 5 and 6).
c) 1 jul of gel purified BamH 11 Acc I digested clone 15, 420 bp insert (lane 8) and 1 pi 
of gel purified BamH 11 Acc I digested pBluescript®SK(+) (lane 7) were 
electrophoresed in a 1% (w/v) agarose gel next to a low DNA mass marker (lane 9). It 
was estimated that the concentration of the 420 bp fragment was 8 ng/pl and that of 
the vector was 10 ng/pl.
d) Three aliquots each containing 3 jug of pSK(+).Six were digested with BamH I and 
partially digested with Xho I and electrophoresed in a 2.5% (w/v) LMP agarose gel 
from which the 426 bp fragment was gel purified.
e) 5 pi of gel purified 272 bp insert from Acc I digested pGEX.HD (lane 14) and 5 pi 
of gel purified Acc I digested pGEX.Six (lane 13) were electrophoresed in a 2% (w/v) 
agarose gel next to a low DNA mass marker (lane 15). It was estimated that the 
concentration of the insert was 2 ng/pl and that of the vector was 40 ng/pl.
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Figure 4.7 Subcloning of the Six box and the Six+homeobox into pGEX4T3
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transformed with pSK(+).Six. Fortunately, this time, the Acc I site was cleaved and 
13 out of the 17 clones tested contained the correct sized insert. pSK(+).Six was 
sequenced with T7 and T3 primers and the expected sequence of pSK(+).Six was 
confirmed (results not shown).
pGEX4T3 and pSK(+).Six were digested with BamH I and Xho I. Although an Xho 
I site exists within the Six box (figure 4.6), Xho I cuts with only 70-100% efficiency 
in the restriction endonuclease buffer used (Boehringer Mannheim buffer B). 
Therefore, due to incomplete digestion by Xho I, three different sized fragments were 
released from pSK(+).Six, the largest (426 bp) being the one required (figure 4.7d). 
Both, pGEX4T3 and the 426 bp fragment released from pSK(+).Six were purified 
from 1% and 2.5% (w/v) LMP agarose gels respectively, using hot phenol and the 
Six box containing fragment was ligated into pGEX4T3 to give pGEX.Six (figure 
4.8). TOPIO cells were transformed with pGEX.Six. 15 out of 18 colonies analysed 
contained the insert. pGEX.Six was sequenced using primers pGEXFl and pGEXBl 
and this confirmed that the insert was present in the correct reading frame and no base 
changes had occurred (results not shown).
4.2.3 Subcloning of the Six+HD into pGEX4T3
pGEX.Six (figure 4.8) was digested with Acc I, to linearise the construct, and CIAP 
treated to prevent it religating and the DNA extracted using phenol/chloroform. 
pGEX.HD (figure 4.5) was also digested with Acc I which released an insert 
containing most of the homeobox plus 80 bp of 3’ flanking sequence, which included 
53 bp of exon B and pMOSBlue sequence from the T cloning site to the Acc I site. 
This insert was purified from a 3% (w/v) LMP agarose gel and ligated into pGEX.Six 
to give pGEX.Six+HD (figures 4.7e and 4.9). TOPIO cells were transformed with 
the construct. Clones were tested for the presence of an insert by digesting the 
construct with Sac II as a Sac II site exists in both the Six box and in the homeobox 
(figure 4.9). One of the positive clones was sequenced using primers pGEXFl and 
pGEXBl and this confirmed that the insert was present in the correct reading frame 
and no base changes had occurred (results not shown).
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glutathione S-transferase
Ptac
EcoR  V 4100
MCSpGEX.Six 
5.30 kb
lacIQ
Amp
pBR322
ori P st I 1900
MCS
Bam H I, EcoR  I, Sma I, Sal I, Xho  I, N ot I
keyXho I Acc I
homeobox
Figure 4.8 S tructure of pGEX.Six
A 426 bp fragment, containing the Six box, 56 bp of upstream DNA and 17 bp of the 
homeobox was released from pSK(+)Six by digestion with BamH  I and Xho I and 
subcloned into the BamH  I/Xho  I sites of pGEX4T3 to generate pGEX.Six..
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glutathione S-transferase
Ptac
MCS,aciq pGEX.Six+HD 
5.57 kb
Amp
pBR322
ori Pst I 1900
MCS
BamH  I, EcoR  I, Sma  I, Sal I, Xho  I, Not I
AccXho I Sac II Acc I Sac II pMOS Blue 
pSK(+)
Figure 4.9 Structure of pGEX.Six+HD
The homeobox was released from pGEX.HD by digestion with Acc  I and subcloned into 
the Acc  I site of pGEX.Six to generate pGEX.Six+HD which contains the entire Six and 
homeobox plus 136 bp of flanking DNA.
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4.3 Expression of Recombinant GST-DMAHP Proteins
Recombinant GST-DMAHP proteins were expressed from the pGEX4T3 constructs 
described above (pGEX.HD, pGEX.Six and pGEX.Six+HD). GST protein tag was 
also expressed both as a positive control for the expression experiments and also as a 
negative control for the binding experiments (chapter 5). The expected molecular 
weights of the recombinant proteins were estimated using Mac Vector: GST-HD (41 
kDa), GST-Six (45 kDa) and GST-Six+HD (53 kDa).
4.3.1 Optimisation of the Expression of Recombinant GST-DMAHP 
Proteins
A protein expression time course (section 2.3.12.2) was required to determine the 
optimum growth and recombinant protein synthesis conditions for each protein. 1 mM 
IPTG was used to induce expression of recombinant protein for 5 hours at 37°C and 
readings were taken every hour with a sixth reading, after overnight expression (21 
hours). SDS-PAGE analysis of the crude cell lysate was used to detect overexpressed 
recombinant proteins. The growth kinetics of each recombinant GST fusion protein 
were analysed by measuring the optical density of the cells at each time point.
a) GST -HD protein expression time course
No overexpressed GST-HD protein was detected by SDS-PAGE analysis of the crude 
cell lysate, produced in the time course experiment (results not shown), although GST 
protein of the expected size (29 kDa) was clearly visible in the supernatant fraction of 
the pGEX4T3 cultures (figure 4.10a). Induction of the expression of GST protein had 
little effect on the growth of the culture (figure 4.11). However, the growth rate of the 
culture of TOPIO cells transformed with pGEX.HD and induced with 1 mM IPTG 
was reduced, compared to the non-induced culture, which grew at about the same rate 
as both GST cultures.
In an attempt to produce detectable amounts of GST-HD, cultures were induced for 
longer periods of time (up to 30 hours), with 0.5 mM, 1 mM, 2 mM and 5 mM 
concentrations of IPTG. No overexpressed GST-HD protein was detected by SDS- 
PAGE analysis of the crude cell lysate, in any of the samples (results not shown).
It was hypothesised that the GST-HD protein was toxic to the cells, which would 
explain the reduced growth rate o»f the cultures induced with IPTG. It is known that 
basal level expression occurs whe;n using the tac inducible promoter present in
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Figure 4.10 SDS-PAGE analysis of the protein extracted from the supernatant 
fraction of GST and GST-HD protein expression time course experiments.
6% (v/v) of the supernatant fraction of 1 ml aliquots from 100 ml cultures of 
pGEX4T3 and pGEX.HD were analysed by SDS-PAGE analysis in a 10% (w/v)
SDS polyacrylamide gel. GST (pGEX) expression was induced in the absence of glu­
cose and GST-HD (HD) was induced in the presence of 2% (w/v) glucose. 0-21 = ali­
quot taken 0-21 hours after addition of IPTG, i = 1 m M  IPTG added, u/i = no IPTG 
added. 29 kDa GST protein can be seen in lanes: l ipGEX, 2ipGEX, 3ipGEX, 
4ipGEX, 5ipGEX and 6ipGEX, but not in any of the u/i lanes. A 30 kDa protein can 
be seen in lanes: liHD, 2iHD, 3iHD, 4iHD and 5iHD, decreasing in concentration 
with time. It is not visible in any of the u/i lanes.
— 29 kDa 
(GST)
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Figure 4.11 Growth curves of pGEX and pGEX-DMAHP cultures
T h e  o p t i c a l  d e n s i t y  o f  1 m l o f  c e l l s  a t  6 0 0  n m  w a s  p l o t t e d  a g a i n s t  t i m e .
pGEX4T3 1 mM IPTG
pGEX4T3 no IPTG
• pGEX.HD ImM IPTG
pGEX.HD no IPrG
- pGEX.HD 1 m.Vl IPTG 
2% (w/v) glucose
pGEX.HD no IPTG 
2% (w/v) glucose
pGEX.Six ImM IPTG
pGEX.Six no IPTG
pGEXSix+HD ImM IPTG 
2% (w/v) glucose
pGEX.Six+HD no IPrG 
2% (w/v) glucose
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pGEX4T3 and may be due to the presence of a lac promoter located upstream 
(Pharmacia Biotech). The cells may already have been dying when the IPTG was 
added and maximum protein production may have taken place. The addition of 2% 
(w/v) glucose decreases the basal level expression associated with the lac promoter 
(Pharmacia Biotech). Therefore, a protein expression time course was performed in 
the presence of 2% (w/v) glucose. SDS-PAGE analysis did not detect an 
overexpressed protein of the expected size (41 kDa). However a 30 kDa protein 
(which is just heavier than the GST protein, alone) was detected in the supernatant 
fraction of the crude cell lysate (figure 4.10b). As a truncated GST-DMAHP protein 
had previously been reported (Winchester, 1997), it was decided to investigate this 
protein by affinity purification (section 4.3.2b) and western blot analysis (section 
4.3.3). The growth rate of the culture of TOPIO cells transformed with pGEX.HD 
induced with 1 mM IPTG and 2% (w/v) glucose was reduced, with respect to 
uninduced culture and the absorbance at 600 nm actually decreased after 4 hours 
induction (figure 4.11). The amount of protein produced, as visualised by SDS- 
PAGE analysis also decreased with time (figure 4.10b).
b") GST-Six protein expression time course
The growth rate of the culture expressing GST-Six was reduced only slightly, with 
respect to the uninduced culture (figure 4.11). SDS-PAGE analysis detected a protein 
of 42 kDa in the pellet fraction of the crude cell lysate (figure 4.12). The predicted size 
was 45 kDa. From two hours post-induction, GST-Six could also be visualised in the 
pellet fractions containing no IPTG, due to basal level expression (section 4.3.1a).
c) GST-Six+HD expression time course
2% (w/v) glucose was added to the culture to prevent basal level expression, which 
had proven to be a problem when expressing GST-HD protein. No overexpressed 
GST-Six+HD protein was detected by SDS-PAGE analysis of the crude cell lysate 
(results not shown). The growth rate of the culture of TOPIO cells transformed with 
pGEX.Six induced with 1 mM IPTG and 2% (w/v) glucose was reduced, with 
respect to the uninduced culture and the GST cultures, with the absorbance at 600 nm 
decreasing after 4 hours of induction (figure 4.11). This suggested that any expressed 
recombinant GST fusion protein was toxic to the cells. As no overexpressed protein 
could be detected by SDS-PAGE analysis, even with the addition of 2% (w/v) 
glucose, the presence of recombinant GST-Six+HD was investigated by western blot 
analysis (section 2.3.16). GST antiserum detected a doublet of 52 and 50 kDa and a
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Figure 4.12 SDS-PAGE analysis of the protein extracted from the 
pellet fraction of a GST-Six protein expression time course
5 %  ( v / v )  o f  t h e  p e l l e t  f r a c t i o n  o f  1 m l  a l i q u o t s  f r o m  a  1 0 0  m i  c u l t u r e  
o f  p G E X . S i x  w e r e  a n a l y s e d  b y  S D S - P A G E  a n a l y s i s  in  a  1 0 %  ( w / v )  g e l .  
0 - 2 1  =  a l i q u o t s  t a k e n  0 - 2 1  h o u r s  a f t e r  t h e  a d d i t i o n  o f  I P T G .  
i =  I m M  I P T G  a d d e d ,  u / i  =  n o  I P T G  a d d e d .  T h e  4 2  k D a  G S T - S i x  ( S i x )  
r e c o m b i n a n t  p r o t e i n  c a n  b e  s e e n  in  l a n e s :  l i S i x ,  2 i S i x ,  3 i S i x , 4 u / i S i x ,  4 i S i x ,  
5 u / i S i x ,  5 i S i x ,  21  u / i S i x  a n d  21 iS i x .
kDa u/i  s / n  P
9 4  
6 7
4 3
3 0  
20
Figure 4.13 SDS-PAGE analysis of the protein extracted from a large 
scale culture of GST-Six protein
0 . 0 2 %  ( v / v )  o f  a  5 0 0  m l  u n i n d u c e d  ( u / i )  c u l t u r e  o f  p G E X . S i x ,  0 . 1 0 %  ( v / v )  o f  t h e  
s u p e r n a t a n t  ( s / n )  f r a c t i o n  a n d  0 . 1 3 5 %  ( v / v )  o f  t h e  p e l l e t  ( p )  f r a c t i o n  o f  a  c u l t u r e  
i n d u c e d  f o r  4  h o u r s  w i t h  I m M  I P T G  a t  3 0 ° C  w e r e  e l e c t r o p h o r e s e d  in  a  1 0 %  ( w / v )  
S D S  p o l y a c r y l a m i d e  g e l .  T h e  4 2  k D a  G S T - S i x  p r o t e i n  i s  v i s i b l e  in  t h e  p e l l e t  f r a c t i o n .
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Figure 4.14 W estern blot analysis of the protein extracted from GST- 
Six+HD protein expression time course
5 %  ( v / v )  o f  t h e  p e l l e t  ( P )  f r a c t i o n  a n d  6 %  ( v / v )  o f  t h e  s u p e r n a t a n t  ( S )  
f r a c t i o n  o f  1 m l  a l i q u o t s  f r o m  1 0 0  m l  c u l t u r e s  o f  p G E X - S i x + H D  ( S i x + H D )  
a n d  p G E X  ( G S T )  w e r e  e l e c t r o p h o r e s e d  in  a  1 0 %  ( w / v )  S D S  p o l y a c r y l a m i d e  
g e l  a n d  e l e c t r o b l o t t e d  o n t o  H y b o n d - N  E C L  n i t r o c e l l u l o s e  m e m b r a n e .  T h e  
m e m b r a n e  w a s  p r o b e d  w i t h  G S T  a n t i s e r u m  0 - 2 1  =  a l i q u o t  t a k e n  0 - 2 1  
h o u r s  a f t e r  t h e  a d d i t i o n  o f  I P T G .  i =  1 m M  I P T G  a d d e d ,  u / i  =  n o  I P T G  a d d e d .  
T h e  G S T - S i x + H D  p r o t e i n  is  v i s i b l e  in  a l l  p e l l e t  l a n e s ,  d e c r e a s i n g  in  
c o n c e n t r a t i o n , w i t h  t i m e .
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30 kDa protein in the pellet fractions of the crude cell lysates and the concentration of 
these proteins decreased with time (figure 4.14). The expected size of the protein was 
53 kDa. A 70 kDa protein was also detected, in both supernatant and pellet fractions. 
The 30 kDa protein is presumably a partial GST-Six+HD protein and the 70 kDa is 
thought to be a product of the E.coli dnaK gene, which is involved in the degradation 
of abnormal proteins in E.coli (Pharmacia Biotech). The supernatant fractions also 
contained a 29 kDa protein, which was assumed to be GST.
4.3.2 Large Scale Expression and Purification of Recombinant GST- 
DMAHP Proteins
To produce greater amounts of recombinant GST fusion protein, for affinity 
purification, 500 ml cultures were grown (section 2.3.12.3). Sonication was used to 
lyse the cells, rather than freeze/thawing as this had previously been shown to be a 
more efficient method, when using larger cultures (Winchester, 1997). Recombinant 
GST fusion protein was affinity purified using Glutathione Sepharose® 4B beads 
(section 2.3.12.5). 20 ml of sonicated cell lysate or 8 ml of solubilised pellet fraction 
was mixed with 1.6 ml of 50% (w/v) Glutathione Sepharose® 4B beads resuspended 
in MTPBS buffer. Recombinant GST fusion protein was eluted from the glutathione 
Sepharose® 4B beads by the addition of 6 ml of elution buffer [50 mM Tris (pH 8.0), 
120 mM NaCl, 10 mM DTT, 1 mM PMSF, 20 mM reduced glutathione].
a) GST expression and purification
From the growth kinetics experiments carried out when optimising the expression of 
the 3 fusion proteins, 4 hours was chosen as the optimum expression time for GST 
protein (figure 4.10a). SDS-PAGE analysis of affinity purified protein detected a 29 
kDa protein (figure 4.15a).
bl GST-HD expression and purification
As the protein had been shown to be toxic to the cells, cultures were induced at 30°C 
for 1 hour. SDS-PAGE analysis of affinity purified protein detected a doublet of 38 
kDa and 40 kDa (figure 4.15b). The expected size of the protein was 41 kDa.
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Figure 4.15 SDS-PAGE analysis of the stages of affinity purification of 
GST and GST-HD
0.04% (v/v) unbound protein, 0.07% (v/v) wash 1, 0.13% (v/v) eluted protein 
and 0.13% (v/v) protein remaining bound to the beads were analysed by SDS- 
PAGE analysis in a 10% (w/v) gel. To obtain sufficient protein for use in gel 
retardation assays, three 400 ml cultures of pGEX.HD were prepared.
^  40 kDa 
—  38 kDa
(GST-HD)
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c) GST-Six expression and purification
As GST-Six was present in the pellet fraction of the cell lysate during the time course 
experiment, cells were induced at 30°C, as lower growth temperatures have been 
shown to increase fusion protein solubility (Schein, 1989). Four hours was chosen as 
the optimum time for protein expression and 2% (w/v) glucose was added to the 
culture to reduce basal level expression. SDS-PAGE analysis showed that GST-Six 
was still present in the pellet fraction (figure 4.13) and therefore inclusion bodies were 
solubilised (section 2.3.12.4). The stages of inclusion body solubilisation were 
analysed by SDS-PAGE analysis (figure 4.16) and the 42 kDa protein could be 
visualised in the solubilised pellet fraction. SDS-PAGE analysis of affinity purified 
GST-Six detected a major band of 42 kDa with a fainter band running at about 41 
kDa. A faint band of 30 kDa, which is presumably GST protein plus a small amount 
of DMAHP, that has separated from the main fusion protein by proteolytic cleavage, 
could also be seen (figure 4.17). Much of the protein remained on the Glutathione 
Sepharose® 4B beads.
dl GST-Six+HD expression and purification
Cells were induced at 30°C, to increase the solubility of the protein. One hour was 
chosen as the optimum time for protein expression and 2% (w/v) glucose was added 
to the culture to reduce basal level expression. No recombinant GST-Six+HD was 
detected by SDS-PAGE analysis (result not shown). However, western blot analysis, 
with R254 DMAHP anti serum, to confirm that the overexpressed protein was a 
DMAHP protein, showed that the recombinant protein was now in the supernatant 
fraction (figure 4.18) which would facilitate affinity purification. SDS-PAGE of 
affinity purified protein detected a doublet of 52 kDa and 50 kDa (figure 4.19).
4.3.3 Western Blot Analysis of GST-HD and GST-Six Proteins
To confirm that the proteins visualised by SDS PAGE analysis were GST-DMAHP 
recombinant proteins they were transferred to Hybond™-N ECL nitrocellulose 
membrane and analysed with polyclonal antisera (section 2.3.16). GST antiserum and 
R254 DMAHP antiserum were used as primary antisera, with HRP-conjugated 
secondary antibodies, to detect the recombinant GST-DMAHP proteins.
Affinity purified GST-Six, GST-HD and GST protein were analysed. GST antiserum 
detected the 42 kDa and the 30 kDa affinity purified GST-Six proteins, the affinity
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Figure 4.16 SDS-PAGE analysis of GST-Six obtained from inclusion 
bodies
GST-Six protein was obtained by solubilising the inclusion bodies present in 
the pellet fraction of the cell lysate. Aliquots of the supernatants produced at each 
stage of the solubilisation procedure were electrophoresed in a 10% (w/v) SDS 
polyacrylamide gel. The lanes are as follows: 0.02% (v/v) of supernatant 1 (lane 
1), 0.02% (v/v) of supernatant 2 (lane 2), 0.07% (v/v) of supernatant 3 (lane 3), 
0.07% (v/v) of supernatant 4 (lane 4) and 0.1% (v/v) of solubilised and dialysed 
GST-Six (lane 5).
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Figure 4.17 SDS-PAGE analysis of the stages of afFinity purification of 
GST-Six
0.04% (v/v) unbound protein, 0.07% (v/v) wash 1, 0.13% (v/v) eluted protein 
and 0.13% (v/v) protein remaining bound to the beads were analysed by SDS- 
PAGE analysis in a 10% (w/v) gel. Despite 3 elutions the majority of the protein 
remained bound to the beads.
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 ___ 52 kDa
—  50 kDa 
(GST-Six+HD)
—  30 kDa
Figure 4.18 W estern blot analysis of the protein extracted from a large 
scale culture of GST-Six+HD protein
0.01% (v/v) of an uninduced 500 ml culture of pGEX-Six+HD (lane 1), 0.05%
(v/v) of the pellet fraction (lane 2) and 0.1% (v/v) of the supernatant fraction 
(lane 3) of a culture overexpressing GST-Six+HD and 0.1% (v/v) of  the supernatant 
fraction of a culture overexpressing GST (lane 4) were analysed by western blotting and 
probing with R254 DM A HP antiserum. GST-Six+HD was detected in the supernatant 
fraction (lane 3).
&jjc
/  52 kDa 
—  50 kDa
(GST-Six+HD)
Figure 4.19 SDS-PAGE analysis of the stages of affinity purification of 
GST and GST-Six+HD
0.04% (v/v) unbound protein, 0.07% (v/v) wash 1, 0.13% (v/v) eluted protein 
and 0.13% (v/v) protein remaining bound to the beads were analysed by SDS- 
PAGE analysis in a 10% (w/v) gel. To obtain sufficient protein for use in gel 
retardation assays, three 400 ml cultures of pGEX.HD were prepared.
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Figure 4.20 W estern blot analysis of affinity purified GST-Six, GST-HD 
and GST recom binant proteins
250 ng of affinity purified GST-Six (lanes land  5), 200 ng of affinity purified 
GST-HD (lanes 2 and 6) and 1000 ng of affinity purified GST (lanes 4 and 8) 
were electrophoresed in a 10% (w/v) SDS polyacrylamide gel and electroblotted 
onto Hybond-N ECL nitrocellulose membrane. Lanes 1-4 were probed with GST 
antiserum and lanes 5-8 with R254 DM A HP antiserum. Lanes 3 and 7 are not 
applicable to this experiment.
5 6 7 8
40 kDa (GST-HD) 
— 38 kDa
29 kDa 
(GST)
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purified GST-HD protein doublet and affinity purified GST protein (figure 4.20). A 
30 kDa protein in the GST-HD lane could also be seen after a 10 minute exposure 
(result not shown). R254 DMAHP antiserum detected only the affinity purified 
homeodomain doublet (figure 4.20). As R254 DMAHP antiserum was raised against 
only a small part of the Six domain it was not expected to detect GST-Six.
4.4 Concentrating Recombinant GST-DMAHP Proteins
4.4.1 Estimating the Concentration of Recombinant GST-DMAHP 
Proteins
The concentrations of affinity purified GST-HD and GST-Six were estimated from 
figure 4.21 as described in section 2.3.12.6. 8 pi affinity purified protein was 
electrophoresed in a 10% (w/v) SDS-polyacrylamide gel, alongside Coomassie Blue- 
stained BSA standards. It was estimated that the concentration of GST-HD was 25 
ng/pl and GST-Six was 31 ng/pl.
4.4.2 Concentrating the Affinity Purified Recombinant Proteins
Although the affinity purified proteins produced were relatively pure, they were not 
very concentrated. To enable an intensive study of their functional properties it was 
necessary to obtain them at a higher concentration.
a) 2 ml of affinity purified GST-HD and GST-Six were reduced to 200 pi using a 
Centricon 10 membrane unit, according to the manufacturer’s instructions. 8 pi 
concentrated protein was electrophoresed in a 10% (w/v) SDS-polyacrylamide gel, 
alongside Coomassie Blue-stained BSA standards (figure 4.21). The concentration of 
GST-HD was estimated to be 2.5 ng/pl. No GST-Six recombinant protein was visible 
on the gel.
b) 500 pi cold 100% (v/v) ethanol and acetone were used to precipitate affinity 
purified GST-HD, GST-Six and GST-Six+HD (section 2.3.12.7b). The pellet was 
dried and resuspended in 50 pi cold 50 mM Tris (pH 8.0), 120 mM NaCl, 10 mM 
DTT, 1 mM PMSF and 10.5% (v/v) glycerol. The sample was either snap frozen 
immediately or dialysed against 50 mM Tris (pH 8.0), 120 mM NaCl and 10.5% (v/v) 
glycerol, with 10 mM DTT and 1 mM PMSF being added before being snap frozen. 
Dialysis was performed to ensure that the correct salt concentration was maintained, 
for further experiments. 10 pi aliquots of each of the 4 samples and unconcentrated 
GST-HD were analysed by SDS-PAGE. The two samples that had been precipitated 
but not dialysed contained more protein than the unconcentrated sample. The sample
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Figure 4.21 SDS-PAGE analysis to determine the concentration of affinity 
purified recom binant protein
Dilutions of BSA standards in the range of 10-500 ng, were electrophoresed in 
a 10% (w/v) SDS polyacrylamide gel and stained with Coomassie Blue. These 
standards were used to determine the concentration of recombinant protein 
before and after concentration. Lane 1 contains 8 pi (250 ng) affinity purified 
GST-Six, lanes 2 and 5 contains 8 pi (200 ng) affinity purified GST-HD, lanes 
3 and 4 contain 8 pi of GST-Six and GST-HD that have been reduced in volume 
using Centricon 10 membrane units. Lanes 6, 7, 8 and 9 contain 8 pi acetone 
precipitated, ethanol precipitated, ethanol precipitated and dialysed and 
acetone precipitated and dialysed GST-HD, respectively.
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that had been precipitated by acetone was about three times more concentrated and the 
ethanol precipitated sample was about twice as concentrated as the unconcentrated 
sample. Unfortunately most of the protein was lost during dialysis (figure 4.21). 
Similar experiments on GST-Six and GST-Six+HD failed to precipitate and thus to 
concentrate any protein with any degree of efficiency (results not shown).
4.5 Thrombin Cleavage of GST-DMAHP Recombinant 
Proteins
To obtain recombinant DMAHP protein more representative of native protein, removal 
of the GST-tag was attempted. A thrombin cleavage site is present in pGEX4T3, 
upstream of the MCS to allow the GST and the translated product of the subcloned 
DNA fragment to be separated. Pharmacia Biotech recommend using 10U thrombin 
per 1 mg of protein to be cleaved. Therefore, 0.01U thrombin were mixed with 1.0 
pg affinity purified GST-HD or 1.0 pg affinity purified GST-Six in a total volume of 
200 pi and incubated for 24 hours. 15 pi aliquots were taken for SDS-PAGE 
analysis, every 2 hours. However, due to the low concentration of protein,
Coomassie Blue failed to stain the proteins sufficiently to allow visualisation and the 
proteins were stained using silver nitrate (section 2.3.14.2). This revealed only the 
presence of the GST-HD and GST-Six proteins plus some faint degradation products 
that were visible in all samples including those, containing no thrombin (results not 
shown).
As low concentrations of protein were used, it was thought that small amounts of 
cleaved protein might not be visible and the experiment was repeated using 0.05U 
thrombin and 5.0 pg protein. However, even after silver staining the recombinant 
proteins, no differences could be seen between the samples (results not shown). As 
the recommended concentration of thrombin had no visible effect on the fusion 
proteins, the experiment was repeated using 0.1U thrombin (twice that recommended 
by Pharmacia Biotech) and 5.0 pg protein, but still no cleavage occurred and the 
experiments were ceased.
4.6 Discussion
The aim of the work described in this chapter was to express and affinity purify 
recombinant GST-DMAHP proteins that could be used in functional studies of the 
protein. At the time the work was initiated, nothing was known about the function of 
DMAHP, although AREC3/Six4 another member of the Six subfamily of proteins had 
been shown to be a DNA binding protein (Kawakami et al., 1996a).
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A bacterial fusion protein expression system was chosen because it allows for fast and 
efficient purification of protein under nondenaturing conditions. Other DNA binding 
proteins have been successfully expressed as recombinant fusion proteins and shown 
to retain their binding activity (Veirijzer and Vandervliet, 1993). Murine members of 
the Six subfamily (Six2, Six3 and 57x5) have now been expressed as GST fusion 
proteins and successfully used to investigate the binding activity of these proteins 
(Kawakami et a l,  1996b).
4.6.1 Subcloning of DMAHP Fragments into pGEX4T3
Five mammalian members of the Six subfamily are known and they all share a region 
of high sequence homology which is composed of the Six box and homeobox. 
Outside of this region the genes have no sequence homology. Therefore it was 
believed that the Six box and homeobox encoded the functional domains of the 
proteins and fragments containing these boxes were subcloned both as a single unit 
and as two separate units to enable their individual and collective functions to be 
characterised.
4.6.2 Expression of Recombinant GST-DMAHP Proteins
The growth kinetics of the three fusion proteins (GST-Six, GST-HD and GST- 
Six+HD) and GST protein were monitored to see the effect of expressing recombinant 
protein on the E.coli cells. Synthesis of recombinant GST protein did not effect the 
growth rate of the cultures. Both constructs expressing the homeodomain drastically 
reduced the growth rates of the cultures in which they were being expressed and the 
construct expressing only the Six domain caused a slight reduction in growth rate. 
These experiments indicate that the homeodomain is toxic to the cells and that this 
toxicity causes proteins expressing the homeodomain to be degraded. A GST- 
DMAHP protein produced by the subcloning of the RT-PCR product present in 
pMOS-DMAHP-ABC (figure 4.1) into pGEX-2T (GST-DMAHP-ABC), caused 
reduced growth of E.coli cultures expressing it (Winchester, 1997). However, in 
contrast to the homeodomain containing proteins expressed for this thesis, GST- 
DMAHP-ABC was not degraded, but was expressed very slowly. Optimum 
expression was obtained after 21 hours of induction by 1 mM IPTG at 37°C.
GST-HD was never expressed in high enough concentrations to be visible on a 
Coomassie Blue stained gel, in the presence of bacterial proteins, as it was masked by 
a bacterial protein of the same weight. However, a 30 kDa GST fusion protein could 
be seen after induction at 30 °C. After affinity purification the bulk of the recombinant
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GST-HD protein was detected as a doublet, with the two bands of 38 and 40 kDa 
staining with equal intensity. Both bands were detected by GST antiserum and R254 
DMAHP antiserum indicating that they are GST fusion proteins containing the 
homeodomain of DMAHP. The 30 kDa protein was detected by GST antiserum, but 
not by R254 DMAHP antiserum, indicating that it consisted mainly of recombinant 
GST. It was assumed that the 40 kDa protein, represented the full length expressed 
protein. The 38 kDa protein may be a truncated version of this protein or alternative 
folding may have caused half of the protein sample to electrophorese slightly faster 
than the other half during SDS-PAGE.
Expression of GST-Six did not significantly reduce the growth of the culture in which 
it was being expressed and relatively large amounts of this protein were produced. 
However, even when the recombinant GST-Six was induced at 30°C it was insoluble. 
This is a common problem with recombinant proteins produced in bacteria and may be 
due to the high concentration of the protein within the bacterial cell or to the particular 
amino acid sequence of the protein causing it to aggregate into inclusion bodies 
(Schein, 1989). Inclusion body solubilisation of GST-Six appeared to have been 
successful as the 42 kDa protein could be visualised in the solubilised pellet fraction. 
However, after affinity purification only a small fraction of the protein was present in 
the eluant suggesting that the Six domain part of the fusion protein had interacted with 
the matrix and could therefore not be eluted using reduced glutathione. Alternatively, 
the majority of the protein had precipitated in the 1 x PBS, after dialysis and was 
simply being pelleted during the centrifugation stages of affinity purification. GST-Six 
was detected by GST antiserum and was not detected by R254 DMAHP antiserum, 
indicating that it was indeed a GST fusion protein. No Six domain antiserum was 
available to confirm that the Six domain was present in this recombinant protein, but 
sequence analysis of the pGEX.Six construct indicated that this should be so.
Like GST-HD, GST-Six+HD was never expressed in high enough concentrations to 
be visible by Coomassie Blue staining, in the presence of bacterial proteins, as it was 
masked by a bacterial protein of the same weight. GST-Six+HD was detected in the 
pellet fraction of the cmde cell lysate, produced during a time course experiment, by 
R254 DMAHP antiserum. The amount of recombinant protein detected decreased with 
time, indicating that the protein was being degraded. When GST-Six+HD was 
induced in a 500 ml culture at 30°C for 1 hour the protein was detected in the 
supernatant fraction of the crude cell lysate. This may have been due to either the 
reduced temperature increasing the solubility of the protein or to sonication being a 
more efficient way of lysing bacterial cell walls than repeated freeze/thawing.
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GST-Six+HD was detected as a doublet in an SDS polyacrylamide gel. The two 
bands of 50 and 52 kDa were detected by R254 DMAHP antiserum, indicating that 
they contained the homeodomain of DMAHP. They were visible with equal intensity 
when stained with Coomassie Blue. It was assumed that the larger protein (52 kDa), 
represented the full length expressed protein and that the 50 kDa protein may be either 
a shorter version of this protein or alternative folding may have caused half of the 
protein sample to electrophorese slightly faster than the other half during SDS-PAGE. 
It was interesting that the two proteins expressing the homeodomain were detected as 
doublets, in SDS polyacrylamide gels, with the upper and lower bands being 
visualised with equal intensity when stained with Coomassie Blue. In both cases the 
upper band was two kDa larger than the lower band. It is possible, that a site 
susceptible to proteolytic cleavage exists at the C-terminus of the homeodomain or that 
the structure of the homeodomain, when expressed as a recombinant protein in 
bacteria, allows it to fold in two different ways. It is also possible that the lower band 
in each doublet represented truncated expressed protein. A GST-DMAHP protein 
produced by the subcloning of the RT-PCR product present in pMOS-DMAHP-ABC 
into pGEX-2T was always detected as a single band. However, the predicted 
molecular weight of this protein was 71 kDa, but was detected as 37 kDa (Winchester, 
1997). It was thought to be truncated at the C-terminus which would mean that 
translation was ceasing at about the same position as in the homeodomain proteins that 
were expressed for this thesis, if the smaller bands did indeed represent truncated 
expressed protein. GST fusion proteins made containing murine Six2, Six3, 
Six4/AREC3 and Six5/Dmahp homeodomains were all detected as single bands on 
SDS polyacrylamide gels (Kiyoshi Kawakami, personal communication).
4.6.3 Concentrating Recombinant GST-DMAHP Proteins
Although the affinity purified GST-DMAHP proteins produced were relatively pure, it 
was only possible to obtain them at between 15 and 30 ng/pl of eluted protein. This is 
sufficiently concentrated for gel retardation assays, but leaves little scope for carrying 
out titration experiments to determine the optimum ratio of DNA:protein. This 
information would be beneficial when calculating the amount of protein to use in the 
whole genome PCR screen (chapter 6). Therefore, ultrafiltration was used in the form 
of Centricon 10 columns, to concentrate GST-Six and GST-HD. Unfortunately, the 
proteins appeared to bind permanently to the membranes, which is a common problem 
when using proteins with binding activity (Martin Boocock, personal 
communication). Although this was disappointing with regard to concentrating the 
proteins, it was encouraging from the point of view that proteins showed binding
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activity. As GST-Six and GST-HD both attached permanently to the membrane, when 
GST-Six+HD was purified it was not concentrated by ultrafiltration.
As the recombinant proteins could not be purified by ultrafiltration, precipitation by 
organic solvents was tried. Both acetone and ethanol were used although acetone is 
thought to carry less risk of denaturing the protein. Only GST-HD was successfully 
concentrated in this manner and about 70% of the protein was lost when using 
acetone, which was more efficient than ethanol. Ammonium sulphate was also 
considered a possibility for precipitating the proteins. However, for this to work with 
any degree of efficiency an initial concentration of 1 fig/pl is required and so this was 
not attempted. These experiments indicate that the recombinant proteins are at least 
partially soluble in 50% (v/v) acetone and ethanol. Lyophilisation was also considered 
as a possibility for concentrating the recombinant proteins. However previous 
experiences in our laboratory, of lyophilising GST fusion proteins, had shown that 
only 25% of the protein which had been lyophilised was recovered. Therefore, it was 
decided to proceed with gel retardation assays using unconcentrated recombinant 
protein and to test the concentrated GST-HD to see if it greatly improved the binding 
activity of this particular recombinant protein (chapter 5).
4.6.4 Thrombin Cleavage of Recombinant GST-DMAHP Proteins
Although DNA-protein binding experiments have been successfully carried out using 
complete GST fusion proteins (Verrijzer et a l, 1992), it was decided to attempt to 
remove the GST moiety from GST-HD and GST-Six to obtain more authentic 
proteins. However, despite using twice the recommended amount of thrombin, no 
cleavage occurred. It is possible that the GST-HD and GST-Six fusion proteins folded 
in such a way as to make the cleavage site inaccessible to the thrombin. A GST- 
DMAHP protein produced by the subcloning of the RT-PCR product present in 
pMOS-DMAHP-ABC into pGEX-2T also failed to cleave using thrombin 
(Winchester, 1997) and the inefficient cleavage of several other GST fusion proteins 
has been reported (Guan and Dixon, 1991). Guan and Dixon (1991) improved the 
cleavage efficiency of several fusion proteins by introducing a glycine-rich linker, 
immediately following the thrombin cleavage site in the pGEX vector. It is thought, 
that the tandem glycine residues alter the structure at the protease cleavage site within 
the fusion protein, thus making the site more accessible to thrombin. To address the 
common problem of inefficient cleavage by thrombin, Pharmacia Biotech have now 
introduced a new pGEX vector that contains a specific cleavage site for a genetically 
engineered protease, PreScission™ Protease, which they report greatly enhances 
cleavage efficiency.
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As thrombin cleavage of GST-Six and GST-HD failed, no attempt was made to cleave 
GST-Six+HD once it was affinity purified. Unfortunately no substrate was available 
on which to test the activity of the thrombin. All further experiments were carried out 
using complete GST fusion proteins.
4.7 Conclusion
Three recombinant GST-DMAHP fusion proteins, containing the Six domain, the 
homeodomain and both the Six domain and homeodomain together, were successfully 
overexpressed in a bacterial system. The recombinant fusion proteins were affinity 
purified with glutathione as the affinity ligand.
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Chapter
5
Characterisation of the DNA Binding Properties of 
Recombinant DMAHP Proteins
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5.1 Introduction
The recombinant GST fusion proteins (GST-Six, GST-HD and GST-Six+HD) 
described in the previous chapter were used in gel retardation assays to investigate 
putative DNA binding targets of DMAHP and the functions of its two conserved 
domains. Double stranded oligonucleotides representing putative DNA binding sites 
were utilised as DNA fragments in the assays.
AREC3/Six4 binds to the Na+ K+ ATPase a  1 subunit gene regulatory element (ARE) 
and is a cell-type specific factor involved in the regulation of this gene (Kawakami et 
a l,  1996a). The AREC3/Six4 binding site within the ARE (GGTGTCAGGTTGC) 
differs from all previously reported homeodomain binding sites, the majority of which 
include a core tetranucleotide ATTA (Gehring et a l , 1994). The amino acid at position 
50 of the classical homeodomain specifies the two bases immediately 5’ to the core 
sequence. DMAHP has a lysine at position 50 which would indicate that its binding 
site might be GGATTA. However, it is known that arginine at position 5 of the 
homeodomain which is conserved in 97% of known homeodomains binds to the core 
sequence (ATTA) (Gehring et a l, 1994). DMAHP and AREC3/Six4 have a valine at 
this position and other members of the Six subfamily have serine or threonine (section
1.8.2). Therefore, it is likely that the Six subfamily of homeodomain proteins bind to 
their target DNA at an entirely different recognition site to other homeodomain 
proteins. The Six domain may play an important role in modulating binding 
specificity, either as a DNA binding domain or a protein binding domain or both.
It was hypothesised that DMAHP regulates DMPK (the protein kinase gene present at 
the DM locus) as prior to the start of this project both genes had been shown to be 
expressed in a similar range of tissues and levels of expression of DMPK had been 
shown to be altered in DM patients (Boucher et a l, 1995; Carango et a l, 1993; Fu et 
a l,  1993; Krahe et a l, 1995a; Sabourin et a l, 1993; Wang et a l,  1995). A site 
similar to the AREC3/Six4 binding site was identified in the promoter region of 
human DMPK, along with a GGATTA homeodomain consensus site which is 
conserved in both mouse and human.
5.2 Subcloning of DNA Fragments into pBluescript® SK(+)
Three putative DNA binding sites of DMAHP were identified: 1) The 13 bp 
AREC3/Six4 binding site, GGTGTCAGGTTGC (Suzuki-Yagawa et a l, 1992). 2) A 
Bestfit analysis of the AREC3/Six4 binding site to the promoter region of DMPK 
identified CCCCTCAGGTTCC (nucleotides 733-745, accession number L08835) as
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the most similar in this region. This sequence was termed ARE-like. 3) A GGATTA 
consensus site in the promoter region of DMPK (nucleotides 1323-1328, accession 
number L08835). 40 bp double stranded oligonucleotides representing the genomic 
sequences containing the putative sites and flanking regions were produced. A mutant 
ARE sequence, GGTGTGAGGTTGC, that differed by a single base pair (highlighted 
in bold) from the true ARE sequence and had been shown not to bind AREC3/Six4 
(Kawakami et a l,  1996a) was also made as a negative control. The oligonucleotides 
(sequences are shown in table 2.4) were subcloned into pBluescript® SK(+) (section 
2.3.17.1).
5.3 Gel Retardation Assays Using Affinity Purified 
Recombinant Protein
Gel retardation assays were performed using affinity purified GST, GST-Six, GST- 
HD and GST-Six+HD and radiolabelled DNA fragments designated, ARE, AREmut, 
ARE-like and GGATTA (section 2.3.17). Plasmids containing the putative binding 
sites were digested with Hind HI and Xba I to release a 66 bp fragment, containing the 
40 bp genomic sequence and 26 bp of plasmid sequence, from pBluescript SK(+). 
Both pBluescript SK(+) and the DNA fragment containing the putative binding site 
were radiolabelled (section 2.3.17.2). The pBluescript SK(+) DNA acted as a non­
specific DNA competitor. Reactions contained 6 pmoles (10 pi of eluant from the 
affinity purification process, section 4.3.2) of recombinant protein and 3 fmoles of 
DNA fragment and were carried out in both the presence and absence of 0.01 pg/pl of 
poly[dl/dC].poly[dl/dC], which also acted as a non-specific competitor. It was 
decided to add 10 pi of undiluted affinity purified recombinant protein to a reaction 
mix with a final volume of 15 pi because the concentration of the affinity purified 
GST-DMAHP recombinant proteins was relatively low (15-30 ng/pl = 0.6 pM). This 
made the final concentration of the binding buffer 33 mM Tris-HCl (pH 8.0), 80 mM 
NaCl, 7 mM DTT, 0.7 mM PMSF which is similar to buffers used for other 
homeodomain protein gel retardation assays (Affolter et a l, 1990; Wilson et a l,
1993). Affinity purified GST recombinant protein was diluted in 1.5 x binding buffer 
so that it too was at a concentration of 0.6 pM. Reactions were electrophoresed in a 
standard 8% (w/v) low ionic strength or 1 x Tris/glycine, non-denaturing 
polyacrylamide gel (section 2.3.17.4).
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5.3.1 Binding Reactions Analysed in a Standard Low Ionic Strength Non- 
Denaturing Polyacrylamide Gel
GST-Six+HD was combined with each of the radiolabelled DNA fragments and the 
reactions were analysed in a standard low ionic strength non-denaturing 
polyacrylamide gel. Binding of the recombinant protein to the DNA fragments was not 
detected under these conditions (figure 5.1a). Therefore, a 1 x Tris/glycine gel and 
buffer system was utilised as this system had been reported to stabilise certain 
protein/DNA complexes that had proven to be unstable under standard conditions 
(Bednarz et al., 1990).
5.3.2 Binding Reactions Analysed in 1 x Tris/Glycine Non-Denaturing 
Polyacrylamide Gels
GST-Six+HD was combined with each of the radiolabelled DNA fragments and the 
reactions were analysed in a 1 x Tris/glycine non-denaturing polyacrylamide gel. Two 
retarded complexes were detected in the lanes containing the ARE fragment (Cl and 
C2), but not in any of the other lanes (figure 5.1b). The binding activities of all 4 
recombinant proteins (GST, GST-Six, GST-HD and GST-Six+HD) were tested with 
the ARE fragment. GST-Six-HD formed 2 complexes and GST-HD formed a single 
complex (C3). Neither GST nor GST-Six showed any binding activity with the ARE. 
A lower yield of complex was formed by GST-HD than GST-Six+HD and the 
complex was of an intermediate mobility (figure 5.1c). The binding activity of GST- 
HD was tested using ARE, AREmut, ARE-like and GGATTA. Binding was only 
detected with ARE (C3, figure 5.Id). The presence of 0.01 jLLg/^ il of 
poly [dl/dC]. poly [dl/dC] as a non-specific DNA competitor had no effect on the 
formation of the retarded complexes. GST-Six and GST showed no binding activity 
when tested with AREmut, ARE-like or GGATTA (results not shown).
The experiments described above indicate that both GST-Six+HD and GST-HD 
display specific DNA binding activity. However, the extent of binding to the ARE 
fragment was not substantial. Less than 10% (w/w) of the labelled fragment was 
bound by the recombinant proteins. This may have been due to the relatively low 
concentration of protein used. Attempts to concentrate the recombinant proteins met 
with little success (section 4.4.2). However, GST-HD was successfully precipitated 
by ethanol and acetone and then resuspended in 1.5 x binding buffer to give 
concentrations of 1.2 pM (50 ng/pl) and 1.8 pM (75 ng/pl) respectively (section 
4.4.2b). The binding activity of concentrated GST-HD was tested with the ARE 
fragment; it was shown to have lost all binding activity (figure 5.2).
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Figure 5.1 Gel retardation assays using affinity purified GST-DMAHP 
recom binant proteins
Reactions contain 6 pmoles of affinity purified recombinant protein and 3 fmoles of 
labelled DNA fragment. All reactions were performed in the presence (+) and absence 
(-) of O.Olpg/pl poly [dl/dC].poly [dl/dC]. GST-Six+HD was tested with: ARE (lanes 1, 
2, 9 and 10) ARE-like (lanes 3, 4, 11 and 12), GG ATTA (lanes 5, 6, 13 and 14), ARE­
mut (lanes 7, 8, 15 and 16). The reactions were anlaysed in a standard low ionic 
strength gel and buffer system (a) or a Tris/glycine gel and buffer system (b). GST- 
Six+HD (lanes 17 and 18), GST-HD(lanes 19 and 20), GST-Six (lanes 21 and 22), 
GST (lanes 23 and 24) were tested with ARE in a Tris/glycine system (c). GST-HD 
was tested with ARE (lanes 25 and 26), ARE-like (lanes 27 and 28), GGATTA (lanes 
29 and 30), AREmut (lanes 31 and 32) in a Tris/glycine system (d).
DNA
vector
Cl
C2
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Figure 5.2 Comparison of binding activity of precipitated and non-precipitated 
GST-HD
10 pi of affinity purified, unprecipitated (lanes land  2), acetone precipitated 
(lanes 3 and 4), ethanol precipitated (lanes 5 and 6), ethanol precipitated and 
dialysed (lanes 7 and 8) and acetone precipitated and dialysed (lanes 9 and 10) 
GST-HD were tested against ARE in the presence (+) and absence (-) of 0.01 pg/pl 
poly [dl/dC]. poly [dl/dC],
GST-Six GST-Six 
GST lys. GST lys. AP +HD lys. +HD lys. AP 
-(- Triton - Triton GST + Triton - Triton GST-Six+HD
_L
W W LU UJw we* oc
Figure 5.3 Gel retardation analysis using purified ARE fragm ent
The binding activities of 10 pi of 1/10 dilutions of cell lysate (lys.) prepared with 
(+ Triton) and without (- T riton)l%  (v/v) Triton X-100, from bacteria expressing 
GST or GST-Six+HD and affinity purified (AP) GST and GST-Six+HD, were test­
ed with 3 fmoles of gel purified ARE and AREmut.
133
5.3.3 Gel Retardation Assay Using Purified ARE Fragment
The homeodomain of Drosophila sine oculis was reported to bind the core sequence 
(C/T)GATAC present within the 3.1 kb pUC119 plasmid (Hazbun et a l, 1997). This 
sequence is also represented 4 times in the related plasmid pBluescript SK(+), which 
was present as a non-specific competitor in the gel retardation experiments described 
above. Therefore, to determine the effect of pBluescript SK(+) in gel retardation 
assays the putative binding sites were separated from the vector sequence. The 66 bp 
fragment released from pBluescript SK(+) by digestion with Hind III and Xba I was 
purified from a 3.5% (w/v) NuSieve agarose gel using a Qiagen gel extraction DNA 
purification kit. The purified fragment was radiolabelled (section 2.3.17.2, with the 
exception that purified fragment plus 1 x Life Technologies Ltd React 2 was used in 
place of the restriction digest reaction). The binding activities of affinity purified GST- 
Six+HD and GST were tested with gel purified ARE and AREmut. 0.01 jitg/ptl of 
poly[dI/dC].poly[dI/dC] was used as a non-specific DNA competitor, as it was in all 
further gel retardation assays. No increase in the amount of either DNA fragment 
binding to affinity purified GST-Six+HD was detected and affinity purified 
recombinant GST bound to neither ARE nor AREmut (figure 5.3). Therefore, it was 
decided that it was not necessary to separate the putative binding sites from the vector 
sequence prior to a gel retardation assay.
5.4 Gel Retardation Assays Using Crude Cell Lysate 
Containing Recombinant Protein
As the binding activities of affinity purified DMAHP fusion proteins were relatively 
low, the binding activities of GST, GST-Six+HD and GST-HD in crude cell lysate 
were investigated. GST-Six was unsuitable for this experiment due to its insolubility 
in the cell lysate (section 4.3.2c). 500 ml cultures containing pGEX4T3, 
pGEX.Six+HD or pGEX.HD were grown and recombinant protein expression 
induced by the addition of 1 mM IPTG (section 2.3.12.3). The cells were lysed by 
sonication at room temperature and either 1% (v/v) Triton X-100 was added and 
incubated at room temperature for 30 minutes before the sample was centrifuged and 
the supernatant snap frozen, or the sample was centrifuged and the supernatant snap 
frozen immediately. Triton X-100 was added to samples prior to affinity purification 
to aid the solubilisation of the fusion proteins. However, there was concern that the 
presence of detergent in the crude cell lysate would disrupt DNA-protein complexes 
formed by protein present in the cell lysate.
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Crude cell lysate from bacteria expressing GST-Six+HD was diluted 1/10 with 1.5 x 
binding buffer. The binding activity of 10 pi of diluted cell lysate containing 
overexpressed GST-Six+HD, both with and without 1% (v/v) Triton X-100, was 
tested with gel purified ARE and AREmut. The crude cell lysate in the absence of 
Triton X-100 bound strongly to the ARE and also bound with a lower affinity to 
AREmut. The crude cell lysate in the presence of Triton X-100 bound very weakly to 
the ARE and no binding was observed to AREmut (figure 5.3). It was observed that 
the lower complex, formed by the crude cell lysate (C4) had an apparent molecular 
weight that was less than that of the lower complex formed by affinity purified GST- 
Six+HD (C2). To demonstrate that it was the overexpressed GST-Six+HD forming 
the retarded complexes with the DNA and not another protein present in the cell lysate, 
the binding activity of cell lysate from bacteria expressing recombinant GST was 
investigated. GST cell lysate in the presence of Triton X-100 did not bind to either of 
the fragments. In the absence of Triton X-100 it bound weakly to both ARE and 
AREmut, (figure 5.3). This binding was very weak and the complex was of a 
different molecular weight to the complexes detected when using unpurified GST- 
Six+HD and so it was concluded that the complexes detected in the presence of crude 
cell lysate from bacteria expressing GST-Six+HD were indeed formed by the GST- 
Six+HD.
The binding activities of both GST-Six+HD and GST-HD, from crude cell lysates 
prepared without the addition of Triton X-100, were investigated using the 4 putative 
DNA binding sites. The reactions were carried out in the presence of radiolabelled 
DNA fragment and vector (pBluescript SK(+)), plus 0.01 ng/pl of 
poly[dI/dC].poly[dI/dC]. Interestingly, in the presence of pBluescript SK(+), GST- 
Six+HD bound strongly to the ARE, forming 2 retarded complexes, but bound to 
AREmut with much less affinity than in the absence of pBluescript SK(+). The upper 
complex formed with the ARE contained about 3 times as much DNA as the lower 
complex. No complexes were detected with ARE-like or GGATTA (figure 5.4). The 
binding activity of GST-HD appeared unaltered when present in crude cell lysate. 
Weak binding was observed to the ARE, but not to AREmut, ARE-like or GGATTA 
(figure 5.4).
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Figure 5.4 Comparison of the binding activities of affinity purified and unpuri­
fied GST-DMAHP recom binant proteins
The binding activities 10 pi of 1/10 dilution of cell lysates containing GST-Six+HD 
or GST-HD were compared to the binding activities of 6 pmoles of the same recom­
binant proteins that had been affinity purified either with (A PI)  or without (AP2) the 
addition of 1% (v/v) Triton X-100. 3 fmoles of ARE, ARE-like, GGATTA and 
AREmut were used as probes.
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5.5 Investigations into the Cause of the Increased Binding 
Activity of Unpurified GST-Six+HD
Several explanations for the increase in binding activity, particularly the increase in 
DNA present in the upper complex, when GST-Six+HD remained in the crude cell 
lysate were investigated. These are as follows:
1) Triton X-100 is present in affinity purified GST-Six+HD at a low concentration 
causing the DNA-protein complex to partially dissociate.
2) Affinity purification is inefficient, causing a reduction in the concentration of GST- 
Six+HD in the purified eluant compared to the unpurified cell lysate.
3) The protein is highly susceptible to degradation in its affinity purified form.
4) Affinity purification modifies the GST-Six+HD in such a way as to reduce its 
binding activity.
5) A cofactor, similar to a natural cofactor present in the human cell, is present in the 
E.coli cell lysate that enhances binding activity.
5.5.1 Affinity Purification of Recombinant Proteins in the Absence of 
Triton X-100
The presence of Triton X-100 in the crude cell lysate greatly reduced the formation of 
DNA-protein complexes. Therefore, it was possible that trace amounts of Triton X- 
100 in affinity purified GST-Six+HD partially disrupted the formation of the DNA- 
protein complexes. Therefore, GST-Six and GST-Six+HD were affinity purified 
(section 2.3.12.5) without the post-sonication addition of 1% (v/v) Triton X-100. The 
yield of affinity purified protein was reduced from between 15 and 30 ng/pJ to 10 
ng/jLtl. This was presumably due to the reduced solubility of the recombinant proteins 
in the absence of Triton X-100. GST-Six+HD and GST-HD purified in this manner, 
showed no binding activity when tested with ARE and AREmut (figure 5.4). This 
was likely to be due to the decrease in the concentration of the recombinant proteins. 
This experiment indicated that the increase in binding activity was not due, solely, to 
the absence of Triton X-100 in the binding reaction.
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5.5.2 Analysis to Determine Relative Amounts of Binding Activity in 
Affinity Purified Recombinant Proteins and Crude Cell Lysates
As the lower binding activity of affinity purified GST-Six+HD did not appear to be 
due to the presence of Triton X-100 in the binding reaction other factors were 
investigated. It was hypothesised that either total recombinant protein or the binding 
activity of the recombinant protein was reduced by affinity purification. 10 pi of 
affinity purified eluant represents 0.17% (v/v) of total eluant, whereas 10 pi of a 1/10 
dilution of crude cell lysate represents only 0.005% (v/v) of total cell lysate. Therefore 
if the affinity purification were 100% efficient, reactions containing affinity purified 
protein would contain 34 times as much recombinant protein as those performed with 
crude cell lysate.
A titration assay was performed to determine the concentration of crude cell lysate 
from bacteria expressing GST-Six+HD required to produce the level of binding 
observed when using 10 pi (6 pmoles) of affinity purified GST-Six+HD. Cell lysate 
from bacteria expressing GST-Six+HD was diluted 1/10, 1/20, 1/40, 1/80, 1/160 and 
1/320 in 1.5 x binding buffer. 10 pi of each dilution were tested in a binding assay 
using ARE. The intensity of the 2 complexes gradually decreased, until at the dilution 
of 1/160 the level of binding was approximately that seen with affinity purified GST- 
Six+HD (figure 5.5). A 1/10 dilution of GST-HD cell lysate gave a level of binding 
equivalent to 10 pi (6 pmoles) of affinity purified GST-HD (figure 5.4).
5.5.3 Western Blot Analysis of Affinity Purified and Unpurified GST- 
Six+HD and GST-Six+HD
To determine the efficiency of the affinity purification process it is necessary to know 
the concentrations of the recombinant fusion proteins in both their affinity purified 
forms and in crude bacterial cell lysate. However, it was not possible to determine the 
concentration of the affinity purified recombinant fusion proteins using standard 
assays as they were not present at a high enough concentration. The concentrations of 
the unpurified recombinant fusion proteins could not be determined by such an assay 
due to the presence of bacterial proteins. Therefore, the relative concentrations of 
affinity purified and unpurified GST-Six+HD and GST-HD were determined by 
western blot analysis. Serial dilutions of cell lysates from bacteria expressing GST- 
Six+HD and GST-HD and undiluted affinity purified recombinant proteins were 
electrophoresed in 10% (w/v) SDS polyacrylamide gels. Protein was transferred to 
Hybond™-N ECL nitrocellulose membrane and probed with R254 DMAHP 
antiserum (section 2.3.16). A 20 minute exposure to detection solution was required
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Figure 5.5 Gel retardation analysis of a serial dilution of GST-Six+HD celi 
lysate
S e r i a l  d i l u t i o n s  o f  c e l l  l y s a t e  e x p r e s s i n g  G S T - S i x + H D  w e r e  m a d e .  T h e  b i n d i n g  
a c t i v i t y  o f  10  p i  o f  e a c h  d i l u t i o n  w a s  t e s t e d  w i t h  3 f m o l e s  o f A R E .  A s  t h e  c o n c e n ­
t r a t i o n  o f  c e l l  l y s a t e  d e c r e a s e d  t h e  i n t e n s i t i e s  o f  b o t h  C l  a n d  C 4  d e c r e a s e d .
G S T - S i x + H D  G S T - H D
Figure 5.6 W estern blot analysis of serial dilutions of GST-Six+HD and GST- 
HD cell lysates
10  p i  o f  a f f i n i t y  p u r i f i e d  G S T - S i x + H D  a n d  G S T - H D ,  u n d i l u t e d  c e l l  l y s a t e  c o n t a i n i n g  
e a c h  o f  t h e  r e c o m b i n a n t  p r o t e i n s  a n d  d i l u t i o n s  o f  e a c h  o f  t h e  r e c o m b i n a n t  p r o t e i n  
c e l l  l y s a t e s  w e r e  e l e c t r o p h o r e s e d  in  1 0 %  ( w / v )  S D S  p o l y a c r y l a m i d e  g e l s .  T h e  p r o ­
t e i n  w a s  t r a n s f e r r e d  to  H y b o n d - N  E C L  n i t r o c e l l u l o s e  m e m b r a n e  a n d  p r o b e d  w i t h  
R 2 5 4  D M A H P  a n t i s e r u m .
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to visualise 6 pmoles of affinity purified GST-Six+HD (membranes are normally 
exposed for a maximum of 5 minutes). The amount of GST-Six+HD and GST-HD, 
detected in the cell lysate gradually decreased as the cell lysate became less 
concentrated. After a 20 minute exposure, GST-Six+HD was no longer visible at a 
dilution of 1/80 (figure 5.6). Therefore, R254 DMAHP antiserum has the equivalent 
affinity for approximately 10 pi of a 1/60 dilution of crude cell lysate from bacteria 
expressing GST-Six+HD as for 10 pi (6 pmoles) of undiluted affinity purified GST- 
Six+HD. GST-HD could still be detected in a 1/80 dilution of crude cell lysate from 
bacteria expressing this recombinant protein, but could no longer be detected at a 
concentration of 1/160. It was estimated that R254 DMAHP antiserum would have an 
equivalent affinity for GST-HD in a 1/60 dilution of crude cell lysate as 10 pi (6 
pmoles) of undiluted affinity purified GST-HD. Although cell lysates from bacteria 
expressing GST-Six+HD needed to be diluted to the same degree as those from 
bacteria expressing GST-HD, for R254 DMAHP antiserum to bind with the same 
affinity to both unpurified and 10 pi (6 pmoles) of affinity purified recombinant 
protein, it had a stronger overall affinity for GST-HD.
If the antibodies bound to affinity purified and unpurified recombinant proteins to the 
same extent then the western blot analysis suggests that affinity purification, purified 
only 0.5% of the overexpressed GST-Six+HD. This would mean that 10 pi of crude 
cell lysate from bacteria expressing the recombinant proteins would contain 
approximately 20 pg of GST-Six+HD and 15 pg of GST-HD (approximately 350 
pmoles) and this mass of protein should have been detected by SDS-PAGE analysis. 
No overexpressed recombinant proteins were detected by SDS-PAGE analysis of the 
crude cell lysates (section 4.3.1).
Recombinant GST-Six+HD in a 1/160 dilution of crude cell lysate from bacteria 
expressing it, bound to the ARE with the same affinity as undiluted purified GST- 
Six+HD. However, undiluted purified recombinant protein was detected by R254 
DMAHP antiserum, whereas the 1/160 diluted unpurified GST-Six+HD was not. 
GST-HD in a 1/10 dilution of crude cell lysate from bacteria expressing it, bound the 
DNA with the same affinity as affinity purified GST-HD. However, R254 DMAHP 
antiserum had a stronger affinity for the recombinant protein in the 1/10 dilution of cell 
lysate than for the undiluted purified protein. These results indicate that the increase in 
the binding activity of GST-Six+HD when unpurified may not have been simply due 
to an increase in concentration of recombinant protein. They also infer the possibility 
that affinity purification of both GST-Six+HD and GST-HD altered their 
conformation in such a way as to reduce antigenicity.
140
5.5.4 Binding Activity of the Cell Lysate
The possibility that a cofactor, present in the crude cell lysate was responsible for the 
enhanced binding activity of GST-Six+HD was investigated. A gel retardation assay 
was performed with 9 pi of affinity purified GST-Six+HD (5.4 pmoles) and 1 pi of 
undiluted crude GST cell lysate with ARE as the DNA bait. Control experiments 
included reactions with 10 pi of affinity purified GST-Six+HD (6 pmoles), lOpl of 
1/10 dilution of crude cell lysate from bacteria expressing recombinant GST-Six+HD 
and crude cell lysate from bacteria expressing recombinant GST. All reactions were 
repeated using AREmut as the DNA fragment. The reaction containing 5.4 pmoles of 
affinity purified protein and lp l of recombinant GST containing cell lysate resulted in 
about 80% (w/w) of the ARE DNA forming a single retarded complex (C5). The 
complex had a mobility consistent with a higher molecular weight than the upper 
complex formed by unpurified and affinity purified GST-Six+HD. Unpurified GST, 
in the absence of affinity purified GST-Six+HD produced no retarded complexes 
(figure 5.7). Due to the toxicity of GST-Six+HD to bacterial cell cultures (section 
4.3.1c), the concentration of all proteins (with the exception of GST-Six+HD) was 
higher in the GST expressing cell lysate than in the GST-Six+HD expressing cell 
lysate. After induction with 1 mM IPTG, the cell density of the GST expressing 
culture was 1.3 times higher than that expressing GST-Six+HD (section 2.3.12.3). 
This experiment strongly suggests that a cofactor was present in the crude cell lysate 
that enhanced the binding of GST-Six+HD to the ARE.
5.6 Specific Binding of GST-HD to the ARE
Affinity purified and unpurified GST-HD bound to the ARE with low affinity. To 
determine the specificity of this binding, gel retardation assays were carried out using 
affinity purified GST-HD and ARE in the presence of a 10 fold molar excess of 
unlabelled competitor DNA. The competitor DNA fragments used were ARE and 
AREmut. An excess of unlabelled ARE successfully competed for the recombinant 
protein. However, an excess of AREmut had no effect on the binding of GST-HD to 
the labelled ARE (figure 5.8) indicating that although only a small proportion of ARE 
(less than 1% (w/w)) bound to the recombinant protein, this binding was specific.
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Figure 5.7 Gel retardation analysis of affinity purified GST-Six+HD in the 
presence and absence of cell lysate
The binding activity of affinity purified GST-Six+HD combined with cell lysate 
from bacteria expressing recombinant GST was investigated by gel retardation anal­
ysis with 3 fmoles of ARE and AREmut. Lanes 1 and 5 contain 10 pi (6 pmoles) of 
affinity purified GST-Six+HD, lanes 2 and 6 contain 10 pi of a 1/10 dilution of 
GST-Six+HD cell lysate, lanes 3 and 7 contain 9 pi (5.4 pmoles) of affinity purified 
GST-Six+HD and 1 pi of undiluted GST cell lysate and lanes 4 and 8 contain 10 pi 
of a 1/10 dilution of GST cell lysate.
= 5
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■vector
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Figure 5.8 Competition asasy of GST-HD
A gel retardation asasy was performed using 6 pmoles of affinity purified GST-HD 
and 3 fmoles of radiolabelled ARE. Lane 1 contains 30 fmoles of unlabelled ARE, 
lane 2, 30 fmoles of unlabelled AREmut and lane 3, no competitor.
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5.7 Discussion
When this work was instigated no binding studies involving DMAHP/Six5 had been 
reported. Of the other mammalian members of the Six subfamily of proteins to which 
DMAHP belongs, only the binding activity of AREC3/Six4 had been investigated. 
AREC3/Six4 had been identified by virtue of its role as a cell-type specific factor that 
binds to a 13 bp sequence within the Na+ K+ ATPase a  1 subunit gene regulatory 
element (ARE). DNase I footprinting and methylation interference analyses identified 
the precise region within the ARE to which AREC3/Six4 bound (Suzuki-Yagawa et 
a l , 1992). The minimal region for sequence specific binding was shown to be 
encoded by the Six box and homeobox (Kawakami et al., 1996a). The experiments 
described in this chapter investigated the DNA binding properties of 3 GST-DMAHP 
recombinant fusion proteins, GST-Six, GST-HD and GST-Six+PID.
5.7.1 Non-denaturing Polyacrylamide Gel Electrophoresis
Initially a standard low-ionic strength polyacrylamide gel and running buffer were 
utilised. Low-ionic strength buffers generate less heat than high ionic strength buffers 
and increase the speed of migration by raising the fraction of the current carried by the 
macromolecules. They also reduce the disruption of ionic bonds which may increase 
the stabilisation of complexes entering the gel (Kleinschmidt et a l,  1991). The 
Tris/acetate buffer chosen had been successfully used in other DNA/protein binding 
studies (Chodosh et a l, 1986). However, it was not suitable for the recombinant 
proteins and DNA fragments used in this study as no complexes were detected using 
this method. Specific complexes formed between phage Mu repressor and its 
operators could not be detected using a standard TBE buffer but could be detected 
with a Tris/glycine (pH 9.4) buffer (Alazard et a l,  1992; Bednarz et a l, 1990). 
Therefore, experiments were repeated using this buffer and complexes were detected.
5.7.2 Specific Binding of DMAHP to the ARE
Recombinant GST-Six+HD and GST-HD both bound to the ARE but not to the 
mutant ARE that differed by only a single base pair within the 13 bp AREC3/Six4 (C- 
G at nucleotide 6) recognition sequence, indicating that this binding was specific. 
GST-Six did not bind to the ARE, indicating that the Six domain is not directly 
involved in sequence specific DNA-protein interactions at this DNA site. However, 
GST-Six was insoluble in the cell lysate and therefore underwent a further stage of
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purification to remove inclusion bodies (section 4.3.2c). It is possible that any DNA 
binding activity was destroyed by this aggressive procedure. When present in 
conjunction with the homeodomain, the Six domain enhances the affinity of the 
homeodomain for the ARE and allows two complexes to form, rather than one. It is 
likely that the upper complex is due to a protein dimer binding to the DNA (see section
5.7.3). Further evidence that the extremely weak binding of GST-HD to the ARE was 
sequence specific was demonstrated by the addition of a 10 fold molar excess of 
unlabelled ARE or AREmut to the gel retardation assay. The excess ARE successfully 
competed for the protein, but an excess of AREmut did not.
An AREC3/Six4 homeodomain GST fusion protein also showed weak affinity for the 
ARE (Kawakami et al., 1996a). GST fusion proteins containing both the Six domain 
and the homeodomain of AREC3/Six4 displayed a much stronger affinity for the 
ARE. Binding of the AREC3/Six4 homeodomain containing fusion protein was not 
specifically to the 13 bp AREC3/Six4 binding site. An excess of a specific 
oligonucleotide (C3WT, figure 5.9), which contains the 13 bp sequence but not the 
entire ARE did not compete for the binding of this fusion protein to a Na+ K+ ATPase 
a  1 subunit gene (ATP1A1) Pvu VL-Mlu I fragment (figure 5.9). This indicates that the 
AREC3/Six4 homeodomain containing fusion protein was binding elsewhere on the 
ARE. The fact that the DMAHP GST-HD fusion protein complex was not competed 
by an excess of unlabelled mutant ARE fragment that differed only by a single base 
pair within the 13 bp AREC3/Six4 binding site, indicates that it was binding to at least 
the part of the 13 bp sequence where the mutation is. This indicates the possibility that 
the true binding site of DMAHP is similar but distinct from that of AREC3/Six4. 
Therefore, it is possible that DMAHP binds to and regulates the transcription of genes 
which contain a DNA binding site that is similar to the 13 bp sequence in the ARE to 
which AREC3/Six4 binds. However, GST-Six+HD contains 17 amino acids from the 
3’ end of the Six domain and this may be sufficient to alter the binding specificity of 
the homeodomain.
GST fusion proteins encoding the Six domain and the homeodomain of murine 
Dmahp/Six5 and Six2, but not Six3 have now been shown to bind specifically to the 
same region of the ARE as AREC3/Six4. Six3 bound to the ATP1A1 Pvu II-Mlu I 
fragment, but unlike Six2, AREC3/Six4 and Six5 the binding could not be competed 
by a 20 fold molar excess of C3WT (Kawakami et a l , 1996b).
A binding site has been reported for 3 sine oculis homeodomain containing peptides 
that were expressed in E. coli. The peptides were modified by covalently linking the 
chemical nuclease 1, 10-phenanthroline-Cu to a unique native cysteine (OP-Cu). The 
sine oculis -OP peptides were used to locate preferred binding sites in the 3.1 kb
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pUC119 plasmid. (C/T)GATAC was identified as a core consensus sequence for the 3 
peptides (Hazbun et a l , 1997). As this sequence is present 4 times in the related 
plasmid pBluescript SK(+) which was included in gel retardation assays as a non­
specific competitor, there was concern that the recombinant fusion proteins might be 
binding preferentially to the plasmid rather than to the fragments against which they 
were being tested. However, when the assays were carried out in the absence of the 
plasmid, the affinity of the purified GST-Six+HD for the ARE and AREmut did not 
significantly change. However, the GST-Six+HD in crude cell lysate, bound with 
relatively low affinity to AREmut (figure 5.3). This indicates that there may be a site 
or sites in pBluescript SK(+) for which GST-Six+HD has a higher affinity than it has 
for AREmut. The 3 peptides contained the homeodomain of sine oculis, with the 
longest containing only 28 amino acids of the Six domain and the shortest containing 
none of the Six domain. Therefore, these experiments defined a preferred binding site 
for the homeodomain of sine oculis, without the Six domain. As the experiments with 
AREC3/Six4 indicated, the preferred in vitro DNA binding sites of the 
Six+homeodomain and the homeodomain are not necessarily the same (Kawakami et 
al., 1996a).
5.7.3 The Presence of a Cofactor in Bacterial Crude Cell Lysate 
Enhances the Binding Activity of GST-Six+HD
Unpurified GST-Six+HD showed a stronger affinity for the ARE than affinity 
purified GST-Six+HD. Control experiments using unpurified recombinant GST 
indicated that it was the recombinant GST-Six+HD in the cell lysate and not a bacterial 
protein that was binding to the ARE. Initially it was assumed that GST-Six+HD had 
been modified or degraded in such a way by the affinity purification process that it had 
lost most of its binding activity. Western blot analysis indicated that either the 
concentration of the protein had been drastically reduced by affinity purification and/or 
the folding of the protein had been altered in such a way as to make to make the 
antigenic region of the recombinant protein less accessible to the R254 DMAHP 
antiserum. However, adding recombinant GST expressing cell lysate to affinity 
purified GST-Six+HD enhanced the binding activity of the protein to levels that were 
greater than those seen using cell lysate that had expressed GST-Six+HD. Therefore, 
any changes that occurred during affinity purification were reversible by the addition 
of cell lysate. The binding activity of GST-HD to the ARE was not enhanced by the 
presence of cell lysate. Therefore, it is likely that any factor present in the cell lysate 
that enhanced binding activity requires the Six domain to do so. It is possible that a 
cofactor binding to the Six domain altered the folding of the fusion protein, thus
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allowing R254 DMAHP antiserum access to the antigenic region of GST-Six+HD. 
However, this does not explain the greater affinity of R254 DMAHP antiserum for 
unpurified rather than affinity purified GST-HD.
Although many homeodomain proteins bind as monomers in vitro, evidence is now 
emerging that many can and do bind as dimers (section 1.7.3.4). GST-Six+HD but 
not GST-HD formed 2 complexes with the ARE and the higher molecular weight 
complex was presumed to be a dimer complex, sine oculis and eyes absent (both 
Drosophila eye development proteins) interact in yeast and in vitro through the Six 
domain of sine oculis and an evolutionarily conserved domain in eyes absent (Pignoni 
et al., 1997). Therefore, it is likely that the Six domain of DMAHP also acts as a 
protein binding domain, which in vitro allows GST-Six+HD to bind to DNA as a 
homodimer. To confirm that the upper complex is indeed a dimer, cross-linking 
experiments could be performed and the products analysed by SDS-PAGE as was 
done for the POU protein Pit-1 (Ingraham et al., 1990). The Six domain may also be a 
DNA binding domain and both domains may be required to interact with the DNA to 
allow high affinity specific DNA binding as is the case with homeodomains containing 
a paired domain or a POU domain (section 1.7.3). GST-Six may have lost DNA 
binding activity due to its method of production (section 5.7.2). The presence of the 
bacterial cell lysate greatly enhanced the formation of the putative dimer complex 
which suggests that it contains a cofactor that alters the structure of the DNA in such a 
way as to increase the likelihood of dimer formation. There are many examples of 
prokaryotic and eukaryotic factors that can bend DNA to enhance the interaction of 2 
or more transcription factors (Wemer and Burley, 1997). Eukaryotic high mobility - 
group (HMG) domain proteins bind to the DNA in the minor groove, through a 
conserved domain, and bend the double helix. There are 2 classes of HMG-domain 
proteins, one of which contain multiple HMG domains and bind DNA with little or no 
specificity and the second class contain a single HMG domain and bind to a specific 
DNA sequence (Love et al., 1995). Similar factors are present in prokaryotic cells and 
again there are sequence specific DNA binding factors, for example the integration 
host factor (IHF) and non sequence specific factors, for example HU (Rice et al., 
1996). It appears that a cofactor is present in the bacterial crude cell lysate that is 
sufficiently similar to a natural cofactor present in the human cell to alter the structure 
of the DNA enough to enhance dimerisation. It may be possible to determine if the 
cofactor is a small DNA binding protein by dialysing the crude cell lysate to remove 
small proteins and then testing the lysate to see if it retains its ability to enhance 
protein-DNA interactions and the formation of the dimer complex.
147
5.7.4 Solubility of the GST-DMAHP Fusion Proteins
GST-Six+HD and GST-HD were both soluble in the crude cell lysate, whereas GST- 
Six formed inclusion bodies, possibly due to the greater levels of protein produced 
(section 4.6.2). However, the 3 fusion proteins were all partially soluble in 50% (v/v) 
acetone or ethanol and the only one of the 3 that was successfully concentrated by 
precipitation with organic solvent was GST-HD (section 4.4). The precipitation, 
however, led to a loss of detectable binding activity. This may have been due to the 
solvent causing irreversible denaturation of the protein (Schein, 1990).
5.7.5 DMAHP as a Regulator of DMPK Transcription
Experiments using GST-HD and GST-Six+HD recombinant proteins in gel 
retardation assays indicate that the homeodomain of DMAHP does not bind to the 
GGATTA consensus site as do other homeodomain proteins with a lysine at position 
50 of the homeodomain. However, as DMAHP (and other members of the Six 
subfamily) lack the arginine at position 5 of the homeodomain, which is known to 
bind to the ATTA core sequence, this is perhaps not surprising. It also appears that 
DMAHP does not bind to the ARE-like sequence in the promoter of DMPK and 
therefore if DMAHP is controlling DMPK, it is not doing so by binding to either of 
these putative DNA binding sites.
5.8 Conclusion
The DNA-protein binding activities of 3 GST-DMAHP recombinant proteins have 
been characterised. GST-Six displayed no detectable DNA-protein binding activity to 
any of the DNA fragments tested. GST-HD showed weak, but specific binding 
activity to the 40 bp ARE fragment to which AREC3/Six4 has been reported to bind. 
GST-Six+HD bound with moderate affinity to the ARE fragment to give 2 complexes. 
The upper complex was presumed to be formed by a protein dimer and the lower 
complex by a protein monomer. The binding of affinity purified GST-Six+HD was 
greatly enhanced by the addition of a bacterial crude cell lysate to the reaction. The 
experiments suggest that the Six domain of DMAHP is a protein-protein binding 
domain that enhances the specific DNA binding activity of the homeodomain.
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Chapter
6
Whole Genome PCR to Identify Target DNA Binding Sites of
DMAHP
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6.1 Introduction
The experiments described in the previous chapter indicate that in vitro, GST fusion 
proteins containing the homeodomain of human DMAHP display specific binding 
activity to the ARE within the promoter region of the Na+ K+ ATPase a  1 subunit 
gene. However, DM is a multisystemic disease and as such, several genes are likely to 
be implicated in the manifestation of its symptoms. Therefore, it is expected that 
DMAHP binds to and regulates a number of genes that contribute to the symptoms 
associated with DM.
To identify other genes that may be controlled by DMAHP, a whole genome PCR 
based screen was performed using GST-Six+HD bound to a Glutathione Sepharose® 
4B affinity matrix (section 2.3.18). Whole genome PCR for the identification of 
sequences bound by gene regulatory proteins was first used to identify human 
sequences that bound to Xenopus transcription factor IIIA (Kinzler and Voglestein, 
1989). Immune precipitation was used to separate protein bound DNA from unbound 
DNA. This system was adapted for use with GST fusion proteins bound to a 
Glutathione agarose matrix, which dispensed with the need for the 
immunoprecipitation step (Fainsod et a l, 1991). GST fused to the chicken CHox-cad 
protein was bound to Glutathione agarose beads and used to identify genomic 
fragments capable of being bound in a gel retardation assay by extracts from bacteria 
producing the recombinant fusion protein (Margalit et a l, 1993). Target sites for 
recombinant Spl DNA binding protein were selected that closely matched the known 
Spl consensus site using synthetic DNA templates that contain randomised 12 bp 
oligonucleotides flanked by primer binding sites, in place of genomic DNA (Thiesen 
and Bach, 1990). Therefore, both genomic DNA and random oligonucleotides have 
been used, successfully, to identify known binding sequences for the proteins tested. 
Novel target genes have now been identified for an oestrogen receptor (Inoue et a l, 
1993) and a thyroid hormone receptor (Caubin et a l, 1994) using similar whole 
genome PCR screens.
Although the use of random oligonucleotides is technically less complicated, it was 
decided to use genomic DNA, as the main objective of the work was to identify genes 
to which DMAHP binds rather than just the sequence of the binding site. However, it 
has been demonstrated that the consensus binding site of the chicken homeodomain 
protein CDXA, identified by DNase I footprinting of chicken genomic DNA 
fragments isolated by whole genome PCR, was very similar to the sequence deduced 
from analysis of random oligonucleotides that bound to the protein (Margalit et a l, 
1993). Therefore, the work described in this chapter could lead to the identification of
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a consensus DNA binding site for DMAHP as well as to the identification of target 
genes.
GST-Six+HD was chosen as the DMAHP fusion protein for these experiments rather 
than GST-HD because the Six domain was shown to enhance the binding activity of 
the homeodomain (section 5.3.2). Sequences isolated in the whole genome screen 
were tested for their ability to be bound specifically by crude cell lysates of bacteria 
expressing the GST-Six+HD recombinant protein. The sequences which displayed 
specific binding activity to GST-Six+HD were analysed further by computer analysis.
6.2 Whole Genome PCR Based Screen
GST Six+HD and GST recombinant proteins were immobilised by binding to 
Glutathione Sepharose® 4B beads (section 2.3.12.5). The beads and recombinant 
protein were resuspended in 33 mM Tris (pH 8.0), 80 mM NaCl, 6.7 mM DTT, 0.67 
mM PMSF and 20% (v/v) glycerol to give a 50% (v/v) slurry. Aliquots of the 
recombinant proteins were analysed by SDS-PAGE and the amount of protein 
estimated by comparison with Coomassie Blue stained BSA standards (results not 
shown). GST-Six+HD-coated Glutathione Sepharose® 4B beads contained 
approximately 20 ng of recombinant protein per pi of 50% (v/v) slurry and GST- 
coated Glutathione Sepharose® 4B beads 60 ng/pl.
6.2.1 Optimisation of the Binding of DNA to GST-Six+HD-coated 
Sepharose® 4B Beads
To determine the optimum length of time required for the maximum concentration of 
specific DNA to bind to the GST-Six+HD-coated Glutathione Sepharose® 4B beads, a 
time course was performed (section 2.3.18.2). 1,000 cps of radiolabelled ARE 
fragment and vector were mixed with 200 pi of GST-Six+HD (about 4 pg of 
recombinant protein) or GST (about 12 pg of recombinant protein) bound to the 
beads. The beads were washed in 1 x DNA-protein binding buffer and the DNA 
eluted in 1 x DNA-protein binding buffer plus 1 M NaCl. The specific activity (cps) of 
supernatant and beads at each stage of the experiment was measured. The results are 
displayed in table 6.1.
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100 pi 
of
supema 
tant 1
100 pi
of beads
1 ml of
wash
buffer
100 pi 
of beads 
after 
washing
100 pi 
of eluant
100 pi
of beads
after
elution
%age of 
total 
DNA in 
eluant
GST
15 minutes
300 99 14 22 7 9 2%
GST
30 minutes
198 80 9 8 3 3 1%
GST
60 minutes
215 74 11 8 4 3 1%
Six+HD 
15 minutes
142 65 11 13 11 8 5%
Six+HD 
30 minutes
99 55 9 13 8 5 5%
Six+HD 
60 minutes
120 71 10 14 13 9 7%
Table 6.1 Specific activity (cps) of the ARE at each stage of the 
binding to and elution from GST and GST-Six+HD-coated Glutathione 
Sepharose® 4B beads
After a 60 minute binding time the amount of DNA that was eluted from GST- 
Six+HD (measured as a percentage of the total counts in supernatant and the beads 
before washing) was seven times greater than that eluted from GST. This indicated 
that the ARE was binding specifically to the GST-Six+HD and not to any other part of 
the matrix. 50% of the original specific activity was incorporated in the pBluescript® 
SK(+), for which GST-Six+HD does not display a strong affinity. Therefore the 
actual percentage of ARE bound to GST-Six+HD-Glutathione coated Sepharose® 4B 
beads was between 7 and 14. The experiment also showed that the longer the DNA 
was allowed to bind to the GST-Six+HD-Glutathione coated Sepharose® 4B beads 
(up to 60 minutes) the greater the percentage of total DNA that bound. As 60 minutes 
was the longest binding time tested, it was postulated that a longer binding time would 
result in more DNA binding. However, as protein is susceptible to degradation at 
room temperature it was decided that a longer binding time was not feasible. 
Therefore, the time course experiment was repeated using 500 pi of a 50% (v/v)
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slurry of GST-Six+HD-coated Glutathione Sepharose® 4B beads (about 10|Lig of 
recombinant protein). This did not increase the amount of DNA bound to and eluted 
from the protein (results not shown). Therefore, 200 [i\ of a 50% (v/v) slurry of GST- 
Six+HD-coated Sepharose® 4B beads (about 4 p,g of recombinant protein) and a 60 
minute binding time were used in the whole genome PCR based screen.
6.2.2 Optimisation of PCR Conditions
1 p,g of high molecular weight human lymphocyte DNA was cleaved to completion 
with either Sau3A  I or Tsp509 I and PCR linkers were added (section 2.3.18.1). PCR 
conditions for use in the whole genome screen were optimised using 1 ng of each 
linkered genomic DNA library as templates and V-NL as the primer (section 
2.3.18.4). Initially 1 mM and 2 mM spermidine, 1% and 5% (v/v) DMSO and 
annealing temperatures of 55°C and 59°C were tried. Unlinkered cleaved genomic 
DNA was used as a negative control to ensure that the V-NL did not amplify 
unlinkered DNA. 60% (v/v) of the PCR products were electrophoresed in 1% (w/v) 
agarose gels (figure 6.1). The greatest amount of product, from both libraries was 
achieved with no spermidine, 5% (v/v) DMSO and an annealing temperature of 59°C. 
Optimisation was finalised with the use of 3, 4, 5, 6 and 7% (v/v) DMSO (figure 
6.1). 5% (v/v) DMSO and an annealing temperature of 59°C were chosen as the 
optimum conditions.
6.2.3 Whole Genome PCR
200 jllI (about 4 p,g of recombinant protein) of a 50% (v/v) slurry of GST-Six+HD- 
coated Glutathione Sepharose® 4B beads was incubated with 300 ng of linkered 
genomic DNA (either Sau3A I or Tsp509 I cleaved). The beads were washed in 1 x 
DNA-protein binding buffer, bound DNA eluted in 1 x DNA-protein binding buffer 
with 1 M NaCl added and the eluted DNA amplified by PCR (section 2.3.18.3). After 
five rounds of binding and PCR no further change to the pattern of PCR products was 
visible (figure 6.2) and they were subcloned into pGEM®-T Easy vector (section 
2.3.18.6). Eighteen clones from each library were sequenced using primers T7 and 
SP6. Seven independent clones were identified in each of the two libraries and the 
average length of the fragments selected was 420 bp. One clone contained two 
plasmids with different sized inserts and therefore would not sequence. Table 6.2 
shows the lengths of the selected sequences and number of times each clone was 
represented.
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Sau3A I Tsp509 I
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1.1 kb 
506 bp
annealing temp 59°C ------- ►
Figure 6.1 Optimisation of PCR for whole genome screen
1 ng of each of the linker libraries, Sciu3A I and Tsp509 I, was amplified using primer 
V-NL under various PCR conditions. 60% (v/v) of each reaction was electrophoresed 
in a 1% (w/v) agarose gel. 1% (v/v) DM SO (lanes 3, 8, 15 and 20), 5% (v/v) DM SO 
(lanes 4, 9, 16, and 21), 1 mM spermidine (lanes 5, 10, 17 and 22) and 2 mM spermi­
dine (lanes 6, 11, 18 and 23) were used with annealing temperatures 55°C and 59°C. 
3% (v/v) DM SO (lanes 26 and31) 4% (v/v) DM SO (lanes 27 and 32) 5% (v/v) DM SO 
(lanes 28, 33, 36 and 37), 6% (v/v) DM SO (lanes 29 and 34) and 7% (v/v) DM SO 
(lanes 30 and 35) were then used with an annealing temperature of 59°C. 1 ng of 
unlinkered genomic DNA (lanes 12 and 36) and LLO (lanes 13 and 37) were used as 
negative controls. Lanes 1, 24 and 25 contain 1 kb ladder.
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Figure 6.2 Whole genome PCR
Five rounds of binding and PCR were performed. After each round of binding 5 pi of 
eluate and l/lO  and in later rounds l/lOO and 1/1000 dilutions of eluate were ampli­
fied by PCR using primer V-NL. 50% (v/v) of each reaction was electrophoresed in a 
l%  (w/v) agarose gel. Linkered genomic DNA was used as a positive control for each 
round of PCR.
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Clone Length of sequence (bp) Number of times represented
SauA 336 4
SauB 448 5
SauC 524 2
SauD 424 1
SauE 437 3
SauF 464 1
SauG 414 1
TspA 469 8
TspB 359 5
TspC 383 1
TspD 434 1
TspE 388 1
TspF 406 1
TspG 391 1
Table 6.2 Analysis of selected sequences
Interestingly, all sequences contain the expected restriction endonuclease site at only 
one end of the novel sequence. As the linkers were joined to the digested genomic 
DNA by the ligation of two halves of a staggered restriction site it was expected that 
the genomic sequence in each clone would start and finish with such a site, as shown 
below. Bold indicates genomic sequence and a SauiA  I restriction site is underlined.
G T C C G A T C N N N N N G A T C G G A C  
C A G G C T A G N N N N N C  T A G C C T G
Two possible explanations for this are:
1) Non-specific internal priming of PCR primer V-NL may have allowed preferential 
amplification of smaller fragments of DNA during later rounds of PCR.
2) Linkers may have ligated to Sau3A I and Tsp5091 half sites that have been 
overdigested by the enzymes. Restriction endonucleases can contain contaminating 
exonucleases which remove bases from 5’ or 3’ ends of digested DNA if the reactions
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are incubated for longer than the optimum time. For this experiment restriction 
endonuclease reactions were incubated overnight to ensure that all sites were cut.
In an attempt to determine the cause of the above anomaly, PCR was performed on 
DNA that did not bind to GST-Six+HD-coated Glutathione Sepharose® 4B beads, 
during the first round of selection. PCR products were shotgun subcloned into 
pGEM-T Easy vector. DNA of one clone from each library was sequenced. Both 
DNA sequences were shown to contain the relevant restriction site at only one end of 
the sequence.
6.3 Gel Retardation Analysis of the Selected Sequences
To investigate whether DNA recovered from the whole genome PCR selection 
represented genuine GST-Six+HD binding sites, each independent clone was tested 
by a gel retardation assay. The sequence containing the selected DNA was released 
from pGEM®-T Easy by digestion with Not I and both vector and insert were 
radiolabelled (section 2.3.17.2). Gel retardation assays (section 2.3.17) were 
performed using 10 (il of crude cell lysates from bacteria expressing either the GST- 
Six+HD recombinant protein or GST diluted 1/10 in 1.5 x binding buffer or 10 pi of 
1.5 x binding buffer and 100 cps of each of the 14 selected DNA sequences. At the 
time these experiments were performed it was not known that affinity purified GST- 
Six+HD mixed with cell lysate from bacteria expressing recombinant GST showed a 
higher affinity for the ARE than unpurified GST-Six+HD. Reactions were analysed in 
4% (w/v) non-denaturing 1 x Tris/glycine polyacrylamide gels (figure 6.3). GST- 
Six+HD bound to all 14 clones to give 1 or more retarded complexes. However, 1 of 
the complexes formed with each of clones SauD, SauE, TspA and TspC also formed 
with crude cell lysate from bacteria expressing recombinant GST, suggesting that 
these complexes were formed by the interaction of a bacterial protein or the GST-tag 
with the DNA. In addition to the complexes formed with recombinant GST containing 
cell lysates, each of these 4 sequences also formed other complexes only in the 
presence of cell lysate from bacteria expressing GST-Six+HD. This suggested that 
these other complexes were formed between GST-Six+HD and the DNA fragment.
To test the specificity of the binding of GST-Six+HD to the 14 sequences, gel 
retardation assays were performed with crude cell lysates from bacteria expressing the 
GST-Six+HD recombinant protein in the presence of a 100 fold molar excess of 
unlabelled ARE fragment (figure 6.3). The complexes formed by the binding of GST- 
Six+HD to 5 of the clones, SauD, TspA, TspC, TspD and TspE were not competed 
by the presence of excess ARE as were the complexes formed between the GST 
containing cell lysate and selected DNA. GST-Six+HD showed the strongest affinity
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Figure 6.3 Gel retardation analysis of whole genome PCR selected sequences
T h e  s e l e c t e d  s e q u e n c e s  f r o m  e a c h  l i n k e r  l i b r a r y  w e r e  t e s t e d  f o r  b i n d i n g  t o  D M A H P  b y  
g e l  r e t a r d a t i o n  a s s a y s  w i t h  c e l l  l y s a t e s  f r o m  b a c t e r i a  e x p r e s s i n g  G S T - S i x + H D  a n d  
G S T .  N o  p r o t e i n  n e g a t i v e  c o n t r o l  a s s a y s  w e r e  a l s o  p e r f o r m e d .  G e l  r e t a r d a t i o n  a s s a y s  
w e r e  t h e n  r e p e a t e d  u s i n g  c e l l  l y s a t e  f r o m  b a c t e r i a  e x p r e s s i n g  G S T - S i x + H D  a n d  a  1 0 0  
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Sau3A  I c l o n e s  Tsp509 I c l o n e s
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for TspA, which formed 3 complexes with GST-Six+HD and a fourth non GST- 
Six+HD complex. SauD formed 2 complexes, one of which was with GST-Six+HD. 
TspC formed 4 complexes of which 3 were with GST-Six+HD and in the presence of 
excess ARE, 2 further complexes formed. TspD and TspE formed 1 and 2 complexes 
respectively. The DNA sequences of these 5 clones are shown in figure 6.4.
6.4 Computer Analysis of Selected Sequences
The sequences of SauD, TspA, TspC, TspD and TspE were tested by Bestfit analysis, 
in both the forward and reverse orientation, to determine a likeness to the 
AREC3/Six4 minimal sequence as defined in Suzuki-Yagawa et al. (1992) 
(GGNGNCNGGTTGC) (table 6.3).
AREC3SEQ G G N G N C N G G T T G C
SauDF G G A G C C T G G G G A G
SauDR G G A G G C T G G G A T C
TspAF A G G G T C A G G T T T C
TspAR G G A T A G G G G T T G c
TspCF G T G G T C T G G A A T c
TspCR G G T G G C T G G G T T c
TspDF G G G G A c A G C A G C c
TspDR T G A G G c A G A T T C A
TspEF G G A G C c T G T T C C T
TspER G G T G T c C A G T A G A
Table 6.3 Bestfit analysis of the AREC3/Six4 binding site to the 
selected sequences. The letters in bold indicate a deviation from AREC3/Six4 
consensus site. F indicates a match with the AREC3/Six4 consensus site in the 
forward orientation and R a match in the reverse orientation.
The following weak consensus site was identified: GNGNCA/TG. LALIGN analysis 
(HGMP resource centre) which finds the 10 best local alignments between 2 
sequences and will align sequences as short as 10 nucleotides, was utilised. Each 
sequence was compared with every other sequence in both forward and reverse 
orientations. Any short sequences present in 2 of the clones were searched for in the 
other clones in an attempt to identify a strong consensus sequence. None was 
identified.
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S a u D
1
5 1
101
1 5 1
201
2 5 1
3 0 1
3 5 1
4 0 1
T s p A
1
51
101
1 5 1
201
2 5 1
3 0 1
3 5 1
4 0 1
4 5 1
GATCCCAGCC TCCTACTTGG GAGGCTGAGG TGGGAGGATT GCTGGAGCCT 
GGGGAGGTTG AGACTGCAGT GAGCCATGAT TGCATCACTG CACTGCAGCC 
TGGGTGACAC AGCAAGAGCC TGTCTCAAAA GAAAAATAAG ATACCTCAGA 
CAAAGCCAGA AAACCAAATA AACAAGGAAG AGTGAGGCAA GGTCTCTGAA 
AATGTCCTGT TCTCGGGAGC TATTATGGCA GGAGCCCCCA CCCACGTTGC 
TGAATGTTTT ACTTTTCATG AGAGTTCTCA GTTGCACAGT GTGTTAGTCA 
GGGTTCTCCA GAGAAGCAAA ACCAACAGGA TGTATACACA GAGAGAAAGG 
GAGTTATTAC AAAGCACTGG CTCCCACAAT TACGGAGGCT GGCAAGTCCC 
AAGCTCTGCA GGGGGAATTG GCCA
AATTGGGTGC
TGGACTCATG
TCAGGTTTCC
TGTCATTTCT
CACTGCTGAT
AGTTACAGTT
AAAGTACTTC
GAAAACCCCT
GAGAATAGCA
CGTCCCTCCC
ACTTTGGAGG
TGGGAACAGT
CATCTCTGAC
GAGAGACAGC
AAGGACACCC
CCACGTGGCT
TTACATCATG
GGTAAACCCA
TGGGAGAGAC
ACATGTGGG
CAAAGCTGGG
GGGCCTGCTG
TGCAACCCCT
CAGACTTACG
GAGACTGGGA
GGGGAGGCCT
GCGGCAATAG
TCAGATCTCG
TGGCCCCCGT
GCAGAAGAGT
TTCCCTGGAG
ATCCCACTCC
TGTGTATTAG
AGAAATAGAG
CAGAATCATG
AAAATGAAGA
TGAGACTTAT
GATTCAGTTA
GGAATAAGGA
CCCCACAGGG
CACAGGAAGG
TCTGTATTCA
GTTTAGTTGG
GTGGGAGGCA
AGCACAAGTG
TCACTATCAC
CCTCCCCCTG
160
T s p C
1 AATTCTATGT GAGGGACAAA CACTCAGAAC CCATCAGCAG TGTTCTGGAA
5 1  TCCTACATGA TGGACAAACA CTCTGAACCC AGCAGCAGTG TTCTGGCATC
1 0 1  CTATGTGGGG GACAAACACT CAGAACCCAG CCACCGTGTT CTGGAATCCT
1 5 1  ATCTGTCTGA TAAATATTCA GACACTCATA GAAATGTTCT GGAATCCTAA
2 0 1  GTGATGGAGA AACACTCAGA AATCAGCAGC AGTCCTCTGG AATCCTTTGT
2 5 1  GAAGGATAAA CAAAGAGAAC CCACCAGCAG TGTTCTGGAA TCTTTCTGAG
3 0 1  TGAAAAACAT TCAGAACCTA GTAGCAGTGG TCTGGAATCC AATGTGAGGG
3 5 1  AGAAACACTC AGAACCCAGC AGCAGTGTGC TGG
T s p D
1 CCACTGGGGA CAGCAGCCTA CTTACAGAAG CGAAGCCAAC TGCAGCTGGG
5 1  ATAAAGTGAT AATAGATAGG ACTGACAAGG AGGCGTGGCC TTCCATCACA
1 0 1  GGAACAGAGA CTGAATCTGC CTCAGAATGT ACTACAGACA CTGACTCTGC
1 5 1  CTCCAACTGT GGCTCAGAGA ACAGTAGCAT GGCTACAGGG AGTGCCCAGG
2 0 1  GCAACTTCAC TGGACATACC AAGAAGACAA ATGGCAATAA TGGCACCAAT
2 5 1  GGCGCACTCG TCCAAAGCCC TTCTAATCAG AGTGCCCTTG GAGCAGGGGG
3 0 1  AGCGAACAGT AATGGAAGTG CGGCCAGAGT GTGGGGTGTA GCCACAGGCT
3 5 1  CCAGCTCTGG CCTGGCTCAC TGCTCTGTCA GTGGTGGGGA TGGAAAAATG
4 0 1  GACACTATGA TTGGAGATGG GAGAAGTCAG AATT
T s p E
1 CCAGCCTCAT GGTGTTGAGG GAGGGGCTGG GGGAAGCGGG AGCCTGTTCC
5 1  TAGGAGACAC TGTCTACTGG ACACCTCATC CTAGAAGGCT TCCCTGAGTT
1 0 1  CTGACACTGT TCTAGGAGTA GGAATCATTA TCCCACGCTG TGGAGAAGGA
1 5 1  AACCAAGGCC GGGTAAAGTA ATGTAGGGCC CTTAAAGTTG CAGAGCCAGG
2 0 1  AATAAAGTCC GGATTGGGAC TCAGGTCTGT GGGCAATCCA AGGCCGTCCC
2 5 1  CTTTACACTT CAAATGCTCT TTCCCCCTCC GGAAGCCCTC GCGTCTTCAT
3 0 1  CCCTACCCCA CCTCTTGTTC CCCAAGCGTG GCTAGGGCTA GGGCTCCAGG
3 5 1  GCTACACCAA GCACCCTTCG GTCTTCCCGG GAAGAATT
Figure 6.4 Sequences that bind specifically to GST-Six+HD
Sequences identified by Bestfit analysis are underlined.
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The sequences of each selected clone were compared to the GenBank, EMBL, DDBJ 
and PDB databases using the BLASTN program at NCBI. TspE showed 92% identity 
to a human dopamine D5 receptor gene, 5’ flanking and promoter region. The 388 bp 
TspE sequence maps from -965 to -578 of this sequence (accession number U21164) 
and starts 1161 bp 3’ of the transcription initiation site (Beischlag et a l, 1995). TspC 
contains non-alphoid repetitive sequence, but matches no specific region of the 
genome. SauD, TspA and TspD showed no significant matches to any sequences in 
the databases.
6.5 DNase I Footprinting of TspA
Confirmation of the GST-Six+HD binding site(s) within the selected sequences 
requires DNase I footprinting. It was decided to footprint sequence TspA as this 
bound most strongly to GST-Six+HD. To prepare a DNA fragment for use in a 
DNase I footprinting experiment TspA was digested with Nco I and Nsi I to release a 
fragment containing the selected sequence (figure 6.5). This fragment was gel purified 
from a 1% (w/v) agarose gel using a Qiagen gel extraction DNA purification kit. As 
Nsi I leaves no overhanging Gs the fragment was radiolabelled at the Nco I end only, 
using [a-32P] dCTP (section 2.3.19.1). To create size markers for electrophoresing 
alongside the DNase I reactions, restriction endonuclease sites were identified within 
the sequence. Alu I, Dde I, BstX  I and Saul)A I cut 25, 162, 264 and 111 bp 
respectively from the start of the selected sequence closest to the radiolabelled end of 
the fragment released from pGEM®-T Easy (figure 6.5).
DNase I footprinting was performed using 10 pi of crude cell lysate from bacteria 
expressing either recombinant GST-Six+HD or recombinant GST diluted 1/10 or 1/20 
with 1.5 x binding buffer or 10 pi of 1.5 x binding buffer and 200 cps of 
radiolabelled TspA (section 2.3.19.2). No discrete footprint could be distinguished, 
but evidence of GST-Six+HD binding to the sequence was indicated by changes in the 
DNase I restriction pattern in the reactions containing GST-Six+HD when compared 
to reactions containing GST or no protein (figure 6.6). The decrease in intensity of 
bands was noted in the regions identified by Bestfit analysis as being those most 
closely resembling the AREC3/Six4 binding site. The assay indicated the presence of 
a substance in the crude cell lysate that enhanced the activity of the DNase I. Although 
the pattern of digestion was similar in all lanes, digestion was increased in lanes 
containing cell lysate.
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Figure 6.5 S tructure of TspA
A schematic diagram showing the structure of clone TspA and the restriction sites thal 
were used to create size markers for DNase I footprinting of the clone: Alu  I, Dde I, 
B stX  I, S a id  A  I.
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Figure 6.6 DNase I footprint of TspA
TspA was analysed by DNase I footprinting with GST-Six+HD. The lanes are as 
follows: 1/10 dilution of GST lysate with 12.5 ng, 6.25 ng and 3.13 ng of DNase I (lanes 
1, 2 and 3 respectively), 1/20 dilution of GST lysate with 12.5 ng, 6.25 ng and 3.13 ng of 
DNase I (lanes 4, 5 and 6 respectively), 1/10 dilution of GST-Six+HD lysate with 12.5 
ng, 6.25 ng and 3.13 ng of DNase I (lanes 7, 8 and 9 respectively), 1/20 dilution of GST- 
Six+HD lysate with 12.5 ng, 6.25 ng and 3.13 ng of DNase I (lanes 10, 11 and 12 
respectively), no protein with 12.5 ng, 6.25 ng and 3.13 ng of DNase I (lanes 13, 14 and 
15 respectively), no DNase I control (lane 16). d=bands that decreased in intensity in the 
presence of 1/10 dilution GST-Six+HD and 12.5 ng of DNase I. i = bands that increased 
in intensity. The positions of TspAF and TspAR are indicated.
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6.6 Discussion
The principal objective of the whole genome PCR based screen was to identify human 
genomic sequences to which recombinant GST-Six+HD binds. Sequences identified 
by the screen can be utilised to identify genes that are controlled by DMAHP. To date 
no in vivo targets of DMAHP have been identified and therefore this screen was the 
first stage in the identification of what is potentially a significant number of genes 
controlled by DMAHP.
6.6.1 Analysis of Isolated Sequences
Sequencing of 35 clones indicated that 14 independent sequences with an average 
length of 420 bp had been identified. The anomaly of the sequences containing the 
expected restriction site at only one end was investigated. The fact that after only one 
round of PCR, sequences contained a restriction site at just one end suggests that it 
was not caused by internal priming leading to the preferential amplification of smaller 
fragments. It also supports the argument that the assay was not biased for a small 
number of fragments containing a restriction site at only one end. Therefore, the most 
likely explanation is that the restriction endonuclease digestion reaction to generate 
fragments of genomic DNA for linker ligation was incubated for too long and that 
nucleotides were removed from the ends of the DNA fragments through exonuclease 
activity. This will have lead to the inefficient ligation of linker DNA. Linkers at DNA 
ends with incomplete sequence can only partially ligate and single strand synthesis 
from a correctly ligated linker would possibly have been required before priming from 
the partially ligated linker could occur. Therefore, a complete overhang would be 
required at one end of each fragment for it to be successfully amplified.
The 14 independent sequences were tested by gel retardation assays and GST- 
Six+HD showed specific binding activity to 5 of them. Four of the sequences formed 
multiple complexes with the recombinant protein. The higher molecular weight 
complexes may have been caused by GST-Six+HD binding to the DNA fragment as a 
homodimer (section 5.7.2). Alternatively, the sequences contained multiple binding 
sites and the higher molecular weight complexes contained multiple molecules of 
GST-Six+HD per molecule of DNA. TspC formed 2 extra complexes when a 100 
fold molar excess of ARE was added to the binding reaction. This may have been an 
experimental artefact, but it is possible that TspC contains a DNA binding site for the 
Six domain of DMAHP and when the ARE was added to the reaction this bound to the
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homeodomain and a supercomplex formed, that consisted of GST-Six+HD, TspC and 
the ARE fragment.
Bestfit analysis of the AREC3/Six4 consensus site to the 5 selected sequences, failed 
to identify an exact match, although putative sites in each sequence and a weak 
consensus sequence were identified. LALIGN analysis did not identify a consensus 
site. However, LALIGN can only analyse 2 sequences at a time and so only strong 
consensus sites could be identified this way. An algorithm which assumes that the 
binding site is a contiguous region of DNA whose essential features reside within the 
individual bases of a sequence can be used to identify consensus patterns in several 
unaligned DNA sequences (Hertz et al., 1990). However, this algorithm has only 
been tested on sequences up to 200 bp in length and is not suitable for sequences of 
the length identified above. Therefore, confirmation of GST-Six+HD binding sites 
within the sequences identified by the whole genome screen requires DNase I 
footprinting to be performed on each sequence.
TspE was the only sequence identified that showed high similarity to a known gene, 
the dopamine D5 receptor gene. Encouragingly, the sequence is from the 5’ UTR of 
the gene which is where transcription factors are known to bind. The sequence is 
situated between the transcription and translation start sites and may therefore interfere 
with transcription by binding to the DNA. Alternatively, DMAHP may bind to the 
RNA at this position and thus act as a translational repressor. A Drosophila 
homeodomain protein, bicoid, which binds DNA and transcriptionally activates 
different target genes has also been shown to repress the translation of caudal by 
binding to the 3’ UTR of the mRNA (Dubnau and Struhl, 1996). Dopamine receptors 
belong to a superfamily of receptors that exert their biological effects through guanine 
nucleotide-binding (G) proteins and are the primary targets for genes used to treat 
psychomotor diseases like Parkinson’s disease and schizophrenia. Two main 
dopamine subtypes have been identified, D1 and D2. D5 belongs to the D1 subtype 
that stimulate adenylyl cyclase activity. The distribution of D5 receptor gene 
transcripts are neuron-specific (Sunahara et a l, 1991). Two dopamine D5 receptor 
pseudogenes have been identified (Nguyen et a l, 1991) that share 92% and 91% 
identity to the dopamine D5 receptor gene. It is possible that the sequence identified by 
the whole genome PCR screen is the 5’UTR of one of these pseudogenes. However, 
the 5’ UTR’s of these sequences are not in the databases and therefore at present this 
cannot be confirmed. Even if the sequence identified is a pseudogene it is likely to 
contain the same regulatory elements as the dopamine D5 receptor gene and therefore 
would not eliminate it as a candidate for regulation by DMAHP.
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It has been reported that the dopamine receptors of pituitary prolactin cells might be 
impaired in DM patients (Sakuma et al., 1988). DM patients suffer from psychological 
problems (Harper, 1989) which may be due to defects in their dopamine receptors. 
Therefore the dopamine D5 gene is a good candidate for being causative in DM. 
Further studies into the levels of D5 receptor mRNA and protein in DM patients and 
normal controls need to be performed to confirm any role in the pathology of DM.
The other 4 sequences identified by the whole genome PCR screen showed no 
significant matches to any sequences in the databases. Therefore, these sequences 
need to be characterised further (section 7.5). The Na+ K+ ATPase a  1 subunit gene 
was not identified by this screen, neither was a sequence identical to the AREC3/Six4 
minimal sequence as defined in Suzuki-Yagawa et al. (1992). This suggests that 
DMAHP has a greater affinity for some other sequence, possibly related to the 
AREC3/Six4 binding site, than for the AREC3/Six4 binding site itself as does the fact 
that 100 x excess of ARE does not compete for the binding of GST-Six+HD to 5 of 
the sites selected by this assay.
6.6.2 DNase I Footprinting of TspA
An initial DNase I footprinting analysis of TspA, the sequence to which GST-Six+HD 
bound most strongly, displayed no discrete footprint. However, the activity of DNase 
I at several regions of the sequence was either enhanced or repressed indicating that 
although the sequence did not contain a single site for which GST-Six+HD has a 
strong affinity, it may contain several weaker sites. This would explain the multiple 
complexes formed in the gel retardation assay.
6.6.3 Conclusion
A whole genome PCR based screen of the human genome, for target DNA binding 
sites of DMAHP, identified 5 sequences. One of the sequences is contained within the 
5’ flanking region of the dopamine D5 receptor gene.
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Chapter
7
Final Discussion and Future Directions
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7.1 Introduction
The initial aim of the work carried out for this thesis was to identify a full length 
DMAHP cDNA that could be subcloned whole and in fractions into a bacterial 
expression vector for the production of recombinant DMAHP proteins. The failure to 
obtain such a cDNA was overcome by the use of a genomic cosmid and a RT-PCR 
product. From these, 3 recombinant proteins were successfully prepared and used to 
characterise the binding properties of DMAHP, using a known binding site of the 
related protein AREC3/Six4, and putative binding sites present in DMPK. The final 
objective involved the use of a whole genome PCR based screen to identify genomic 
regions to which DMAHP binds, as an initial stage in the identification of genes 
controlled by this transcription factor.
7.2 Expression Levels of DMAHP and DMPK
Changes in the levels of expression of both DMAHP and DMPK have been implicated 
in causing the symptoms associated with DM. Early reports on the levels of DMPK 
expression in DM patients were contradictory (section 1.5.2). However, more recent 
evidence suggests that equal levels of unprocessed pre-mRNA are produced by both 
normal and expanded alleles, but that transcripts from the DM allele are retained in the 
cytoplasm, leading to a reduction in processed mRNA levels from this allele relative to 
the normal allele. As the size of the (CTG)n expansion increases, the levels of 
processed mRNA from the DM allele decreases (Hamshere et a l, 1997; Krahe et a l, 
1995a; Taneja et a l, 1995; Wang et a l, 1995).
In an attempt to determine the function of DMPK and to understand how it may be 
involved in DM, 2 groups have generated Dmpk deficient homozygous null mice (Jansen 
et a l, 1996; Reddy et a l, 1996). To nearly all extents they are indistinguishable from wild 
type mice, displaying few symptoms similar to the DM phenotype. A very slight alteration 
in the ratio of small to large fibres in skeletal muscle was the only apparent abnormality 
(Jansen et a l, 1996). Interestingly, altered calcium homeostasis in Dmpk deficient cultured 
myocytes was observed, suggesting possible defects in conduction or the actual contractile 
mechanism. A late-onset, progressive skeletal myopathy was observed by Reddy et al 
(1996), similar to that seen in DM. Again, variation in fibre size was observed in these 
mice along with increased fibre degeneration and fibrosis. Therefore, DMPK may be 
necessary for the maintenance of skeletal muscle structure and function. However, the 
minimal phenotypes detected, were only present in homozygous Dmpk null mice and not 
heterozygotes. As DM is dominant, these models do not accurately simulate the disease. In
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mice overexpressing DMPK, due to insertion of multiple copies of a DMPK transgene, no 
phenotype suggestive of DM was observed (Jansen et a l, 1996). Patchy cardiac 
hypertrophy was seen, however, this is not the same as the fatty infiltration and fibrosis of 
the cardiac conduction system seen in DM patients.
These studies appear to have ruled out haploinsufficiency of DMPK or overexpression 
of this gene as the main cause of DM and emphasise the need to investigate 
neighbouring genes and the effect of the (CTG)n expansion in general. An animal 
model where the (CTG)n expansion itself is replicated might yield more information 
particularly regarding its effects on neighbouring genes, for example DMAHP, the 
expression of which has now been demonstrated to be reduced in DM patients (section 
1 .6 .2 ).
DMAHP and DMPK have been shown by RT-PCR to be expressed in a similar wide 
range of tissues (Boucher et a l, 1995; Heath et a l, 1997) and it was hypothesised 
that DMAHP is a transcription factor involved in the control of several genes involved 
in the pathology of DM, including DMPK. Therefore, putative DMAHP DNA binding 
sites were searched for in the promoter of DMPK and 2 were identified. Binding to 
these sites was tested by gel retardation assays and DMAHP showed no affinity for 
either of them. Therefore, if DMAHP is a transcription factor involved in the 
regulation of DMPK it is doing so by binding to some other site and it is important 
that any such site be identified. Cis elements that may activate expression of DMPK 
preferentially in myoblasts over fibroblasts have been reported (Storbeck et a l, 1998).
It was demonstrated that DMPK transcription is at least partially regulated by a 51 bp 
MyoD-responsive element located in the first intron of the gene and that this 
cooperated with DMPK promoter elements one of which is an Spl binding site. The 
experiments implied that distinct cis elements located elsewhere in the gene are 
involved in the regulation of DMPK transcription in other tissues. Only 2 putative 
sites in DMPK were tested in this project and therefore the promoter region and intron 
1 could be divided into fragments and each fragment tested for its ability to bind 
DMAHP. DMPK was not identified in the whole genome screen, but this may have 
been due to the binding site being located within a genomic fragment that was too long 
to be efficiently amplified by the PCR or DMAHP may only bind to DMPK in the 
presence of a cofactor. Alternatively, DMAHP may not directly interact with DMPK 
but they may be involved in pathways in which there are intermediate genes (section 
7.3).
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7.3 Current Knowledge of the Expression of the Six 
Subfamily of Homeobox Genes and their Implication in DM
Since the initiation of this project several papers have been published reporting 
expression data for members of the Six subfamily of genes in several species. The 
following provides a summary of the recent data and indicates the possible 
involvement of the Six subfamily in the pathology of DM:
Human DMAHP has been detected by in situ hybridisation in the lens, cornea, retina 
and ciliary bodies of adult eye (Winchester et a l , in press) all of which are sites of 
pathological changes seen in DM patients. In situ hybridisation failed to detect 
DMAHP in any other tissue. However, the more sensitive method of RT-PCR 
indicates that DMAHP/Six5 is expressed in a wide range of adult human and mouse 
tissues and mouse embryonic head, limbs, liver, kidney and heart (Boucher et a l, 
1995; Heath et a l, 1997) and transgenic reporter studies using a 4.3 kb murine Six5 
promoter fragment fused in frame to the lacZ reporter gene have also detected 
expression in a range of embryonic tissues (Heath et a l, 1997). Six5 transcripts have 
also been detected by in situ hybridisation specifically in the inner and outer nuclear 
layers, ganglion cell layer and pigment epithelium of mouse adult retina (Kawakami et 
a l, 1996b) and the protein by super-shift assays in rat adult lung, liver and kidney 
and embryonic lung (Ohto et a l, 1998). These data suggest that DMAHP/Six5 is an 
adult type Six gene isoform and the levels of DMAHP/Six5 expression are relatively 
low in all tissues except the adult eye, thus making DMAHP a particularly strong 
candidate for being involved in the cataract development and retinal degeneration 
common to the majority of DM patients. From the results of these experiments it 
would be advisable for future cDNA library screenings to obtain a DMAHP cDNA to 
concentrate on adult eye tissue cDNA libraries. However, there is a recent report of 
Six5 expression being detected by northern blotting in adult mouse heart, lung, 
kidney, liver, skeletal muscle, spleen and testis and embryonic heart and skeletal 
muscle (Murakami et a l, 1998). Therefore, it is likely that changes in DMAHP 
expression are also responsible for other DM symptoms, for example cardiac defects 
and myotonia.
AREC3/Six4 mRNA was detected in adult murine retina and protein was detected in 
the central and peripheral nervous systems from E9.5-14.5 and embryonic lung 
(Kawakami et a l, 1996b; Ohto et a l, 1998). Chicken and zebrafish six4 homologues 
have now been identified and shown to be expressed in the head mesoderm of the 
zebrafish (Bovolenta et a l, 1996; Seo et a l, 1998c). Murine Six2 mRNA was also 
detected in the adult retina (Kawakami et a l, 1996b) and the protein was observed by 
immunohistochemistry in the mesenchyme from E8.5-E13.5 (Ohto et a l, 1998).
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Human SIX2 transcripts have recently been detected in foetal eyes, brain, liver, heart 
and limb and adult ovary, heart and skeletal muscle (Catherine Winchester, personal 
communication). Murine Six3 is also expressed in adult retina (Kawakami et a l , 
1996b). A six3 chicken homologue has been identified (Bovolenta et a l , 1996) that is 
expressed in the most anterior portion of the neural plate, structures derived from the 
anterior neural plate, the optic vesicle, the rostroventral forebrain and later the 
prospective neural retina and lens (Bovolenta et a l, 1998). Three Six3 zebra fish 
homologues (zsix3, zsix6 and zsixT) have also been identified, with expression 
detected in optic vesicles and the rostral forebrain (Kobayashi, 1998; Seo et a l ,
1998a; Seo et a l,  1998b). Overexpression of zsix3 induces rostral forebrain 
enlargement, enhanced expression of pax2 in the optic stalk and leads to a general 
disorganisation of the brain (Kobayashi, 1998). A medaka Six3 homologue is 
expressed at late gastrula/early neural stages in the anterior shield region and then in 
the developing diencephalon, optic vesicle and lens placode (Loosli et a l, 1997). A 
human Sixl homologue (SIX1) has been cloned and transcripts identified in adult 
skeletal muscle (Boucher et a l, 1996).
A sixth human Six subfamily gene has recently been identified (OPTX2) along with 
its chicken, mouse (Optx2 ) and Drosophila (optix) homologues (Toy etal., 1998). 
Chicken Optx2 transcripts have been detected in embryonic retina, optic vesicles, early 
lens placode and corneal epithelium. Drosophila optix is a closer Drosophila 
homologue of mammalian Six3 than sine oculis and is expressed during early 
development of the fly head and eye primordium. A third Drosophila member of the 
family that appears to be a closer relative to DMAHP/Six5 than sine oculis is currently 
being characterised (Graham Hamilton, personal communication).
All of these recent reports describe the expression of the Six subfamily of genes in an 
overlapping wide range of tissues. DMAHP/Six5 has been shown to bind in vitro to 
the same DNA sequence (the ARE) as AREC3/Six4 and Six2 (this thesis and 
Kawakami et a l,  1996b) which suggests that there may be cooperative and/or 
competitive interactions between members of the Six subfamily. Na+, K+ ATPase is 
the enzyme responsible for maintaining the Na+ and K+ gradients across the cell 
membrane, after the propagation of an action potential, which may be involved in the 
myotonia associated with DM. A recent study demonstrated that members of Six 
subfamily bind to the MEF3 site (TCAGGTT) in the promoter of myogenin, a protein 
that is required for myoblast fusion (Spitz et a l, 1998). The MEF3 site matches bases 
5-11 of the 13 bp sequence within the ARE to which DMAHP/Six5, AREC3/Six4 and 
Six2 bind and it is present in clone TspA described in this thesis (chapter 6).
However, it is also present in ARE-like to which GST-Six+HD does not bind (chapter 
5) and the whole genome PCR-based screen did not identify Myf-4 (the human
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homologue of myogenin). Sixl and AREC3/Six4 were identified as being the proteins 
responsible for forming 2 muscle specific complexes with MEF3 in a gel retardation 
assay using nuclear extracts from various adult tissues. A third ubiquitous complex 
was formed by an unidentified protein, possibly Dmahp/Six5 based on its expression 
pattern. It is possible that members of the Six subfamily are partially responsible for 
the various stages of myogenesis. Sixl is expressed in the somites of mouse embryos 
prior to myogenin induction (Oliver et al., 1995b) and therefore may control early 
activation whereas other members of the subfamily may act later in development. A 
downregulation of DMAHP could therefore lead to the muscle atrophy associated with 
classical DM or the delay of muscle maturation in congenital DM patients.
There is now strong evidence for the involvement of both DMAHP and DMPK in 
muscle development and it is possible that they are both factors are active in the same 
pathway. DMAHP/Six5 is a candidate for the regulation of Myf-4/myogenin which is 
also known to be regulated by MyoD (reviewed in Weintraub, 1993). Dmpk was 
shown to be expressed in myogenic cell lines and to be upregulated in cells transfected 
with a MyoD expression vector (Sabourin et al., 1997; Storbeck et al., 1998). 
Upregulation of DMPK was also observed in normal human and DM fibroblasts 
transfected with MyoD (Otten andTapscott, 1995). Therefore, it is likely that MyoD 
also regulates DMPK.
With the exception of Sixl all members of the Six subfamily of genes have been 
shown to be expressed in eye. Therefore together the expression and DNA-protein 
binding data suggest a possible role for the Six subfamily in the eye pathology, 
muscle atrophy and myotonia associated with DM. It would be interesting to 
investigate the expression of S1X1, S1X2, SIX3, AREC3/SIX4 and OPTX2 and the 
genes which they control, in DM patients and normal controls. If the Six subfamily 
proteins are involved in cooperative and/or competitive interactions then the 
downregulation of DMAHP expression could lead to an alteration in the expression 
levels of genes controlled by other members of the subfamily.
To date only one other member of the Six subfamily has been linked to a human 
disease. SIX3 has been localised to a region on chromosome 2 known to be involved 
in holoprosencephaly (HPE), HPE2. Three missense mutations in the homeodomain 
of unrelated patients with sporadic HPE have been identified. One mutation changes 
arginine to proline at position 52 of the homeodomain. This amino acid is conserved 
between species and all Six subfamily members. The second mutation changes leucine 
to valine at amino acid 21 of the homeodomain. This amino acid is conserved between 
human S1X3 and mouse Six3 and Optx2 and Drosophila optix but not the other Six 
genes. The final mutation changes valine to alanine at position 45 of the
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homeodomain. This amino acid is conserved between species and all Six subfamily 
members. (Wallis et a l, 1998). These mutations demonstrate the importance of these 
3 amino acids for the correct functioning of SIX3. As they are all in the homeodomain 
it is likely that they affect the DNA binding specificity of the protein. Therefore, they 
are potential targets for future in vitro mutagenesis experiments to produce either 
dominant gain of function or dominant negative Six3 mutants to determine the normal 
role of the Six3 gene.
7.4 The Functional Domains of DMAHP
The DNA binding activities of the Six domain and the homeodomain were investigated 
by gel retardation assays. GST-Six+HD displayed a greater affinity for the ARE than 
did GST-HD and no DNA binding properties of GST-Six were identified. GST- 
Six+HD bound to the ARE as a dimer and it was suggested that the Six domain may 
act as a protein-protein binding domain as it does in so. Drosophila so and eya were 
shown by genetic and molecular studies to regulate multiple steps in eye development 
and to have identical mutant phenotypes. Therefore, the yeast two-hybrid system was 
used to test the interaction of these proteins. The yeast two-hybrid system (Fields and 
Stemglanz, 1994) works by the interaction of a pair of proteins bringing a 
transactivation domain into close proximity with a DNA binding site that regulates the 
expression of an adjacent reporter gene. Candidate proteins can be tested for their 
ability to bind the target protein and novel proteins can be identified by the use of 
libraries constructed from total cDNA from either a whole organism or a particular 
tissue. Deletion studies localised the interacting regions to the Six domain of so and an 
evolutionarily conserved domain of eya, the eya domain. In vitro binding of 
radiolabelled so and eya to either GST fused to a fragment of so containing the Six 
and homeodomains (GST-Six+HD) or the eya domain (GST-Eya), immobilised on 
glutathione agarose beads, confirmed direct binding between so and eya (Pignoni et 
al., 1997). The identification of proteins with which DMAHP interacts will be an 
important step in determining the pathways in which DMAHP is involved. Three 
murine Eya genes have been identified and the Eya protein binding domain is highly 
conserved in these proteins. Members of the mammalian Eya family are expressed in 
the developing eye and somites (Abdelhak et a l , 1997; Xu et a l, 1997a; Xu et a l, 
1997b; Zimmerman et a l, 1997) and are therefore strong candidates for interacting 
with DMAHP and other members of the Six subfamily. Yeast two-hybrid and in vitro 
binding experiments could be performed using DMAHP/Six5 and the other 
mammalian Six proteins (Sixl, Six2, Six3, AREC3/Six4 and Optx2) with mammalian
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Eya proteins (Eyal, Eya2 and Eya3) to determine relationships between members of 
these 2 conserved families.
To understand further the properties of both the Six domain and the homeodomain it 
will be important to determine their 3 dimensional structures, particularly when bound 
to DNA. This has been done for several other homeodomain proteins by NMR 
spectroscopy, for example Antennapedia and MATa2 (Otting et a l, 1990; Wolberger 
et a l,  1991) and will help to answer the question of whether the Six domain is a DNA 
or protein binding domain or both. It is also important that the transcription activation 
domain of DMAHP is identified as has been done for AREC3/Six4 (Kawakami et a l, 
1996a) as this will confirm its role as a transcription factor.
7.5 Genome Wide Screening for DNA Binding Targets of 
DMAHP
The whole genome PCR based screen identified 5 sequences to which DMAHP 
showed specific binding. From these, one candidate gene (dopamine D5 receptor 
gene) was identified by DNA sequencing and comparison to known genes in the 
databases. The other 4 sequences will require further characterisation in order to 
determine any genes with which they are associated. Although DMAHP was shown to 
bind to a transcribed region of the dopamine D5 receptor gene, transcription factors 
often bind upstream of the transcription start site and these sequences will not be 
present in cDNA libraries. Therefore, the next stage of this project will be to screen 
genomic DNA libraries using the selected sequences as probes, to obtain more 
genomic sequence. From this, known genes may be identified by database searching 
or novel genes can be characterised using gene structure prediction programs and by 
cDNA library screening using predicted coding regions as probes.
An alternative strategy to obtain more genomic sequence is A/w-exon PCR. This 
method involves performing PCR using a primer designed to bind to the end of an Alu 
repeat and a second primer that binds within the known genomic DNA (Buxton et a l, 
1993). As Alu repeats occur, on average, every 4 kb in the human genome, there is a 
high probability of a product containing DNA from the gene of interest being 
amplified.
To demonstrate that the sequences selected can regulate the transcription of genes in 
cell culture they could be cloned into a vector upstream of a promoter that drives the 
expression of a chloramphenicol acetyl transferase (CAT) reporter gene. GST-Six+HD 
could then be subcloned into an expression vector that would allow the expression of 
the protein in the cell culture and the level of CAT activity, from the reporter gene,
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measured. The chicken CDXA protein was shown to mediate an enhancing activity, 
measured by such a CAT assay, using sequences selected by whole genome PCR 
(Margalit et a l , 1993).
7.5.1 Alternative Strategies to Identify Binding Sites of DMAHP
Experiments described in chapter 5 of this thesis demonstrated the importance of a 
cofactor in enhancing the affinity of DMAHP for the ARE site. Therefore, the whole 
genome PCR screen may not have identified sequences to which DMAHP only binds 
in the presence of a cofactor or to which it only binds very weakly in the absence of 
the cofactor. An alternative strategy known as CASTing may be used to identify these 
sequences (Wright and Funk, 1993). CASTing uses crude nuclear extracts in place of 
purified protein, during the selection procedure, which leads to the selection of DNA 
sequences that preferentially bind multicomponent complexes. To identify sequences 
specific to a particular protein, antiserum raised against that protein is used to select 
for complexes containing it. This system was tested using a myogenin antibody to 
detect complexes formed after mixing crude myotube nuclear extracts with a random 
oligomer containing a degenerate core of 35 nucleotides. The clones were shown to 
contain the known myogenin heterodimer binding sites. Gel retardation assays using 
myotube nuclear extracts and selected sequences detected multiple bands. When 
analysed, the sequences were shown to contain consensus sequences, to which 6 
factors with which myogenin interacts, are known to bind. This protocol could be 
adapted for use with nuclear cell extracts known to contain DMAHP. However, the 
only DMAHP antibodies available at present were raised against recombinant DMAHP 
fusion proteins and do not detect endogenously expressed human or mouse DMAHP 
protein (Charles Thornton personal communication and Winchester, 1997).
Although the majority of transcription factors bind untranscribed regions of the 
genome and can bind more than 500 bp upstream of the transcription start site of the 
gene which they are regulating, a method has been described for selecting for 
transcription factor binding sites close to or overlapping with transcribed DNA 
(Caubin et a l , 1994). The DNA selected by the whole genome PCR was hybridised 
with cDNA to select for sequences that were transcribed. Genes controlled by the 
thyroid hormone receptor were successfully selected using this system. However, a 
high percentage of down-regulated genes were identified despite reports suggesting 
that the majority of genes controlled by the thyroid hormone receptor are up-regulated. 
This is likely to be due to the fact that genes whose elements were greater than 500 bp 
upstream of their transcription start sites would not be detected by this method.
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Therefore, this method is not appropriate for the identification of the majority of 
binding sites.
A system for the construction of a library of DNA-protein binding sites that contains 
sequences recognised by many of the DNA binding proteins present in a particular cell 
type has been reported (Nallur et a l , 1996). The library was constructed by the 
repeated selection of a random pool of oligonucleotides by gel retardation analysis 
with nuclear extracts. DNA present in retarded complexes was excised from the gel 
and used in a PCR reaction, the product of which was used in a second gel retardation 
assay. After 4 rounds of selection the sequences obtained were utilised as bait for the 
isolation of optimal sites for cloning transcription factors and therefore this system can 
investigate multiple transcription factors in a given cell type. Transcription factors 
involved upstream or downstream of DMAHP in the same pathway may be identified 
in this manner. This system, like that of CASTing has the advantage of using native 
protein and thus allows binding specificity to be modified by the presence of 
cofactors.
GST-Six+HD bound to the dopamine D5 receptor gene between the transcription and 
translation start sites which suggests that DMAHP could act as an RNA binding 
protein and therefore the RNA-protein binding properties of this protein should be 
investigated. It is possible to carry out whole genome PCR-based screens using RNA. 
The optimum RNA binding sites for T4 DNA polymerase were identified by using in 
vitro transcription to generate a library of RNA transcripts from double stranded 
oligonucleotides. Selected RNA was converted to cDNA for the PCR amplification 
step (Tuerk and Gold, 1990). Multiple approaches to the identification of target 
binding sites are advisable to enhance the likelihood of isolating all genes controlled 
by DMAHP.
7.6 Current Theories on the Mechanisms Involved in the 
Pathology of DM
Despite the identification of the mutation responsible for DM and the partial 
characterisation of 3 genes (DMPK, DMAHP and 59) at the locus, the mechanism 
which causes the DNA expansion and the effect of the expansion on 
DNA/RNA/protein is still poorly understood.
177
7.6.1 Triplet Repeat Instability
To investigate the somatic and germline instability of the (CTG)n repeat, several 
groups have created transgenic mice carrying an expanded trinucleotide repeat 
integrated in a random location in the genome. It has been demonstrated that these 
repeats show intergenerational and somatic repeat instability and no correlation has 
been found between the somatic mutation rate and the proliferation rate of the tissues 
involved (Gourdon et al., 1997; Lia et al., 1998; Monckton et al., 1997). This final 
result was surprising and suggests that if instability occurs during cell division some 
tissues have more efficient DNA repair systems than others. Alternatively instability 
may occur independently of cell division. These models require further analysis and 
should aid our understanding of the mechanisms involved in repeat instability.
The instability of the expanded (CTG)n repeat in cultured lymphoblastoid cell lines 
from DM patients was investigated by small pool PCR (Ashizawa et al., 1996). 
Frequent mutations leading to small changes of repeat size were observed and it was 
suggested that they may represent the mechanism responsible for the somatic 
heterogeneity in the blood cells of DM patients. Rare mutations were shown to occur 
that lead to large changes of the (CTG)n repeat size, with a bias towards contractions.
Experiments using CAG/CTG-repeat tracts in yeast and E.coli have shown that the 
stability of these tracts is dependent on their orientation with respect to replication 
origins. The repeat was more unstable when the CTG tract was on the lagging strand 
(Freudenreich et a l, 1997; Wells, 1996). These data suggest a polymerase slippage 
model for the expansion of trinucleotide repeats. In this model dissociation and 
misaligned reannealing of the newly synthesised strand in the repetitive tract results in 
addition (or deletion) of repeats. CTG, CAG and CGG repeats are able to form 
hairpin structures and the lagging strand is single stranded for a longer period of time 
giving it more opportunity to form a hairpin and thus be mutated.
7.6.2 Effects of the Expansion
A (CUG)n triplet repeat pre-mRNA/mRNA binding protein has been isolated and 
characterised (Roberts et al., 1997; Timchenko et al., 1996). It is hypothesised that 
this protein (CUG-BP/hNab50) binds mRNA, regulating transcription/translation of a 
variety of genes. The increase in potential binding sites caused by the repeat expansion 
at the DM locus may reduce the amount of CUG-BP/hNab50 available to bind to other 
genes causing an RNA processing defect leading to some of the DM symptoms. It 
would also explain the accumulation of DM allele transcripts observed in the nucleus 
(Davis et al., 1997). Recently, CUG-BP/hNab50 has been shown to bind to the
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human cardiac troponin T (cTNT) pre-mRNA and regulate its alternative splicing. It 
was demonstrated that this splicing was disrupted in DM striated muscle and in normal 
cells expressing CUG repeats (Philips et a l, 1998). Therefore, altered expression of 
human cardiac troponin T may contribute to the cardiac defects seen in DM. A 
significant decrease in the insulin receptor RNA in both total RNA and RNA poly A+ 
pools relative to normal and myopathic control muscles, measured relative to 
dystrophin and muscle sodium channel RNAs has been reported (Morrone et a l, 
1997). As DM patients are known to show increased insulin resistance (Hudson et a l, 
1987), it would be interesting to determine if CUG-BP/hNab50 binds to this RNA. 
Alternatively, the insulin receptor gene may be a target of DMAHP, which would also 
explain its downregulation in DM patients.
Two recent reports indicate that overexpression of DMPK inhibits the terminal 
differentiation of myoblasts (Okoli et a l, 1998; Sabourin et a l, 1997) and another 
contradictory report indicates that it increases a skeletal muscle phenotype in a muscle 
cell line (Bush et a l,  1996). However, the region responsible for the lack of myoblast 
differentiation was shown to be in the 3’ UTR of DMPK upstream of the (CTG)n 
repeat (Sabourin et a l, 1997) which was not present in the construct which enhanced 
a skeletal muscle phenotype. These data further support the idea that an accumulation 
of DMPK mRNAs in the nucleus could be responsible for many of the symptoms 
associated with DM, in this case the delay of muscle maturation in congenital DM 
patients. However, it should also be remembered that the 3’ UTR of DMPK is also 
the promoter region of DMAHP. Therefore, the inhibition of terminal differentiation 
may be due to the sequestering of proteins that normally regulate DMAHP and other 
genes in the muscle differentiation pathway.
The expanded (CTG)n repeat has been shown to alter chromatin structure thus leading 
to the downregulation of DMAHP (section 7.2) and hypermethylation has been shown 
to reduce the binding of the transcription factor Spl at a site proximal to expanded 
(CTG)nrepeats (section 1.5.1). Therefore, alterations in chromatin structure have been 
demonstrated in regions that are controlling the expression of DMAHP and DMPK. In 
addition to DMAHP, DMPK and 59, 3 further genes have been identified within 200 
kb of the DM expanded repeat; gastric inhibitory polypeptide receptor gene (GIPR), 
20D7, and SYMPLEKIN (Alwazzan et al., 1998). It is important that the expression 
patterns and levels of these 3 genes are investigated in DM patients and normal 
controls to determine their role if any in the pathology of DM. 20D7 is of particular 
interest as it is known to be expressed in the testis and therefore may be involved in 
testicular atrophy and male infertility. GIPR is involved in the stimulation and 
regulation of insulin secretion in a glucose-dependent manner and might therefore be 
implicated in DM-associated diabetes.
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7.7 Conclusion
Since the identification of the genetic defect responsible for DM many theories have 
been proposed and tested for the mechanism by which an expanded (CTG)n repeat in 
the 3’-UTR of one gene (DMPK) and the promoter region of a second gene 
(DMAHP) can lead to the diverse pathology associated with DM. It is becoming clear 
that the mechanism does not affect a single gene, but that the expanded (CTG)n repeat 
alters the local chromatin structure, which in turn affects the expression of several 
genes including DMAHP. It is possible that the greater the expansion, the more genes 
that are influenced. This could explain the increase in the severity of symptoms in 
successive generations, as the repeat expands. It is also likely that the expanded 
(CUG)n tract is sequestering RNA binding proteins, thus preventing them from 
binding to and correctly controlling the translation of many other genes which explains 
the multisystemic pathology of DM. The evidence for the involvement of DMAHP in 
the pathology of DM is now very strong. The work presented in this thesis has 
initiated the identification of genes involved in the pathways downstream of this 
transcription factor which are in turn likely to be involved in the pathogenesis of DM.
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